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Abstract  
Unmodified and modified starches represent a particularly interesting group of 
biodegradable and abundant excipients. They have been widely used as excipients for various 
purposes in tablet formulations, such as binders and/or disintegrants. Spray-dried high-
amylose sodium carboxymethyl starch (SD HASCA) was recently proposed as an innovating 
hydrophilic excipient for sustained-release (SR) in solid oral dosage forms. Amorphous high-
amylose sodium carboxymethyl starch (HASCA) was first produced by the etherification of 
high-amylose corn starch with chloroacetate. HASCA was then spray dried to obtain SD 
HASCA. This new excipient has shown advantageous and effective properties in the 
production of SR delivery systems. SR matrix tablets prepared from SD HASCA are 
inexpensive, simple to formulate and easy to produce by direct compression.  
The main objective of the present research was to continue the development and 
optimization of matrix tablets using SD HASCA as the retarding excipient in view of their 
ultimate application as sustained drug-release delivery systems for oral administration. For this 
purpose, dissolution tests simulating some of the most relevant physiological conditions of the 
gastrointestinal tract, taking into account the nature of the polymer under investigation, were 
employed to evaluate the drug-release characteristics and demonstrate the performance of SD 
HASCA SR formulations. An exploratory clinical study was also carried out to evaluate the 
SR properties of this new drug delivery system in the gastrointestinal tract.  
The first article presented in this thesis evaluated the drug-release characteristics and 
the physical integrity of formulations containing a compressed blend of drug, sodium chloride 
and SD HASCA in biorelevant media. The influence of different acidic pH values and 
residence times was investigated. The SR profile from an optimized SD HASCA formulation 
was not significantly affected by both the acidic pH value and the residence time in the acidic 
medium. These results suggest a limited influence of intra- and inter-subject variability of 
gastric pH on the release kinetics from SD HASCA matrices. In addition, the optimized 
formulation maintained its integrity throughout the duration of the dissolution tests. The 
exploratory in vivo study demonstrated extended drug absorption after oral administration of 
SD HASCA matrix tablets and that the matrix tablets did not disintegrate while passing 
through the stomach and resisted hydrolysis by α-amylase in the intestine. 
 ii 
The second article reports the development of once-daily and twice-daily SD HASCA 
tablets containing tramadol hydrochloride (100 mg and 200 mg). These SR formulations 
presented high crushing strengths without requiring the addition of binders, which facilitates 
tablet processing and handling. The compression force (CF) applied to produce the tablets did 
not significantly affect the drug-release profiles. The total release time from SD HASCA 
tablets increased significantly in function of the tablet weight and can be used to modulate the 
total release time from theses formulations. When exposed to a pH gradient and to a 40% 
ethanol medium, a very rigid gel formed progressively on the surface of the tablets providing 
controlled drug-release properties. These properties indicated that SD HASCA is a robust 
excipient for oral, sustained drug-release, likely to minimize the possibility of dose dumping 
and consequent adverse effects, even when co-administered with high doses of alcohol. 
The third article investigated the effect of α-amylase on drug-release from previously 
developed SD HASCA tablets containing acetaminophen and tramadol hydrochloride 
(Acetaminophen SR and Tramadol SR). Mathematical modeling showed that an increase in α-
amylase concentration resulted in an increase of polymer erosion over drug diffusion as the 
main mechanism controlling drug-release, for both formulations and both residence times in 
acidic medium. However, even if the mechanism of release was affected, α-amylase 
concentrations ranging from 0 IU/L to 20000 IU/L did not significantly affect the drug-release 
profiles from SD HASCA SR tablets, regardless of the residence time in acidic medium, the 
drug used, the polymer content and the different composition of each formulation. 
The work presented in this thesis clearly demonstrates the value of SD HASCA as an 
efficient SR excipient. 
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Résumé 
Les amidons non modifiées et modifiés représentent un groupe d’excipients 
biodégradables et abondants particulièrement intéressant. Ils ont été largement utilisés en tant 
qu’excipients à des fins diverses dans des formulations de comprimés, tels que liants et/ou 
agents de délitement. Le carboxyméthylamidon sodique à haute teneur en amylose atomisé 
(SD HASCA) a été récemment proposé comme un excipient hydrophile à libération prolongée 
innovant dans les formes posologiques orales solides. Le carboxyméthylamidon sodique à 
haute teneur en amylose amorphe (HASCA) a d'abord été produit par l'éthérification de 
l'amidon de maïs à haute teneur en amylose avec le chloroacétate. HASCA a été par la suite 
séché par atomisation pour obtenir le SD HASCA. Ce nouvel excipient a montré des 
propriétés présentant certains avantages dans la production de formes galéniques à libération 
prolongée. Les comprimés matriciels produits à partir de SD HASCA sont peu coûteux, 
simples à formuler et faciles à produire par compression directe. 
Le principal objectif de cette recherche était de poursuivre le développement et 
l'optimisation des comprimés matriciels utilisant SD HASCA comme excipient pour des 
formulations orales à libération prolongée. A cet effet, des tests de dissolution simulant les 
conditions physiologiques du tractus gastro-intestinal les plus pertinentes, en tenant compte de 
la nature du polymère à l’étude, ont été utilisés pour évaluer les caractéristiques à libération 
prolongée et démontrer la performance des formulations SD HASCA. Une étude clinique 
exploratoire a également été réalisée pour évaluer les propriétés de libération prolongée de 
cette nouvelle forme galénique dans le tractus gastro-intestinal. 
Le premier article présenté dans cette thèse a évalué les propriétés de libération 
prolongée et l'intégrité physique de formulations contenant un mélange comprimé de principe 
actif, de chlorure de sodium et de SD HASCA, dans des milieux de dissolution 
biologiquement pertinentes. L'influence de différentes valeurs de pH acide et de temps de 
séjour dans le milieu acide a été étudiée. Le profil de libération prolongée du principe actif à 
partir d'une formulation de SD HASCA optimisée n'a pas été significativement affecté ni par 
la valeur de pH acide ni par le temps de séjour dans le milieu acide. Ces résultats suggèrent 
une influence limitée de la variabilité intra et interindividuelle du pH gastrique sur la cinétique 
de libération à partir de matrices de SD HASCA. De plus, la formulation optimisée a gardé 
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son intégrité pendant toute la durée des tests de dissolution. L’étude in vivo exploratoire a 
démontré une absorption prolongée du principe actif après administration orale des comprimés 
matriciels de SD HASCA et a montré que les comprimés ne se sont pas désintégrés en passant 
par l'estomac et qu’ils ont résisté à l’hydrolyse par les α-amylases dans l'intestin.  
Le deuxième article présente le développement de comprimés SD HASCA pour une 
administration orale une fois par jour et deux fois par jour contenant du chlorhydrate de 
tramadol (100 mg et 200 mg). Ces formulations à libération prolongée ont présenté des valeurs 
de dureté élevées sans nécessiter l'ajout de liants, ce qui facilite la production et la 
manipulation des comprimés au niveau industriel. La force de compression appliquée pour 
produire les comprimés n'a pas d'incidence significative sur les profils de libération du 
principe actif. Le temps de libération totale à partir de comprimés SD HASCA a augmenté de 
manière significative avec le poids du comprimé et peut, de ce fait, être utilisé pour moduler le 
temps de libération à partir de ces formulations. Lorsque les comprimés ont été exposés à un 
gradient de pH et à un milieu à 40% d'éthanol, un gel très rigide s’est formé progressivement 
sur leur surface amenant à la libération prolongée du principe actif. Ces propriétés ont indiqué 
que SD HASCA est un excipient robuste pour la production de formes galéniques orales à 
libération prolongée, pouvant réduire la probabilité d’une libération massive de principe actif 
et, en conséquence, des effets secondaires, même dans le cas de co-administration avec une 
forte dose d'alcool. 
Le troisième article a étudié l'effet de α-amylase sur la libération de principe actif à 
partir de comprimés SD HASCA contenant de l’acétaminophène et du chlorhydrate de 
tramadol qui ont été développés dans les premières étapes de cette recherche (Acetaminophen 
SR et Tramadol SR). La modélisation mathématique a montré qu'une augmentation de la 
concentration d’α-amylase a entraîné une augmentation de l'érosion de polymère par rapport à 
la diffusion de principe actif comme étant le principal mécanisme contrôlant la libération de 
principe actif, pour les deux formulations et les deux temps de résidence en milieu acide. 
Cependant, même si le mécanisme de libération peut être affecté, des concentrations d’α-
amylase allant de 0 UI/L à 20000 UI/L n'ont pas eu d'incidence significative sur les profils de 
libération prolongée à partir de comprimés SD HASCA, indépendamment de la durée de 
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séjour en milieu acide, le principe actif utilisé, la teneur en polymère et la différente 
composition de chaque formulation. 
Le travail présenté dans cette thèse démontre clairement l'utilité de SD HASCA en tant 
qu'un excipient à libération prolongée efficace. 
 
 
 
 
 
Mots-clés : administration orale de médicaments ; libération prolongée ; excipient hydrophile ; 
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Chapter 1. Introduction 
1.1 Pharmaceutical dosage forms intended to oral drug 
administration 
1.1.1. General principles 
The general objective of the administration of a pharmaceutical dosage form is to 
deliver an adequate dose of drug to a pharmacological target, so that a predictable therapeutic 
response to the drug (or drugs) included in the dosage form, which can be to prevent, cure or 
control a determined diagnosed pathological state, can be achieved. There are numerous 
dosage forms into which a drug can be incorporated in order to achieve a suitable and effective 
treatment of a disease. 
The first requirement to take into consideration when formulating a new oral dosage 
form is a good knowledge of the pathway and the vast anatomical and physiological 
dissimilarities that the dosage form and the drug it contains will encounter during their passage 
throughout the gastrointestinal tract and until the drug reaches its target, so that an adequate 
pharmacokinetic and pharmacodynamic profile is attained. Moreover, the physicochemical 
and biological properties of the drug, the design of the dosage form, the drug-release 
mechanism and the particular disease factors are other factors that can influence the 
bioavailability of a drug and interact with one another. Dosage forms are also subject to intra- 
and inter-patient variability. Therefore, the delivery of an adequate dose of drug to a 
pharmacological target remains a major challenge in the development of new pharmaceutical 
dosage forms. 
Dosage forms are constituted of two main components: pharmaceutical drugs (or 
active ingredients) and excipients (also called auxiliary substances or additives). A dosage 
form can comprise one or several drugs (Le Hir, Chaumeil et al. 2009). A pharmaceutical drug 
is a substance intended to exert a pharmacological activity. In addition to being used in the 
treatment and prevention of a determined disease, a drug can also be used in the medical 
diagnosis of a disease. The excipients are the components in the dosage form, or used in its 
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manufacturing process, which do not possess any pharmacological activity. Initially, the 
excipients were merely inactive substances used as vehicles or diluents for drugs and/or 
included in a pharmaceutical dosage form for varied and specialized pharmaceutical functions 
such as preserve, solubilise, suspend, modify dissolution, improve the compressibility, 
thicken, flavour and/or colour drug products (York 2002). Above all, they aim to improve the 
physicochemical properties of the drug in the dosage form, and ensure that the drug substance 
remains active and stable for a sufficiently long period of time. However, excipients have 
progressed and, although they are still necessary for their original functions, some are used 
nowadays in the control of drug action, contributing, as a result, to the improvement of drug 
efficacy in the human body. 
Dosage forms can be designed for administration by diverse routes of administration to 
maximize therapeutic response. Depending on the route of administration and the type of 
formulation, different excipients may be used. The numerous excipients used in the 
formulation of dosage forms can also be explained by the large variety of physicochemical 
characteristics of drugs (Le Hir, Chaumeil et al. 2009). 
The relationship between the drug, its dosage form and the route by which it is 
administered governs how much of the drug and how fast it enters the systemic circulation 
(Ashford 2002). Some routes, such as the parental routes (intravenous, intramuscular, 
intrathecal, subcutaneous…), imply the irruption of physiological barriers, and others such as 
the oral, the topical and the transmucosal (ocular, nasal, buccal, pulmonary, rectal, vaginal…) 
routes, among many others, do not imply the irruption of any physiological barriers. 
The present thesis is focused on the development and evaluation of a novel excipient 
for oral sustained-release (SR) dosage forms. Besides the oral route, the intravenous route was 
also used in a clinical study using human volunteers. Therefore, only these two routes, and in 
particular the oral, will be described. 
If a drug is given intravenously it is administered directly into the bloodstream, and 
thus the entire amount of drug administered reaches the systemic circulation and is available 
for distribution into other body tissues and the site(s) of action of the drug. On the other hand, 
if a drug is administered by a route other than the intravenous, there is no guarantee that the 
entire dose will reach the systemic circulation, because all routes of administration where a 
systemic action is required, apart from the intravenous, involve the absorption of the drug into 
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the blood from the route of administration (Ashford 2002). Nonetheless, the intravenous route 
has its disadvantages, for instance, patients are not typically able to self-administer, it passes 
most of the natural defences of the body, and it can carry fatal air boluses. 
Among the routes of administration that require an absorption step, the oral route is by 
far the most popular for administration of drugs intended for systemic action because it 
presents certain advantages (Le Hir, Chaumeil et al. 2009), which will be described in the next 
section. 
 
 
1.1.2. Oral drug administration 
Compared with other routes of administration, the oral route is the simplest, the most 
natural and convenient for the patient (non-invasive), and usually the safest and least 
expensive means of drug administration (Kokate, Marasanapalle et al. 2005; Le Hir, Chaumeil 
et al. 2009). The oral route also allows the administration of high doses of drug with only a 
single administration (Aiache, Aiache et al. 2001). It is estimated that currently about 90% of 
pharmaceutical dosage forms are administered orally (Kokate, Marasanapalle et al. 2005), 
being about 80% of the pharmaceutical forms administered by the oral route solid dosage 
forms (tablets, capsules…) (Jivraj, Martini et al. 2000). Although oral dosage forms are 
essentially intended for absorption into the bloodstream through the various epithelia and 
mucosa of the gastrointestinal tract, a few are destined to produce a local effect in the tract, 
such as a temporarily increase of the pH of the stomach. 
The pharmacokinetic properties of the oral route of administration are the result of the 
great variability of environmental conditions and obstacles that the drug will encounter along 
the gastrointestinal tract, during its passage through the gastrointestinal membrane into the 
bloodstream as well as during its passage through the liver. In fact, the relatively slow onset of 
action after administration, the possibilities of reduced and irregular absorption and the 
biodegradation of certain drugs by the enzymes and secretions of the gastrointestinal tract 
constitute some of the disadvantages of this route of administration (York 2002). Other 
disadvantages are a potential altered bioavailability caused by drug and food interactions, the 
modification of the contents and microflora of the gastrointestinal tract by unabsorbed drug 
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and the occurrence of eventual nausea or gastrointestinal tract discomfort due to drugs that 
cause local irritation (Shargel, Wu-Pong et al. 2004). 
 
The progression of a drug in the body is a dynamic process that leads to the therapeutic 
effect of the same. After oral ingestion, the dosage form moves along the oesophagus towards 
the stomach. Then, it remains in the stomach until it can pass the pylorus and be transferred to 
the small intestine, where most of drugs are absorbed. The distinct phenomena that take place 
in the gastrointestinal tract after drug administration and may influence the bioavailability of 
drugs administered orally must be taken into consideration when designing a new oral dosage 
form. Indeed, in order to have the desired pharmacotherapeutic effect, it is necessary that the 
dosage form be able to deliver the drug to the section(s) of the gastrointestinal tract where it 
can be absorbed and assure that the drug is available in the body in a form that permits its 
absorption and passage into the systemic circulation. However, many factors can contribute to 
a decrease of the bioavailability of an orally administered drug. These factors include anything 
that adversely affects the release of the drug from the dosage form, its dissolution into the 
gastrointestinal tract fluids, its stability in solution in the same fluids, its passage through and 
stability in the gastrointestinal tract membrane, and its passage through the liver into the 
systemic circulation (Ashford 2002). After crossing the gastrointestinal tract membrane, drugs 
pass into the hepatic portal system and through the liver before they are transported via the 
bloodstream to its target site. Consequently, the amount of an oral dose of drug that reaches 
the systemic circulation can also be decreased by first-pass or presystemic metabolism by the 
gastrointestinal tract membrane and/or the liver. The factors contributing to a decrease of the 
amount of an orally administered drug that reaches the systemic circulation will be detailed in 
a following section.  
The different stages between drug administration and the attainment of the therapeutic 
effect are generally described as a series of three phases: the biopharmaceutical phase, the 
pharmacokinetic phase, and the pharmacodynamic phase (Figure 1.1).  
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Figure 1.1 Representation of the three phases between drug administration and the attainment 
of the therapeutic effect: the biopharmaceutical phase, the pharmacokinetic phase, and the 
pharmacodynamic phase. 
 
 
1.1.3. Pharmaceutical oral dosage forms 
The dosage forms administered orally can be classified into two major categories 
(Aiache, Aiache et al. 2001): 
1. Liquid forms, which include solutions, syrups, suspensions and emulsions. 
2. Solid forms, which include tablets, powders, granules, pills, capsules (hard and soft 
gelatine capsules) and suppositories (suppositories may be also classified as semi-solid 
dosage forms). 
 
The most popular oral dosage forms are tablets, capsules, suspensions, solutions and 
emulsions (York 2002). Although tablets and capsules are more widely used than liquid 
preparations for oral administration, the latter possess some advantages relatively to solid 
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dosage forms. These advantages include, among others, the immediate availability for 
absorption, as the drug must be in solution to be absorbed, leading to a faster therapeutic 
effect, if required. Liquids are easier to swallow than solids and are, therefore, particularly 
suitable for paediatric and geriatric use. In addition, the administration of a solution of a drug 
is less likely to cause irritation and damage of the gastric mucosa by certain drugs because of 
the immediate dilution by the gastric contents (Billany 2002). However, these dosage forms 
also present some disadvantages, compared with solid dosage forms, which are related, 
mostly, to the storage, transport and stability of the ingredients in aqueous solution (both drugs 
and excipients), which are more susceptible to hydrolysis and to growth of microorganisms in 
solution, and to the administration of solutions, i.e., taste and lower accuracy of each dosage 
(Billany 2002). 
Tablets are the most common solid dosage forms, and contain each a single dose of 
one or more drugs as well as one or more excipients. They are obtained by compression of 
uniform volumes of a mixture of powders held within a confined space. Depending on the type 
of tablet, they can be swallowed in one piece or split, chewed, dissolved or dispersed in water 
before administration, or retained in the mouth, where the drug is released (Alderborn 2002; 
Kottke and Rudnic 2002). Tablets present several advantages, including (Jivraj, Martini et al. 
2000; Aiache, Aiache et al. 2001; Alderborn 2002; Ashford 2002):  
1. It represents a convenient and safe way of drug administration, leading to an improvement 
of the patient compliance. 
2. It is relatively easy to manufacture and transport solid oral dosage forms, as they do not 
need to be sterilized, are compact, and can be produced in large quantities by automated 
machines, allowing robust and quality-controlled production procedures at a relatively low 
price. Tablets can also be prepared in a versatile way with respect to their use and to the 
delivery of the drug.  
3. Oral solid dosage forms, especially the ones in the dry and condensed form, are generally 
physically and chemically more stable, allowing a longer stability of the comprised 
ingredients, including drugs. 
4. The preparation procedure enables accurate dosing of the drug per single dose and 
administration of larger amounts of drug in a restricted volume. 
5. They are suitable for SR preparation. 
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When a solid dosage form is administered orally, the first step to make the drug 
available is its release from the dosage form. This release can be immediate or modified. The 
drug-release mechanism states the dissolution of the drug and, consequently, has an effect on 
its absorption and pharmacokinetics. 
 
 
1.1.4. Drug-release from oral solid dosage forms: immediate versus 
modified drug-release 
The drug-release characteristics of a dosage form generally have a major effect on the 
therapeutic efficacy of the delivered drug. Based on their drug-release characteristics, tablets 
can be classified into two main types, immediate-release (IR) and modified-release (MR).  
 
 
1.1.4.1 Immediate drug-release dosage forms 
IR or ‘conventional’ tablets are designed to release the complete dose of drug 
contained within the dosage form, immediately following administration, i.e., the goal of this 
formulation is fast and complete drug-release in vivo, providing only a single and transient 
burst of drug. The released drug is assumed to be in a form that is therapeutically active and 
immediately available for absorption into the systemic circulation (Alderborn 2002; Collett 
and Moreton 2002). The fast release of drugs from IR tablets is achieved by fragmentation of 
the whole structure of the dosage form. When the tablet comes into contact with the fluids of 
the gastrointestinal tract, the liquid wets the solid and penetrates its pores. Consequently, the 
tablet disintegrates into granules or aggregates of primary particles, which subsequently 
deaggregate into their primarily drug particles. A deaggregation directly into fine particles will 
set up conditions for the fastest dissolution of the drug (Leblanc, Aiache et al. 1997; Alderborn 
2002; Hoener and Benet 2002). However, drug dissolution can start before the complete 
fragmentation of the tablet. After the drug is in solution in the gastrointestinal tract, absorption 
may take place. The rate-limiting step in the dissolution process can be either the rate of 
disintegration of the dosage form and the size of the resulting aggregates or the deaggregation 
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process (Hoener and Benet 2002). A disintegrant is usually included in the formulation of IR 
tablets to ensure that the tablet, when in contact with a liquid, breaks up into small fragments, 
promoting rapid drug dissolution. The two main mechanisms of action of disintegrants are 
(Alderborn 2002; Kottke and Rudnic 2002):  
1. The promotion of liquid penetration into the pores of the tablet, resulting in the tablet 
breaking into fragments. 
2. The induction of the rupture of the tablet by swelling of the disintegrating particles when 
in contact with liquids, by formation of gas or by enzymatic action. The smaller the 
primary particles obtained are, i.e., the larger the effective surface area, the faster will be 
the dissolution of the drug. 
 
 
 
Figure 1.2 Difference between the plasma drug concentrations versus time profiles for 
immediate-release and sustained-release dosage forms.  
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The pharmacokinetic behaviour of IR dosage forms consists generally of a fast 
increase of the plasma drug concentration until a maximum is attained (high maximum 
concentration, Cmax, and short time to reach the maximum concentration, Tmax) followed by 
the decaying of the plasma concentration corresponding to the elimination phase.  
For most drugs there is an optimum plasma concentration range, usually known as 
therapeutic window or therapeutic range within which desired therapeutic effects are 
achieved. The therapeutic window lies between the MEC and the MTC (Figure 1.2), which 
represent the minimum effective (or therapeutic) concentration and minimum toxic 
concentration of drug, respectively. The minimum effective concentration is the minimum 
concentration of drug that has to be achieved in the plasma for the desired therapeutic or 
pharmacological effect to be elicited. The minimum toxic concentration is the concentration of 
drug in the plasma above which side effects or toxic effects occur. 
For many diseases, the ideal dosage regimen is that by which an optimum therapeutic 
concentration of drug in the blood plasma, and hence at the site(s) of action of the drug, is 
attained immediately and then maintained as stable as possible within the therapeutic window 
for the desired duration of the treatment. Provided dose size and frequency of administration 
are correct, plasma concentrations of a certain drug lying within its therapeutic window can be 
achieved promptly and maintained by means of multiple administrations of IR oral dosage 
forms (Collett and Moreton 2002). Nonetheless, this dosage regimen has a few limitations. 
When IR dosage forms are administered, the plasma concentration-time profile of a drug 
fluctuates over successive dosing intervals, even when the 'steady-state' condition (when the 
overall rate of drug supply equals the overall rate of drug elimination from the body) is 
achieved. As long as the amount of drug is above the minimum effective concentration, a 
pharmacological response is observed. However, it is not possible to maintain a stable drug 
concentration within the therapeutic window for the duration of treatment. In addition, these 
fluctuations can lead to a patient being undermedicated or overmedicated for periods of time. 
The first situation happens if, following the oral administration of equal doses of a drug, the 
interval between each administered dose is longer than the time required for complete 
elimination of the previous dose. In this case, the plasma concentration-time profile 
corresponds to a series of isolated single-dose profiles and the plasma concentration only lies 
within the therapeutic window of the drug for a relatively short period following the 
  
10 
administration of each dose. On the other hand, if the time interval between successive equal 
doses is less than that required for complete elimination of the previous absorbed dose, 
overmedication leading to eventual toxicity may occur due to accumulation of the drug in the 
body and plasma following successively administered doses (Proudfoot 2002). These 
limitations are even more significant for drugs with short biological half-lives, because of their 
more frequent dosing constraint, which makes it more difficult to keep plasma concentrations 
within the therapeutic window, especially when the therapeutic window is very narrow. An 
example of such a drug is theophylline, which has a narrow therapeutic window and a 
relatively short half-life in children (Kadlec, Ha et al. 1978). Furthermore, poor patient 
compliance is more likely to happen in the case of regimens requiring frequent administration, 
and is often an important reason for therapeutic inefficiency or failure (Li, Robinson et al. 
1987; Collett and Moreton 2002). 
 
 
1.1.4.2 Modified drug-release dosage forms 
The limitations and requirements regarding the administration of IR dosage forms led 
pharmaceutical scientists to put a vast amount of work into designing MR dosage forms, 
which are intended to provide the drug at more precise temporal and spatial placement within 
the body. The United States Pharmacopeia definition of MR system is: “the one for which 
drug-release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms…” 
Some authors have suggested two main distinct classifications within the MR dosage 
forms: sustained-release (referred herein as SR) dosage forms and controlled-released 
(referred herein as CR) dosage forms. According to this terminology, SR denotes any dosage 
form designed to maintain therapeutic plasma or tissue concentrations of the drug for an 
extended period of time by providing drug at a decreased release rate and, thus, slowing down 
the absorption rate. The Cmax attained after a single administration of a SR dosage form will be 
usually lower than that attained after the administration of a single IR dosage form containing 
the same amount of drug, and the Tmax will be longer compared to the IR dosage form (Figure 
1.2). CR, on the other hand, indicates that the delivery system is able to provide some actual 
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therapeutic control, whether this be of a temporal nature, spatial nature, or both; that is, it 
attempts to control drug concentrations in the target tissue or cells. These definitions suggest 
that SR systems, which only prolong therapeutic blood or tissue concentrations of the drug for 
an extended period of time, cannot be considered as CR systems (Li, Robinson et al. 1987; 
Jantzen and Robinson 2002). However, there has been considerable confusion regarding the 
terminology of these dosage forms (Li, Robinson et al. 1987; Buri and Doelker 1997; Jantzen 
and Robinson 2002). 
Thus, CR may be considered to include a broad number of objectives such as, among 
others, 1) to increase drug solubility and dissolution rates in order to improve absorption and, 
as a result, bioavailability; 2) to prolong retention in the stomach in order to control not only 
the rate of release but also the site of release; 3) to protect drugs and bioactive agents, such as 
peptides, proteins and enzymes, from degradation within the gastrointestinal tract; 4) to protect 
the stomach from the irritating effects of some drug by means of, for example, enteric 
coatings; and 5) to deliver drugs to their absorption window or to specific targets within the 
gastrointestinal tract, often the colon (site-specific) (Li, Robinson et al. 1987; Ranade 1991).  
The main goals of oral SR products, on the other hand, can be described as follows (Li, 
Robinson et al. 1987; Ranade 1991; Gupta and Robinson 1992; Collett and Moreton 2002; 
Das and Das 2003; Rajabi-Siahboomi 2003; Kumar, Bhowmik et al. 2010): 
1. To attain a therapeutic concentration of drug in the plasma (within the therapeutic window 
of the drug) quickly, which provides a fast onset of the desired therapeutic response in the 
patient, and, then, to maintain the concentrations within the therapeutic window, with a 
maximum reduction of fluctuations, for a longer period of time after the administration of 
a single dose. The decreased fluctuations of plasma concentrations result in more uniform 
and prolonged clinical effects with lower incidence and/or severity of systemic and local 
side-effects, better treatment of diseases where symptoms exacerbate if the plasma 
concentration of drug drops below the minimum effective concentration, and better 
overnight maintenance of the therapeutic action.  
2. To reduce dosage frequency, which generally improves patient comfort and compliance 
and may reduce the total amount of drug administered over the duration of treatment.  
3. To possibly hinder the drug degradation rate by delaying disintegration or dissolution of 
the dosage form. 
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However, some potential limitations have been described for oral SR dosage forms, 
specifically (Li, Robinson et al. 1987; Ranade 1991; Gupta and Robinson 1992; Collett and 
Moreton 2002; Das and Das 2003; Kumar, Bhowmik et al. 2010):  
1. The time to attain therapeutic blood concentrations is longer when the dosage form is not 
designed to provide a first loading dose. 
2. There may be possible increased variation in bioavailability after oral administration. 
3. Unpredictable and poor in vitro-in vivo correlation (IVIVC) are often observed with such 
formulations, especially when the drug-release rate is very low. 
4. Enhanced first-pass effect may take place for certain drugs. 
5. There are constraints on the types of drugs that are suitable candidates for incorporation 
into oral SR formulations. These restrictions will be discussed in a following section. 
6. These dosage forms usually contain a higher total amount of drug than the single dose 
administered in a conventional dosage form. Therefore, there is a significant risk of 
overdose if the form happens to be defective or misused, which may cause a “dose 
dumping”, i.e., a release of a potentially toxic dose of drug as a bolus, resulting in 
undesired high plasma drug concentrations and potential toxicity. 
7. Variable physiological factors, such as gastrointestinal pH, enzyme activities, gastric and 
intestinal transit rates, food and severity of disease, which often influence drug 
bioavailability from conventional oral dosage forms, may also interfere with the precision 
of control of release and absorption of drugs from oral SR dosage forms. The achievement 
and maintenance of prolonged drug action depends on such control. 
8. SR products, which tend to remain intact, may become lodged at some site along the 
gastrointestinal tract. If this occurs, slow release of the drug may produce a high-localized 
concentration that causes local irritation to the gastrointestinal mucosa.  
9. There is reduced potential for dosage change or withdrawal in the event of toxicity, 
allergy, or poisoning.  
10. There is limited dosage flexibility.  
11. The gastrointestinal transit time of the SR dosage form along the gastrointestinal tract 
represents a physiological constraint to these pharmaceutical products because it limits the 
residence time at the absorption site and, consequently, the maximum period for which a 
therapeutic response can be maintained following administration of a single dose.  
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12. SR dosage forms usually imply superior production costs than conventional dosage forms, 
mostly associated with the more complex production methodology used. However, the 
total cost of the treatment with SR products may be comparable to or even lower than the 
one with IR products. With a decrease in side effects, the overall expense in disease 
management may be reduced. Besides, therapies with SR products require less ‘unit 
doses’. 
13. Variable bioavailability is often observed. However, improved bioavailability has been 
described (Raber, Schulz et al. 1999; Rajabi-Siahboomi 2003). 
 
For the purposes of this thesis, SR and CR will be considered as separate delivery 
processes as suggested.  
 
A zero-order release from the dosage form, i.e., drug-release rate that is independent of 
the amount of drug remaining in the dosage form at any given time (constant release rate), has 
often been considered as ideal for SR forms. However, in practice, it is difficult to obtain a 
zero-order release. Thus, these dosage forms usually try to mimic zero-order release by 
providing drug at a slow first-order rate (i.e. concentration-dependent) (Jantzen and Robinson 
2002).  
The maintenance of constant plasma drug concentrations is also hindered by the 
presence of all the variable physiological conditions associated with the gastrointestinal tract. 
Consequently, even if a zero-order release from the dosage form is achieved, the drug 
absorption kinetics does not necessarily follow the same order of the release from the dosage 
form. Besides, to maintain a constant drug concentration in the plasma and the target tissue, 
the release rate from the dosage form and, thus, the absorption rate should be equal to the rate 
of elimination from the body (Li, Robinson et al. 1987). The rate of drug elimination from a 
tissue or from the body is, however, considered to be a first-order process (both metabolism 
and renal excretion) as well as the absorption and distribution of drug (Ranade 1991; Shargel, 
Wu-Pong et al. 2004; Shargel, Wu-Pong et al. 2004). Furthermore, the elimination kinetics of 
a given drug is also subject to inter and intra-patient variability depending on such factors as 
genetic differences, age differences and differences in the severity of disease, which further 
complicates the achievement of a constant drug concentration. 
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SR dosage forms are often designed so as to release a first amount of drug (loading 
dose) into the gastrointestinal fluids immediately following administration of the dosage form, 
in order to attain the desired therapeutic response promptly. This first dose is followed by a 
slow release of the remaining dose of drug (the main one), thereby resulting in therapeutic 
drug concentrations that, although not remaining constant, decline at such a slow first-order 
rate that they remain within the therapeutic window for an adequately extended period of time 
(Li, Robinson et al. 1987; Ranade 1991; Collett and Moreton 2002). 
For IR dosage forms, the rate-limiting step in drug bioavailability is usually the 
absorption of drug across the gastrointestinal wall, which has been described as a first-order 
kinetic process (Li, Robinson et al. 1987). When designing a SR or CR product, one aims for 
release of drug from the dosage form as the rate-limiting step instead. Thus, drug availability 
is controlled by the kinetics of drug-release from the dosage form rather than absorption. As a 
result, the associated rate constant(s) for drug-release are smaller than the absorption rate 
constant (Li, Robinson et al. 1987). 
For the successful formulation of a SR dosage form it is necessary to take account of 
the physiology of the gastrointestinal tract, the physicochemical and the biological properties 
of the drug, the design of the dosage form, the mechanisms of drug-release (from the 
macroscopic effects of size, shape and structure to chemistry and molecular interactions), and 
the particular disease factors. All of these can influence or interact with each other (Collett and 
Moreton 2002). For example, the interaction between the physicochemical properties of a drug 
and the characteristics of the dosage form in which it is delivered determines the temporal 
release pattern that is observed (Li, Robinson et al. 1987). In addition, the rational design of 
SR dosage forms, where biological, physicochemical and physicomechanical considerations 
have been taken into account during formulation has decreased the risk of dose dumping in 
vivo. 
 
The efficacy of SR compared to conventional formulations has been demonstrated for 
tramadol, the second model drug used in this study (Grond and Sablotzki 2004; Keating 2006).  
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1.2 Solid dosage forms for oral sustained drug-release 
1.2.1 General principles 
The two most common formulation strategies employed to provide sustained drug-
release are to (1) embed the drug in an insoluble or swellable matrix with release-retardant 
materials or (2) enclose the drug or the dosage form in a SR coating. 
 
The majority of SR systems rely on diffusion, dissolution (bioerosion), or a 
combination of both mechanisms, to generate slow release of drug to the biological 
environment (diffusion and/or erosion systems) (Hui, Robinson et al. 1987; Ranade 1991). 
Both formulation strategies described above provide a diffusion and/or erosion barrier to drug-
release. However, other approaches, such as osmotic pressure (osmotically controlled systems) 
and, more rarely, ion exchange (ion exchange systems), have also been used (Doelker 1985; 
Hui, Robinson et al. 1987; Jantzen and Robinson 2002; Kumar, Bhowmik et al. 2010). Indeed, 
one of the classifications proposed for the SR systems is based on the mechanisms controlling 
drug-release (Doelker 1985; Ranade 1991). All these type of systems are made of polymers 
(Kumar, Bhowmik et al. 2010). 
Furthermore, oral SR drug delivery systems can be classified into two major groups: 
single-unit or monolithic dosage forms (e.g., large tablets or capsules) and multiple-unit 
dosage forms (e.g., pellets) (Bodmeier 1997).  
 
 
1.2.2 Multiple-unit dosage forms for sustained drug-release 
Multiple-unit dosage forms are those in which a single dose of a drug is administered 
subdivided into many small dosage units. For oral administration, sufficient units to comprise 
a single therapeutic dose are usually given enclosed in a hard gelatine capsule, a disintegrating 
tablet or in a sachet. These dosage forms are generally used as delayed-release or SR systems, 
though they may provide IR products, (for example, for reduced localized gastric irritation) 
(Melia, Washington et al. 1994). 
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Multiple-unit dosage forms include preparation technologies such as drug-loaded 
pellets, often as coated spheroids, granules, mini-tablets and drug crystals (Rajabi-Siahboomi 
2003). The two strategies used to provide SR mentioned above, i.e. insoluble or swellable 
matrices and SR coatings, have been combined within a single type of multiple-unit dosage 
forms (Melia, Washington et al. 1994; Collett and Moreton 2002). 
These dosage forms offer some advantages in sustained drug-release. For example, 
multiple-unit dosage forms are considered to be less susceptible to the effects of food than the 
monolithic dosage forms (Rajabi-Siahboomi 2003). They can lead to decreased variability 
produced by food intake in the bioavailability of certain drugs due to more reproducible 
gastric emptying patterns when compared to single SR units above a certain size. The small 
size of each unit allows the passage through the pylorus independently of the motility cycles in 
the stomach, contrarily to the large monolithic forms, which are often retained, leading to 
variability in the gastric emptying patterns that are displayed both in fasted and fed subjects 
(Melia, Washington et al. 1994). Another relevant advantage of multiple-unit dosage forms is 
associated with a lower risk of toxicity caused by overdose. When a single monolithic dosage 
form happens to be defective or misused and, consequently, disintegrates within the 
gastrointestinal, it can potentially lead to dose dumping. Failure of a multiple-unit dosage form 
is unlikely to cause disruption of all the particulates, and thus the dosage released will be 
minimal. Multiple-unit dosage forms also reduce the likelihood of localized mucosal damage 
to the gastrointestinal tract, as the probability of many multiple-units becoming entrapped 
within, for example, a single mucosal fold in the stomach or intestine, is small. 
However, these dosage forms also present disadvantages, which are mainly related to 
their manufacturing process. First of all, if the technology chosen is new to a pharmaceutical 
company, a high investment and significant time is generally required in their development 
and introduction. Unforeseen difficulties may occur in stability testing and quality control of 
the new product as a result of lack of a knowledge support and experience in the new 
technology. In addition, filling of the multiple-unit spheroids into capsules can be a problem 
owing to build-up of static charge. But, even if the technology and knowhow is well 
established, production costs and time for manufacture are often higher for multiple-unit 
dosage forms than for tablets. Indeed, monolithic tablets are associated to greatly efficient 
manufacturing technologies and much lower costs (Collett and Moreton 2002). 
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1.2.3 Monolithic dosage forms for sustained drug-release 
Oral single-unit or monolithic dosage forms include tablets of different types as, for 
example, coated tablets and matrix tablets, and some capsules. To facilitate their description, 
solid monolithic dosage forms for SR can be divided into three main groups: reservoir or 
membrane-controlled systems, matrix systems and osmotic pump systems (Collett and 
Moreton 2002). All these systems allow water penetration and, when they come into contact 
with a dissolution medium, drug diffusion will occur from a region of high concentration to a 
region of low concentration, i.e., down its concentration gradient. Initially, the interior of the 
system usually has lower water content than the surrounding medium and the concentration 
difference will be the driving force for drug diffusion out of any of these systems (Collett and 
Moreton 2002). 
Among the many monolithic dosage forms that can be used for sustained drug-release, 
matrix tablets are of major interest in the pharmaceutical industry because of their highly 
efficient manufacturing technology. 
 
 
1.2.3.1 Reservoir systems 
Reservoir delivery systems, also called membrane-controlled systems, are constituted 
by a core of drug, the reservoir, surrounded by a polymeric membrane, usually water-insoluble 
(Figure 1.3). This membrane, through which the drug must diffuse, is the rate-controlling 
element of the system. The nature of the chosen polymer that forms the membrane determines 
the diffusion of drug and, hence, the rate of drug-release from the system (Collett and Moreton 
2002; Jantzen and Robinson 2002). When a dissolution medium diffuses into the reservoir 
system, the membrane hydrates and becomes permeable. After hydration of the membrane, 
dissolution of drug at the interface core-membrane initiates drug diffusion and release. The 
drug diffuses then through the membrane down its concentration gradient, and is subsequently 
released at the interface membrane-external medium (Heller 1987). Unlike hydrophilic matrix 
systems, which will be discussed subsequently in this section, the membrane polymer does not 
usually swell and erode on hydration (Collett and Moreton 2002). However, SR systems with 
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erodible rate-controlling membranes have also been described (Heller 1987). An initial 
loading dose can be achieved by formulating the system with a determined fraction of the dose 
in the membrane (Collett and Moreton 2002). 
 
 
 
 
Figure 1.3 Diffusion of drug across the polymeric membrane of a reservoir system and across 
an inert matrix system. 
 
 
The drug-release rate at time t from reservoir systems with a non-erodible membrane, 
dMt/dt, can be described by the following equation (Jantzen and Robinson 2002): 
 
€ 
dMt
dt =
A.D.K.ΔC
d        Equation 1 
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where Mt is the mass of drug released after time t, A the surface area of the device (effective 
area of diffusion), D the diffusion coefficient of the drug in the membrane in units of 
area/time, K is the partition coefficient (the ratio of drug concentration in the membrane to that 
in the bathing medium at equilibrium), ∆C is the concentration difference across the 
membrane, and d the thickness of the diffusion layer (the diffusional path length). 
 
In theory, these systems should offer the possibility of zero-order delivery. However, 
zero-order release rate can be feasible only if all the variables on the right side of the equation 
remain constant. Consequently, these systems often fail to release drug at a constant rate, since 
it is particularly difficult to maintain all these parameters constant. However, it is possible to 
modulate the kinetics of release from these systems by changing one or more of these 
parameters, in particular, by changing the characteristics of the polymeric membrane, like its 
nature and/or its thickness. These modifications allow, ideally, the adjustment of the kinetics 
of release in order to improve the therapeutic efficacy of the drug (Jantzen and Robinson 
2002). 
Reservoir systems have some disadvantages inherent to their own structure. For 
example, unless the polymer used is soluble, the system must somehow be removed from the 
body after the drug has been released. Another critical aspect to consider is the fact that, 
usually, the reservoir contains a large amount of drug. Therefore, any error in production or 
any accidental damage to the dosage form, like a membrane rupture, which would directly 
expose the reservoir core, could expose the patient to a potentially toxic dose of drug. This 
issue becomes especially important when designing reservoir systems for drugs with narrow 
therapeutic ranges or high toxicity (Jantzen and Robinson 2002). 
Although, for convenience of description the reservoir systems were included as part 
of the monolithic dosage forms for SR, some multiple-unit reservoir systems have been 
developed where the coated drug reservoir is, in this case, a multiparticulate pellet instead of a 
tablet (Collett and Moreton 2002). 
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1.2.3.2 Matrix systems 
A matrix system consists of drug dispersed or dissolved homogenously throughout a 
polymer matrix. This matrix is resistant to its immediate disintegration and controls the release 
of drug. Therefore, whereas in the case of a reservoir system the polymeric membrane that 
controls the release of drug is only at the surface of the system, in a matrix system the rate-
controlling polymer is throughout the whole system. In both cases, it is the hydration of the 
polymer and the consequent dissolution of the drug that allow the drug to diffuse out of the 
system (Collett and Moreton 2002). 
Compared with the reservoir systems, the matrix systems present several advantages, 
which are the reason why they are the most employed systems in the control of drug-release. 
Some of the main advantages are the following (Jantzen and Robinson 2002):  
1. Since the total drug constituent is dispersed in a continuous and unique matrix, the risk 
of dose dumping is less likely to occur and, hence, these systems offer a higher safety 
level.  
2. Matrix systems are much easier and cheaper to produce, usually by direct compression.  
 
Like the reservoir systems, unless the polymer used is soluble, the remaining matrix 
‘ghost’ must be removed from the body.  
 
The classification of the different types of matrix systems (Figure 1.4) usually takes 
into account several criteria, such as the structure of the matrix, the release kinetics, the 
mechanisms controlling drug-release, and the chemical nature and properties of the materials 
forming the matrix (Buri 1987). Drug diffusion, erosion and/or swelling of matrix are the main 
mechanisms by which this type of systems can control the release of drug. The predominance 
of one mechanism over the other will depend on the properties of the polymer used to produce 
the system. 
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Figure 1.4 Drug-release in function of the type of matrix system. The blue represents the 
initial size of the matrix with drug; the yellow represents the region of the polymeric matrix 
with the remaining drug; the gray represents the swollen matrix; and the arrows represent the 
diffusing drug. 
 
 
Erodible polymer matrices 
A method used to decrease the release rate of a drug with high water-solubility and, 
therefore, fast dissolution rate is to incorporating it into a matrix tablet whose main excipient 
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will erode slowly when in contact with the fluids of the gastrointestinal tract. In this case, the 
rate of drug diffusion in the polymer is slow compared to the polymer dissolution 
(Katzhendler, Hoffman et al. 1997) and, therefore, dissolution of the polymer is the rate-
limiting step. In actual fact, therapeutic systems are never dependent on dissolution only or 
diffusion only. However, in practice, SR systems have been classified as either dissolution-
controlled or diffusion-controlled when the predominant release mechanism overshadows 
other mechanisms (Jantzen and Robinson 2002). 
In SR matrix tablets employing dissolution as the rate-limiting step, drug-release is 
controlled by the gradual dissolution (bioerosion) of the polymeric matrix containing the drug 
or by hydrolysis or enzymatic reaction of a bond that attaches the drug directly to the polymer 
(Ranade 1991; Jantzen and Robinson 2002). Moreover, two different modes of erosion have 
been described: surface (heterogeneous) and bulk (homogeneous) erosion. In bulk-eroding 
systems, erosion occurs homogeneously throughout the bulk of the system. In surface-eroding 
systems, on the other hand, erosion is confined to the outer surface of the system (Heller, 
Baker et al. 1978; Heller 1980). The rate of drug-release from a surface-eroding system is 
determined by the relative contribution of the drug diffusion and the erosion of the matrix 
(Katzhendler, Hoffman et al. 1997). 
The mathematical description of the release characteristics from erodible systems is 
complex. One of the difficulties relates to the fact that erodible systems combine dissolution of 
both the polymeric matrix and the drug, and diffusion of drug out of the system after 
dissolution. As the polymer dissolves, the diffusional path length for the drug may change. 
Zero-order release can occur only if surface erosion occurs and surface area does not change 
with time (Jantzen and Robinson 2002). In addition, in the case of a drug compressed with a 
slowly dissolving polymer into a matrix tablet, the rate of drug delivery is controlled by the 
rate of penetration of the dissolution medium into the matrix, which can be, in turn, controlled 
by the porosity of the tablet matrix, the eventual presence of hydrophobic additives, the 
wettability of the tablet and the particle surface (Heller 1987). Nevertheless, a model was 
developed to describe drug-release from matrices of various geometries showing only surface 
erosion and for which the erosion process is the rate-limiting step (Katzhendler, Hoffman et al. 
1997): 
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where Mt is the amount of drug released from the system at time t, M∞ is the total amount of 
drug released when the system is exhausted, and k0 is the erosion rate constant. C0 is the 
uniform initial concentration of drug in the matrix, and a0 is the initial radius for a sphere or 
cylinder or the half-thickness for a slab (geometry of a tablet). The exponent n depends on the 
geometry of the system with n = 1 for a slab, n = 2 for a cylinder, and n = 3 for a sphere.  
 
A major advantage of these systems compared with non-erodible matrices is that, as 
the matrix erodes entirely, the problem related to the removal of the dosage form from the 
body does not apply in this case. However, a particular attention must be given to the 
degradation products, as it is essential that they are not toxic, carcinogenic nor teratogenic. 
 
 
Inert matrix systems 
Inert matrix systems, also called insoluble matrices, are constituted of drug particles 
dissolved or dispersed in a matrix constituted mainly of a polymer insoluble in the 
gastrointestinal fluids (Figure 1.3). When an aqueous medium penetrates the insoluble matrix, 
its structure remains unaffected. The release takes place by simple diffusion of dissolved drug 
from the system along the network of fluid-filled pores, cracks and intergranular spaces of the 
system (Higuchi 1963; Collett and Moreton 2002).  
The release rate of a drug from an inert matrix will be mainly dependent on the 
structure of the matrix, in particular, its total porosity and its tortuosity, i.e., its pore structure, 
but also on the properties of the drug such as its solubility. 
 
The amount of drug released from an inert system with connecting capillaries can be 
determined by the following equation proposed by Huguchi (Higuchi 1963): 
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where M is the amount of drug released at time t per unit exposed area, D is the coefficient of 
diffusion of the drug in the permeating fluid, τ is the tortuosity factor of the capillary system, 
A is the total amount of drug present in the matrix per unit volume, CS is the solubility of the 
drug in the permeating fluid, and ε is the porosity of the matrix. 
 
If the release is ruled only by pure diffusion, the quantity of drug released from matrix 
dosage forms is usually directly proportional (linear correlation) to the square root of time of 
exposure to the dissolution medium (Collett and Moreton 2002), as given by the equation: 
 
€ 
Mt = k.t1/ 2        Equation 4 
 
where Mt is the amount of drug released at time t, and k is the kinetics constant.  
 
A zero-order release is not possible with this type of matrices, as the rate of drug-
release decreases with time of exposure to the dissolution medium. Initially, the diffusion 
pathway that the drug molecules at the surface of the matrix have to traverse is very short. As 
the dissolution process progresses towards the interior of the matrix, the depletion area 
increases and, as a result, the diffusion pathway increases in length. In addition, the area of 
drug exposed to dissolution medium decreases. 
Most of the factors that affect the release of drug from an inert matrix are, somehow, 
related to the capacity of the dissolution medium to penetrate the matrix. The main factors are 
the following (Buri and Doelker 1997; Sajeev and Saha 2001; Collett and Moreton 2002): 
1. The compression force (CF) - an increase of the CF is normally correlated with a decrease 
of the porosity of the matrix. A more rigid and less porous matrix will, generally, release 
drug more slowly than a more porous matrix. 
2. The particle size of the insoluble matrix components – smaller particles usually lead to a 
less porous and more tortuous matrix and, thus, a decreased release rate. 
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3. The concentration of the inert matrix components - when the concentration is high, the 
total porosity (addition of the initial porosity to the porosity created by the dissolution of 
the drug) decreases, which results in a decrease of the release rate. The initial porosity is 
an important factor that can have an influence in the penetration of the dissolution medium 
and, consequently, in the dissolution of the drug in the matrix. 
4. Drug loading - an increase in drug loading tends to augment the release rate, but the 
relationship between the two is not clearly defined (Collett and Moreton 2002), although 
release rate is, normally, related to drug solubility. 
5. The affinity of the inert support for the dissolution medium - the more wettable the inert 
polymer used is, the higher will be the penetration rate of the medium and the higher will 
be the release rate. 
6. The nature of the other excipients in the formulation - usually, water-soluble excipients 
will enhance the release rate as a result of an increase in the wettability of the matrix and 
in its porosity after the dissolution of the excipient. Insoluble substances, on the other 
hand, will tend to decrease the penetration of the dissolution medium and, thus, the release 
rate (Collett and Moreton 2002).  
 
This type of system is not suitable for the release of drugs that are insoluble or that 
have a low aqueous solubility, given that this a totally diffusional system and that the use of 
this type of drugs will result in a weak driving force of diffusion generated by a too low 
concentration of dissolved drug. If the quantity of water that can penetrate the matrix is not 
enough to solubilise the entire amount of drug, the total dose will not be available (Li, 
Robinson et al. 1987; Collett and Moreton 2002). 
 
 
Lipophilic matrix systems 
Like the inert matrices, the lipophilic matrix systems contain drug particles dispersed 
in an insoluble matrix, with drug becoming available as an aqueous medium penetrates the 
matrix and dissolves the particles. These systems are compact wax matrices prepared from 
blends of powdered components using standard direct compression, roller compaction or hot-
  
26 
melt granulation. After entering the matrix, the medium dissolves a channelling agent, which 
was added to the formulation. The dissolved channelling agent leaches out of the system, 
leading to the formation of a porous matrix of tortuous capillaries. The drug dissolves in the 
aqueous medium and diffuses out of the matrix through the water-filled capillaries. The 
hydrophobic matrix remains intact during drug-release. 
The main advantage of this type of system is related to their easy manufacturing with 
no need of a lubricant as the waxes act themselves as a liquid-film lubricant during 
compression. Nevertheless, they offer a rather coarse control of rate and extent of drug-release 
(Collett and Moreton 2002). 
 
 
Hydrophilic matrix systems 
In recent years the value of hydrophilic polymer-based matrix tablets as vehicles for 
SR delivery has been increasingly demonstrated with the publication of numerous patents and 
research papers and their utilization in new products in the pharmaceutical market. The 
widespread and successful use of such polymeric systems can be attributed to the fact that they 
are simple to formulate, relatively inexpensive, easy to produce and generally regarded as safe, 
they have shown favourable in vivo performance with a more precise control of drug delivery 
in the fluids of the gastrointestinal tract, resulting in reproducible profiles and better IVIVC, 
they are versatile in controlling the release of drugs with a wide range of physicochemical 
properties, and they have superior patient acceptability (Collett and Moreton 2002; Durig and 
Fassihi 2002).  
The hydrophilic matrix systems are monolithic systems prepared by compression of a 
powdered mixture of a hydrophilic polymer (swelling agent), one or several drugs, and other 
excipients, if necessary. Those matrices can be also denominated swellable matrix systems.  
As opposed to the inert matrices, the structure of a hydrophilic matrix responds to the presence 
of water or biological fluids, which change the polymer structure with the time of exposure to 
the aqueous medium, enabling the drug to be released from a dosage form. 
Since the dosage forms developed in the work of this dissertation are hydrophilic 
matrix systems, these will be discussed in more detail in a following section. 
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1.2.3.3 Osmotic pumps 
Although osmotic pump systems are described in the present work as a distinct type 
from reservoir systems, osmotic pumps are, in a sense, another form of reservoir delivery 
systems. The essential difference between the two types of systems is that in the case of 
osmotic pumps only one diffusion process is required, which is the passage of aqueous 
medium into the core through the membrane, whereas in the classic reservoir system two 
processes are involved: the diffusion of aqueous medium into the system and the diffusion of 
drug out of the system. Therefore, in the case of osmotic pumps the diffusing species is only 
water. 
The elementary osmotic pump (Figure 1.5) consists of a tablet containing a solid core 
of drug and an agent that is soluble enough to provide the high osmotic pressure difference, 
such as an electrolyte, surrounded by a semipermeable membrane. The membrane is 
permeable to water but not to drug, and has single or multiple holes drilled through it to allow 
drug-release. When this device is exposed to water or any body fluid, water will flow into the 
core owing to the osmotic pressure difference, and will dissolve it. As the core dissolves, a 
hydrostatic pressure builds up and pumps drug solution (or suspension) out of the system 
through the hole (Collett and Moreton 2002; Jantzen and Robinson 2002). 
 
 
Figure 1.5 Elementary osmotic pump with a solid osmotic core, a semipermeable membrane 
and, in this example, a single hole drilled through the membrane. Figure reproduced from 
(Simó, Cifuentes et al. 2003) with permission of  Elsevier Ltd. 
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Other types of osmotic pumps have been described as, for instance, a system consisting 
of a drug layer containing the drug and excipients and a push layer containing osmotically 
active components (Figure 1.6). This osmotically active bilayer core is enclosed in a 
semipermeable tablet shell membrane that is permeable to water but not the drug or osmotic 
components. As water is absorbed from the gastrointestinal tract at a rate determined by 
membrane properties and the osmolality of the core constituents, the push layer expands and 
presses on the drug layer, slowly releasing drug solution/suspension through a laser-drilled 
orifice in the tablet shell (Palangio, Northfelt et al. 2002).  
 
 
Figure 1.6 Osmotic pump consisting of an osmotically active bilayer core enclosed in a 
semipermeable tablet shell membrane, which is permeable to water, but not the drug or 
osmotic components, and has a laser-drilled orifice on the drug-layer side of the tablet. The 
bilayer core is comprised of a drug layer and a push layer. Figure reproduced from (Palangio, 
Northfelt et al. 2002) with permission of  Elsevier Ltd. 
 
 
Another important factor governing the drug-release rate from osmotic systems, 
besides the rate at which water is able to pass in through the membrane, is how quickly the 
drug solution/suspension can pass through the hole. Therefore, and the size of the hole(s) is 
critical (Collett and Moreton 2002). 
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The release of drug from these systems is in theory not dependent on the drug (Bayne, 
Place et al. 1982 ) and, therefore, they are suitable for a wide range of drugs, which are 
normally difficult to deliver by the solution-diffusion mechanism, such as poorly water-
soluble drugs. Since the osmotic gradient remains constant, osmotic pumps can give a 
theoretically zero-order release profile after an initial lag time, which then gradually falls to 
zero (Collett and Moreton 2002; Palangio, Northfelt et al. 2002). With systems such as the 
osmotic pump, dissolution rate may be rendered independent of gastrointestinal variables, 
such as pH and viscosity (Gupta and Robinson 1992). However, these systems can lead to 
dose dumping if there are any defects in the coating membrane. Besides, they are relatively 
expensive and require rigorous quality control (Collett and Moreton 2002). 
 
 
1.2.3.4 Ion exchange systems 
Ion exchange systems consist of resins composed of water-insoluble cross-linked 
polymers. These polymers contain salt-forming functional groups in repeating positions on the 
polymer chain. The drug is bound to the resin and released by exchanging with the ions in the 
gastrointestinal tract, when these are in contact with the ion-exchange groups. The rate of drug 
diffusing out of the resin is controlled by the area of diffusion, diffusional path length, and the 
rigidity of the resin, which is a function of the amount of cross-linking agent used to prepare 
the resin. These systems offer protection of the drug to the enzymes in the gastrointestinal tract 
by temporarily altering the substrate. However, the release of drug is proportional to the 
concentration of ions present in the area where the drug is ought to be released, which is affect 
by variability in diet, water intake, and intestinal content (Jantzen and Robinson 2002). 
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1.2.4 The special case of hydrophilic matrix systems 
Hydrophilic matrix systems are monolithic dosage forms prepared by compression and 
constituted by a homogenous dispersion of drug molecules within a frame in which one or 
several of the excipients incorporated are a hydrophilic polymer. Some examples of these 
polymers will be given in section 1.2.5.1. These systems are currently the preferred strategy 
for producing sustained release solid oral dosage forms (Melia 1991; Mikac, Kristl et al. 
2011). 
The most important factors to be taken into account when developing a formulation 
based on hydrophilic matrices are the percentage, solubility and drug particle size, the type of 
polymer, the percentage incorporated, its degree of viscosity and the polymer particle size, the 
drug/polymer ratio and the amount of water entering the matrix. The CF used to produce the 
matrices can be important because it determines matrix porosity. Other factors have shown to 
be involved in the release of drugs, such as the dimensions of the matrix and, in the case of 
mixtures of polymers, their percentages (Maderuelo, Zarzuelo et al. 2011). 
 
 
1.2.4.1 Drug-release mechanisms from hydrophilic matrix systems 
The most important aspect of the release mechanisms from matrix systems constituted 
by hydrophilic polymers is the formation of a gel layer around the matrix, owing to a change 
of state of the polymer in response to water penetration (Figure 1.7). When a matrix 
containing a swellable glassy polymer comes into contact with an aqueous medium, such as 
the gastrointestinal fluids, there is an abrupt change of state, which corresponds to a transition 
from the glassy, a rigid and compact state, to the rubbery state, an expanded and flexible state. 
The individual polymer chains absorb water and the molecules of water insert themselves 
between the polymeric chains. The presence of water reduces the glass transition temperature 
Tg of the polymer (which is controlled by the concentration and the type of swelling agent, and 
depends on the temperature and the thermodynamic interactions of the polymer-water system) 
to the system temperature T (Colombo, Bettini et al. 2000; Mikac, Kristl et al. 2011). This 
process induces a reduction of the polymer-polymer intermolecular attraction forces and, 
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consequently, an increase in the distance between the chains and in their mobility, i.e., a 
polymer-chain relaxation. The higher chain mobility favours the transport of dissolved drug 
and permits chain reorganization in the form a three-dimensional gel. Therefore, as a result of 
the glassy-rubbery polymer transition, an outer gel layer forms on the matrix surface and the 
matrix increases in volume because of swelling. The gel layer acts as a barrier against the fast 
release of drug while controlling, at the same time, the penetration of aqueous medium and the 
diffusion of drug.  
The formation and the characteristics of the gel layer are crucial parameters regarding 
the control of drug-release from gel-forming matrices. If the polymer gels slowly, the 
dissolution medium can penetrate deep and quick into the glassy matrix and disintegrate the 
matrix before gel layer formation occurs. Therefore, it is essential that the polymer used in the 
manufacture of these matrices is able to form the gel layer quickly and that the 'protective' 
layer maintains its stability during the release process (Colombo, Bettini et al. 2000).  
Initially, when the aqueous medium penetrates into the matrix through its pores, the 
drug present on the surface of the matrix is released quickly while the polymeric chains 
rearrange to form the viscous gel layer surrounding the dry core of the tablet. Here, the 
polymer chains are strongly entangled and the gel layer is highly resistant. The penetration of 
water continues then towards the centre of the matrix, but it is now slowed down by the 
progressively forming gel barrier. The formation of this gel layer also leads to a progressive 
reduction of the release rate of dissolved drug due to an increase of the diffusion path length 
(Chien 1982). To certain polymers, as the gel layer becomes progressively hydrated, the 
quantity of absorbed water can be such that the interactions water-polymer can become 
superior to the interactions polymer-polymer. When sufficient water has accumulated, the 
chains disentangle and the polymer dissolves (Lee and Peppas 1987; Narasimhan and Peppas 
1997). This causes the appearance of progressive erosion on the surface of the matrix.  
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Figure 1.7 Schematic representation of drug-release from hydrophilic polymer matrix tablets. 
 
 
The mechanical behaviour of the swelling process, which is a result of the relaxation of 
polymeric chains, is characterized by the presence of different fronts, where ‘front’ indicates 
the position in the matrix where the physical conditions change abruptly (Figure 1.8) 
(Colombo, Bettini et al. 1995). 
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Figure 1.8 Fronts in the swelling process (swelling, diffusion and erosion) of hydrophilic 
matrices during drug-release. The behaviour of the gel layer was studied using a colorimetric 
technique. HPMC matrices containing soluble and coloured buflomedil pyridoxal phosphate 
were prepared by wet granulation. Swelling studies were performed by clamping each matrix 
between two transparent Plexiglas® disks and the assembled device was introduced into the 
vessel of a USP 23 apparatus 2 containing distilled water (37ºC, 200 rpm). At fixed times 
during swelling, the device was taken out of the vessel and pictures of the disc matrix base 
were video-recorded. The front distance was then measured in pixels and these were converted 
into length units. Figure adapted from (Colombo, Bettini et al. 1999) with permission of 
Elsevier Ltd. 
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From the periphery to the centre of the matrix, the first observed front is the ‘erosion 
front’, which corresponds to the boundary between the surface of the matrix and the 
dissolution medium. It is in this region of the matrix, where the maximum separation and 
solubilisation of chains occur, that the drug is released. A second front, the ‘diffusion front’ 
has been identified (Lee and Kim 1991). This front constitutes an interface that separates 
undissolved from dissolved drug. During drug-release, the diffusion front position in the gel 
phase is dependent on drug solubility and loading and its movement related to drug dissolution 
rate in the gel (Colombo, Bettini et al. 1995). The diffusion front is located between the 
erosion front and the boundary where the glassy polymer transforms into the rubbery polymer, 
called the ‘swelling front’. Some authors described a forth front, referred to as the ‘penetration 
front’, which separates the dry glassy polymer from the hydrated glassy polymer, that is, the 
position of the penetration of the medium into the dry glassy polymer (Brazel and Peppas 
2000; Colombo, Santi et al. 2000; Ferrero, Bruneau et al. 2000). The positions of the different 
fronts within the gel are related to three important parameters of the swelling/dissolution 
process: the rate of water penetration, the rate of drug dissolution and the rate of erosion of the 
polymeric matrix (Colombo, Bettini et al. 1995). 
Besides being exposed to continuous changes in its structure, the gel layer is also 
subject to changes in its thickness. The gel layer thickness as a function of time (Figure 1.9) is 
described as the distance between the relative position of the swelling and erosion moving 
fronts (Colombo, Bettini et al. 2000). In addition, the gel layer thickness dynamics exhibits, 
generally, three different phases during drug delivery. Initially, the thickness increases when 
solvent penetration is the fastest mechanism. Then, it remains constant when the water 
penetration and the disentanglement occur at a similar rate, leading to synchronization 
between the phenomena of swelling and erosion of the polymeric chains. Finally, the gel layer 
thickness decreases when the entire polymer has undergone the glassy-rubbery transition and 
the only process still active is the erosion (disintegration) of the polymer network (Lee and 
Peppas 1987). 
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Figure 1.9 Gel layer thickness as a function of time for HPMC matrices containing different 
percentages of buflomedil pyridoxal phosphate, using the same conditions of Figure 1.8. 
Figure reproduced from (Colombo, Bettini et al. 1999) with permission of Elsevier Ltd. 
 
 
Drug-release depends on the dynamics of gel layer thickness in the sense that an 
increase of thickness is inversely related to the release rate, owing to the increase of the 
diffusion path length. 
A dissolved drug gel layer thickness, which corresponds to the distance between 
diffusion and erosion fronts, has also been described. It was shown that, though the kinetics of 
drug-release depends on the relative position of the three fronts, this section of the gel is the 
reference element for drug-release, instead of the whole gel layer thickness (Colombo, Santi et 
al. 2000). 
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Several authors have proposed different analytical techniques, such as Calorimetry, 
Light Microscopy and Nuclear Magnetic Resonance (NMR), to characterize the matrix 
swelling process and the effects involved in drug-release (Gladden 1994; Gao, Skoug et al. 
1996; Colombo, Bettini et al. 1999; Baille, Malveau et al. 2002; Richardson, Bowtell et al. 
2005; Thérien-Aubin, Baille et al. 2005; Mikac, Kristl et al. 2011; Wang, Assaad et al. 2011). 
In summary, the drug-release mechanisms and kinetics from hydrophilic matrices 
depend on phenomena that govern gel layer formation and dynamics, that is, solvent 
penetration into the matrix, polymer hydration and swelling (relaxation process), drug 
dissolution and diffusion through the gel layer, and matrix erosion. The control of drug-release 
is obtained by diffusion of molecules through the gel layer that can erode. The rate of drug 
diffusion depends on drug dissolution and matrix erosion, both affecting the drug 
concentration gradient in the gel layer (Colombo, Santi et al. 2000). A convective contribution 
to drug transport in the gel layer due to the relaxation of polymer chains was also described 
(Colombo, Bettini et al. 1999).  
 
 
1.2.4.2 Mathematical analysis of drug-release from hydrophilic matrix systems 
Even though the control of drug-release is usually mainly obtained by drug diffusion, 
the release kinetics do not necessarily follow the square root of the time as in the case of inert 
matrices, where the release is exclusively controlled by pure diffusion. A large spectrum of 
mathematical models describing drug-release from the hydrophilic matrix tablets has been 
developed. These models try to include many parameters that affect drug-release and kinetics, 
such as the thickness of the gel layer and the position of the different fronts (Colombo, Bettini 
et al. 1999; Kazarian and van der Weerd 2008), the presence of different excipients (Pillay and 
Fassihi 2000; Baumgartner, Pavli et al. 2008), the properties of the selected polymer and drug 
(Talukdar, Michoel et al. 1996; Saša, Odon et al. 2006; Ferrero, Massuelle et al. 2010), the 
polymer concentration across the gel, the mesh size of the polymeric network (Baumgartner, 
Kristl et al. 2002), and so on. However, in many cases, the use of a simple empirical or semi-
empirical model is sufficient (Siepmann and Peppas 2001).  
 
  
37 
A semi-empirical equation, proposed by Peppas et al. (Peppas 1985) has been 
extensively used to describe drug-release from these systems: 
 
€ 
Mt
M∞
= k.t n         Equation 5 
 
Where Mt and M∞ are the absolute cumulative amount of drug released at time t and infinite 
time, Mt/M∞ is the fraction of drug released, k is a constant incorporating structural and 
geometric characteristics of the device (with units of T-n), t is the release time, and n is the 
release exponent, indicative of the mechanism of drug-release. The values of n can vary 
between 0.43 and 1.00, according to the geometry of the delivery system and the prevalence of 
diffusion (Fickian transport) or erosion (Case-II transport). Table 1.1 resumes the different n 
values for three distinct geometric forms and the associated types of drug-release mechanism.  
 
Table 1.1 Diffusional exponent for drug-release (n) and associated drug-release mechanism 
from polymeric sustained delivery systems. Table reproduced from (Peppas and Sahlin 1989) 
with permission of Elsevier Ltd. 
Diffusional exponent (n) Drug-release mechanism 
Film Cylinder Sphere  
0.5 0.45 0.43 Fickian diffusion 
0.5<n<1.00 0.45<n<0.89 0.43<n<0.85 Anomalous transport 
1.0 0.89 0.85 Case-II transport 
 
Fickian diffusional release corresponds to the molecular diffusion of drug through the 
hydrated outer gel layer due to a concentration gradient, which was described previously, and 
Case-II relaxational release is the drug transport mechanism associated with the 
relaxation/erosion of the polymer as a result of state-transition and swelling upon contact with 
water or biological fluids. The anomalous transport corresponds to the superposition of both 
phenomena, i.e., Fickian diffusion and Case-II transport.  
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However, drug-release from swellable water-soluble polymer systems is typically 
described as an addition of these two simultaneously operating mechanisms. Therefore, a 
model that can identify the contributions of both phenomena to overall kinetics is preferable 
when analysing drug-release from hydrophilic/swellable matrices. Indeed, another empirical 
equation that considers both Fickian diffusional release and relaxation/erosion as additive was 
proposed (Peppas and Sahlin 1989): 
 
€ 
Mt
M∞
= k1.tm + k2 .t 2m        Equation 6 
 
where k1 is the Fickian kinetic constant and k2 is the relaxation/erosion kinetic constant (with 
units of T-n), and the first term of the right hand side represents the Fickian diffusional 
contribution (F), whereas the second term represents the Case-II relaxational contribution (R). 
The coefficient m is the purely Fickian diffusion exponent for a system of any geometrical 
shape which exhibits sustained drug-release. Regardless of the geometry of the system used, 
the value of the exponent for Case-II transport mechanism is twice that of pure Fickian 
diffusional mechanism. 
Both Eqns. 5 and 6 can be used to analyze the first 60% of a release curve, regardless 
of the geometric shape (Peppas 1985; Peppas and Sahlin 1989). 
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The exponent m can be determined by interpolation using a diagram also proposed by 
Peppas et al. (Peppas and Sahlin 1989), shown in Figure 1.10, which represents the values of 
m in function of the Aspect Ratio, 2a/l (where 2a is the diameter and l is the thickness of the 
tablet). 
Figure 1.10 Variation of the Fickian diffusional exponent, m, with the aspect ratio, 2a/l, where 
2a is the diameter and l is the thickness (height) of the device. Figure reproduced from 
(Peppas and Sahlin 1989) with permission of Elsevier Ltd. 
 
Equation 6 can be written as (Peppas and Sahlin 1989): 
 
€ 
Mt
M∞
= k1.tm 1+
k2
k1
.tm
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥        Equation 7 
 
By comparison of Eqns. 6 and 7, it is concluded that m = n when F is much superior to R. The 
percentage of drug released due to the Fickian mechanism, F, is, in that case, calculated as: 
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€ 
F = 1+ k2k1
.tm
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ 
−1
       Equation 8 
 
which leads to the ratio of the relaxational over Fickian contribution as follows: 
 
€ 
R
F =
k2 .tm
k1
        Equation 9 
 
 
1.2.5 Excipients used in hydrophilic matrix systems 
1.2.5.1 Polymers for sustained drug-release systems 
The use of polymers for biomedical applications, especially in the pharmaceutical 
field, has been widespread for many years. These materials constitute the most important 
category of excipients employed in SR. They possess a large range of properties required for a 
precise control of drug-release and are easily adaptable to the usual manufacturing techniques 
of matrix tablets.  
For a polymer to be effective in a pharmaceutical dosage form several of its properties 
must be taken into consideration. These properties include the solubility of the polymer in the 
biological fluids, the porosity, permeability, crystallinity and swellability of the polymer 
structure, its surface characteristics, its toxicity, and the diffusivity of drug molecules through 
the polymer material. 
Among the polymers used in pharmaceutical applications, polysaccharides, like starch 
and cellulose, and their derivatives, are especially interesting for the production of hydrophilic 
matrices for oral SR dosage forms. Polysaccharides are abundant and inexpensive natural 
biomaterials, and are biocompatible and biodegradable. If the uses of these materials in the 
native state are varied, the possibility to produce derivatives has multiplied the possibilities. 
These modifications are made in order to obtain new properties or improve the initial 
properties of these polysaccharides. Unlike the expensive systems based on synthetic 
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polymers, these semi-synthetic compounds have the advantage of being a base material easily 
obtainable. These advantages have made polysaccharides and their derivatives the materials of 
choice for the control of drug-release from matrix systems (Melia 1991). 
Numerous polysaccharides have been studied in the development of hydrophilic matrix 
tablets. The studied polysaccharides include natural gums and materials, such as xanthan 
(Talukdar and Plaizier-Vercammen 1993; Talukdar, Michoel et al. 1996; Varshosaz, Tavakoli 
et al. 2006) guar (Khullar, Khar et al. 1998; Durig and Fassihi 2002; Varshosaz, Tavakoli et al. 
2006) karaya, carrageenan (Raghavendra Rao, Sagar et al. 2009), dextran (Hennink, De Jong 
et al. 2004), sodium alginate (Giunchedi, Gavini et al. 2000 ), chitosan (Tu, Shen et al. 2011), 
and tamarind seeds (Sumathi and Ray 2002). However, cellulose and starch derivatives are the 
most commonly used compounds. Starch and its derivatives will be introduced in the next 
section, since the polymer used to produce the matrix tablets of the research of the present 
thesis was a modified starch. 
The use of cellulose, an abundant naturally occurring biopolymer, and its derivatives as 
a binder or as agent for the MR of drugs has been well documented (Alderman 1984; Blaschek 
1990; Doelker 1990; Doelker 1993; Kamel 2008). Typical modifications of cellulose are 
esterification and etherification of its hydroxyl groups. Most water-soluble and organic 
solvent-soluble cellulose derivatives are prepared by these substitution reactions, which can 
lead to radical changes in the original properties of cellulose (Kamel 2008). Some chemically 
modified cellulose derivatives, including water-soluble cellulose ether derivatives, 
specifically, sodium carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), 
hydroxyethyl cellulose (HEC) and hydroxypropyl methylcellulose (HPMC), have been used in 
solid SR formulations because of their swelling and gel forming capacity when in contact with 
an aqueous medium (Nakano, Ohmori et al. 1983; Rencher, Babu et al. 1995; Dabbagh, Ford 
et al. 1999). In fact, among a large number of natural and synthetic polymers that were tested 
as hydrophilic excipients for the preparation of SR matrix tablets, HPMC has been the most 
extensively studied. This significant use is due to the fast formation of a gel layer on the 
surface of HPMC matrices, which controls initial release, and to the high swellability and 
strong viscosity of the formed gel, which has a significant effect on the release kinetics of an 
incorporated drug. Besides, HPMC is compatible with numerous drugs. However, the gels 
formed show a continued expansion accompanied by erosion, which makes the transport 
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mechanism relatively complex. Drug-release from HPMC matrices follows the mechanisms 
already described for hydrophilic matrices, i.e., drug diffusion through the swelling gel layer 
and release by diffusion out of the system, and matrix erosion of the swollen layer (Siepmann 
and Peppas 2001). 
 
 
1.2.5.2 Other excipients in the formulation of matrix tablets 
In the formulation of matrix tablets it is usually necessary to add excipients that 
improve the flow and compressibility properties of the powdered mixture formed by the drug 
and the polymer. The usual excipients used in solid dosage forms are listed in the Table 1.2. 
 
Table 1.2 Examples of substances used as excipients in tablet formulation (Alderborn 2002; 
Kottke and Rudnic 2002).  
Diluents (or fillers) Surfactants 
Binders Antiadherents 
Disintegrants Antioxidants 
Lubricants Preservatives 
Glidants  Colorants 
Sorbents Flavouring agents 
 
 
The behaviour of the hydrophilic polymer in the presence of these substances in the 
formulation is important because the physicochemical characteristics of the co-excipients may 
alter the release mechanisms of the drug and the release rate from the matrix. For instance, an 
increase in the amount of diluents in matrix formulations generally involves an increase in the 
drug-release rate (Lotfipour, Nokhodchi et al. 2004). This increase in the release rate has been 
demonstrated in the case of matrices formulated with CarbopolTM as the retardant agent, 
ibuprofen and three diluents, i.e., lactose, microcrystalline cellulose and starch (each diluent 
was tested separately) (Khan and Jiabi 1998; Majid Khan and Zhu 1999). Studies on the 
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influence of the presence of magnesium stearate, a well-known lubricant, in the formulation of 
hydrophilic matrices on the drug-release profiles have been contradictory (Lee, Ryu et al. 
1999; Rekhi, Nellore et al. 1999).  
The inclusion of various additives, ranging from sugars to salts and other polymers, in 
SR matrix systems can be employed to affect matrix swelling, erosion and/or solubility of the 
drug and, thus, to modulate release kinetics. Examples of this strategy include the use of 
soluble diluents such as lactose to serve as erosion promoters in combination with swelling 
matrix formers such as HPMC (Gao, Skoug et al. 1996).  
The incorporation of certain excipients within the formulation so as to improve the 
solubility of a weak acid or a weak base drug is one of the main approaches that have been 
used to obtain pH-independent release (Internal addition) (Bassi and Kaur 2010). These pH 
modifiers alter the pH in the microenvironment, i.e., the pH of the saturated solution in the 
immediate vicinity surrounding drug particles (Siepe, Lueckel et al. 2006; Tran, Tran et al. 
2008), and thus bring the pH inside the formulation to a value where drug solubility is higher. 
This increases the drug dissolution and release irrespective of the pH of the external 
dissolution medium. Examples of these excipients are organic acids such as adipic, fumaric, 
tartaric and succinic acid, which can be used to increase the solubility of weak bases by 
decreasing the pH of the microenvironment (Gabr 1992; Siepe, Lueckel et al. 2008), and basic 
excipients such as dicalcium phosphate (DCP), magnesium oxide (MgO) and magnesium 
hydroxide (Mg(OH)2), used to increase the solubility of weak acids by increasing the pH of 
the microenvironment (Doherty and York 1989).  
The incorporation of surfactants, such as sodium dodecyl sulfate, sodium lauryl sulfate, 
cetyltrimethylammonium bromide and sorbitan monostearate has also been studied as a 
possible strategy to modify the release profile of drugs (Ford, Mitchell et al. 1991; Nokhodchi, 
Hassan-Zadeh et al. 2008). 
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1.3 Starch and starch derivatives for sustained drug-release 
1.3.1 Starch 
Starch, a naturally occurring homopolysaccharide of α-D-glucose, has been one of the 
most widely studied pharmaceutical excipients, partially because it is biodegradable and 
metabolized by the human body. Besides safe, starch is an abundant, cost-effective and 
renewable material (Kost and Shefer 1990). Biodegradable synthetic polymers have the 
disadvantage of a possible toxicity following absorption of the degraded products, whereas 
native starch and starch derivatives are a safer alternative. Therefore, unmodified and modified 
starches have been used as excipients for various purposes in tablet formulation such as 
diluents, binders, disintegrants (Biliaderis 1991). Modified starches have also been proposed 
as agents for oral CR (Herman, Remon et al. 1989,; Lenaerts, Dumoulin et al. 1991). These 
starch and starch-derived polymers are subject to biodegradation by α-amylase enzymes 
naturally present in the gastrointestinal tract. Starch is relatively resistant to enzymes other 
than α-amylase and amyloglucosidase (Newman, Mueller et al. 2006).  
Starch is the major storage carbohydrate of all higher plants (Biliaderis 1991). Starch 
granules are mainly found in seeds, roots and tubers, as well as in stems, leaves, fruits and 
even pollen (Pérez and Bertoft 2010). It can be extracted from several economically important 
cereals such as wheat, corn, rye or rice. Thus, it has always been a major source of food 
energy, in the form of carbohydrates, for humans and animals. 
Since a derivatized starch was the base material of the present study, it will be 
described at greater length in this section of this thesis. 
 
 
1.3.1.1 Starch constituents and chemical structure 
Starch appears in the form of granules that have a heterogeneous content. The granules 
occur in all shapes and sizes (spheres, ellipsoids, polygon, platelets and irregular tubules) and 
their diameters vary from submicrons to 100 µm (Pérez and Bertoft 2010). 
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Starch granules consist of two major components: amylose, the non-branched fraction 
(Figure 1.11), and amylopectin, the branched fraction (Figure 1.12). Amylose is primarily a 
linear polysaccharide with α-(1→4)-linked D-glucose units. Some amylose molecules, 
particularly those of large molecular weight may have up to ten or more branches (Susumu 
Hizukuri 1981). Most starches contain a mixture of linear and branched amyloses (Hizukuri, 
Takeda et al. 1981; Takeda, Maruta et al. 1992). Amylopectin is a highly branched molecule 
and is composed of hundreds of short α-(1→4)-linked D-glucose backbones, interlinked by α-
(1→6)-linkages (about 5-6% of total branches) (Buléon, Colonna et al. 1998; Pérez and 
Bertoft 2010). Amylopectin is made up of three classes of glucose chains, A, B and C. The A 
chains bind in clusters only to B chains, B chains bind to other B chains or to a C chain, which 
has a reducing end and of which there is one per molecule (Wang, Bogracheva et al. 1998). 
These two polysaccharides constitute 98-99% of the dry weight (Tester, Karkalas et al. 2004).  
 
 
Figure 1.11 Schematic representation of the linear amylose macromolecule with its α-(1→4)-
linked D-glucose units. 
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Figure 1.12 Schematic representation of the branched amylopectin macromolecule with its α-
(1→4)-linked D-glucose backbones, interlinked by α-(1→6)-linkages. 
 
Besides the two major polysaccharides, starch granules also contain minor components 
such as lipids, proteins, and phosphorus, which content varies according to the botanical origin 
of the starch, just as the main components (Pérez and Bertoft 2010). Normal starch, i.e., non-
genetically modified, such as normal maize, rice, wheat and potato, contains about 70-80% 
amylopectin and 20-30% amylose. However, it is possible to obtain starches with low-amylose 
content, known as waxy starches. Waxy starches contain less than 15% amylose (Tester, 
Karkalas et al. 2004), or even less than 1% in the case of waxy maize starch (Pérez and Bertoft 
2010). Contrariwise, it also possible to produce high-amylose starch, which contains up to 
80% amylose (Pérez and Bertoft 2010). Typical molecular weights of extracted amylose are in 
the range of 105 to 106 g/mol. Amylopectin is one of the largest biopolymers known and its 
multiple branched structure has a molecular weight of about 107 to 109 g/mol, mostly in excess 
of 108 g/mol (Buléon, Colonna et al. 1998; Parker and Ring 2001). 
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1.3.1.2 Starch crystallinity and polymorphic types 
Native starches are biosynthesized as semi-crystalline granules with different 
polymorphic forms and degrees of crystallinity (Buléon, Colonna et al. 1998). These granules 
are complex structures consisting of crystalline and amorphous areas (Wang, Bogracheva et al. 
1998). The crystallinity varies from 15 to 45% depending on the source of starch (Zobel 
1988). 
It is a common standpoint that short chains in the amylopectin molecule are organized 
into double helices, some of which then form crystalline lamellae (or crystallites) (French 
1984; Blanshard 1987). The remaining double helices and the crystallites form the ordered 
part of the semi-crystalline starch granule, the remaining part being called the disordered or 
amorphous part (Wang, Bogracheva et al. 1998). The amorphous part of the starch granule is 
believed to consist of amylose and longer chains from the amylopectin (French 1984). Most 
starch granules are made up of alternating amorphous and semi-crystalline layers. These 
structures are termed ‘growth rings’ (French 1984; Pérez and Bertoft 2010). The semi-
crystalline layers are in turn constituted by periodic crystalline and amorphous lamellae (Pérez 
and Bertoft 2010). 
In native starches, the double helices forming the lamellae are packed in different 
polymorphic types. Generally, most cereal starches give the so-called A-type X-ray diffraction 
pattern. Some starches of tubers (such as potato and lesser yam), rhizomes (e.g. canna) and 
cereal starches rich in amylose yield the B-pattern. C-type starches are found typically in the 
seeds of grain legumes, for example, peas (Wang, Bogracheva et al. 1998; Pérez and Bertoft 
2010), and their diffraction patterns seem to represent a combination of A- and B-type 
polymorphs (Gernat, Radosta et al. 1990; Cairns, Bogracheva et al. 1997). The double helices 
in both A- and B-type are left handed and parallel stranded (Pérez and Bertoft 2010). These 
two types of polymorphs differ in their geometry, the packing density of their double helices 
and in the amount of water within the crystal structure, being the B-type a more highly 
hydrated and open structure (Figure 1.13) (Wang, Bogracheva et al. 1998; Parker and Ring 
2001).  
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Figure 1.13 Comparison of units cells and helix packing in A- and B-amylose. Reproduced 
from (Hsien-Chih and Sarko 1978) with permission of Elsevier Ltd. 
 
 
1.3.1.3 Amylose as simple helices 
Single amylose chains have a unique ability to form complexes with a variety of 
complexing agents. Indeed, when amylose is precipitated from aqueous solution with suitable 
complexing agents such as dimethyl sulfoxide (DMSO) (Germino and Valletta 1964), acetone 
(Buléon, Delage et al. 1990) or iodine (Bluhm and Zugenmaier 1981), it crystallizes as “V” 
amylose complexes, which are left-handed amylose single helices and display the V-type 
diffraction pattern (from the German ‘Verkleisterter stärke’, meaning gelatinized starch, 
because it was first believed that the pattern represented pasted or gelled starch) (Pérez and 
Bertoft 2010). But, the most studied V-amylose complex is the form known as Vh (hydrated), 
which is normally induced by the presence of linear molecules such as linear alcohols 
(Buleon, Duprat et al. 1984; Whittam, Orford et al. 1989; Buléon, Delage et al. 1990; Brisson, 
Chanzy et al. 1991; Helbert and Chanzy 1994) or fatty acids (Godet, Buléon et al. 1993). 
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1.3.1.4 Starch behaviour in aqueous solution 
Native starches are insoluble in cold water, only swelling slightly (10-20%), owing to 
penetration of water into the amorphous regions of the granule. However, this swelling is 
reversible upon drying. Contrarily, when starch is subject to gradual heating in aqueous 
medium, a point is reached where granule swelling becomes irreversible and structural order 
disappears, leading to loss of its crystalline properties. As the granules continue to expand, 
amylose leaches out into the aqueous intergranular phase. These processes result in substantial 
increase in viscosity (Biliaderis 1991). Overall, the disruption of granular structure, swelling 
and hydration, and solubilization of starch molecules are collectively described by the term 
gelatinization (Atwell, Hood et al. 1988).  
Although the phenomenon of gelatinization is irreversible, starch gels are 
nonequilibrium states and, consequently, undergo structure transformation, i.e., further chain 
aggregation and recrystallization, during cooling or prolonged storage of the paste. This 
process is accompanied by gradual increases in rigidity and phase separation between polymer 
and solvent, and is described by the term retrogradation (Biliaderis 1991). NMR and X-ray 
diffraction experiments show that amylose precipitated from dilute aqueous solution contain 
only B-type aggregated double helices (Gidley 1989). 
 
 
1.3.1.5 Starch applications 
Starches and modified starches are widely and safely used, with the approval by the 
Food and Drug Administration (FDA), in the food industry as thickeners, enhancers of 
organoleptic properties and texture modifiers, and in the pharmaceutical industry as fillers, 
binders, disintegrants and glidants (Biliaderis 1991; Newman, Mueller et al. 2006), because, 
among of its other properties, starch is readily available, inexpensive, white, and inert, 
showing compatibility with numerous drugs.  
The function of starch may depend on how it is incorporated into the formulation. 
Starch will function as a disintegrant when it is added in the dry state prior to adding a 
lubricant. It may exhibit both binding and disintegrating properties when it is incorporated 
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either as a paste or dry before granulation with other agents (Newman, Mueller et al. 2006). It 
has been reported that starches deform mainly by plastic flow during compression, depending 
this phenomenon on the particle size, size distribution, and particle shape (McKenna and 
McCafferty 1982). A few mechanisms for the disintegration properties of starch have been 
proposed. The most common explanation is that disintegration is caused by the swelling of 
starch granules when exposed to water, and it has been proposed that amylose is the 
component responsible for the disintegration properties of starch due to swelling. A second 
theory suggests that the disintegration action of starch in tablets is due to capillarity. A third 
proposed mechanism is based on the particle-particle repulsion forces between the tablet 
constituents when in contact with water and the hydrophilic nature of starch (Guyot-Hermann 
and Ringard 1981). 
 
 
1.3.1.6 Modified starches 
In recent years, among polysaccharides, starch has received utmost attention because 
of its usefulness in different industrial products in modified form. Starch can be subjected to 
various physical (i.e. gelatinization) (Svensson and Eliasson 1995), chemical (Fang, Fowler et 
al. 2004), and enzymatic (Rajan, Prasad et al. 2006) modifications, or a combination thereof. 
These modifications are employed to create new starch products with specific or improved 
properties, such as control over drug-release. Indeed, native starches are not suitable for SR 
drug delivery systems because of their poor flow and compressibility and, especially, their fast 
release properties, which are a result of substantial swelling in aqueous media along with rapid 
enzymatic degradation by α-amylase in physiological fluids (Kost and Shefer 1990; 
Dumoulin, Cartilier et al. 1999).  
The main purpose of physical modification of starch is to obtain a completely or 
partially pregelatinized starch through heating in aqueous solution, followed by a rapid 
thermal drying (van Aerde and Remon 1988; Herman, Remon et al. 1989,). This modified 
starch, contrary to native starch, is soluble in cold water and is capable of forming a gel 
barrier.  
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A number of pharmaceutical applications have been reported for physically modified 
starches. The most common use is as binder-disintegrants in immediate release tablet 
formulations. Some examples are a binder-disintegrant constituted of starches physically 
modified by compaction (Short and Verbanac 1971) and modified starches which 
demonstrated low swelling in cold water and are suitable for use as disintegrants in 
compressed tablets (Trubiano 1983). Moreover, physically modified starches have been tested 
as an excipient for SR (Nakano, Nakazono et al. 1987; van Aerde and Remon 1988; Herman 
and Remon 1989; Herman, Remon et al. 1989,; Herman and Remon 1990; A. Odeku and M. 
Picker-Freyer 2010). However, the results vary according to the authors, the types of drying 
methods applied and the origin of the starch. For example, studies (Herman and Remon 1989; 
Herman, Remon et al. 1989,; Herman and Remon 1990) on different types of pregelatinized 
starches found that pregelatinized starches containing a low amount of amylose (25% and 
lower) could produce a strong enough gel layer to ensure a sustained drug-release in vitro, but 
their matrices were not able to preserve their integrity when administered in vivo. These 
authors attributed a negative role to amylose present in thermally modified starches used in 
sustained drug-release tablets. 
Starches can undergo many reactions characteristic of alcohols because of the many 
hydroxyl groups present in their main constituents, amylose and amylopectin. Oxidation, 
ethoxylation, esterification, etherification and carboxymethylation are some of the chemical 
modifications commonly deployed to prepare starch derivatives. The properties of the 
resulting starch derivatives depend on many factors, such as plant source, prior treatment 
(acid-catalyzed hydrolysis or dextrinization), amylose/amylopectin ratio or content, molecular 
weight distribution or degree of polymerization, type of derivative (ester, ether, oxidized), 
nature of the substituted group, and physical form (granular, pregelatinized) (Wurzburg 1972; 
French 1984). Starch, a traditional disintegrant has been replaced extensively by a new class of 
disintegrants, commonly known as “super-disintegrants.” An example of such super-
disintegrant is sodium starch glycolate. It is manufactured by chemical modification of starch, 
i.e., carboxymethylation to enhance hydrophilicity and cross-linking to reduce the solubility of 
the carboxymethylated starch, thereby preventing the formation of a gel (Shah and Augsburger 
2002). The starch used to produce this derivative contains a low content in amylose. 
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Enzymatic modification usually corresponds to degradation by enzymes of starch 
chains. Depending on the enzyme used, specific cleavage of the link α(1-6) or of the link α(1-
4) will be observed. Disentanglement of chains results in a decrease in viscosity of the starch 
solution. The use of enzymatically hydrolyzed starches as excipients for sustained drug-release 
was studied by Te Wierik et al. (Te Wierik, Eissens et al. 1993; Te Wierik, Bergsma et al. 
1996; Te Wierik, Eissens et al. 1997). These derivatives are presented as an alternative to 
conventional pregelatinized starches. A combination of physical modification with enzymatic 
modification was also used to produce SR excipients (Te Wierik, Eissens et al. 1997). The 
same authors studied the potential of debranched starches as suitable candidates for the 
application as filler-binder in tablets for direct compression (Te Wierik, Van der Veen et al. 
1993; Te Wierik, Eissens et al. 1994; Te Wierik, Bergsma et al. 1996). 
Over the last two decades, the chemical modification of high-amylose starch has been 
used to produce modified starches which posses interesting properties as excipients for 
sustained drug-release. One of main advantages of using high-amylose starch derivatives for 
the preparation of hydrophilic matrix tablets is related to the limited swelling and the high 
strength of the gels formed (Jane and Chen 1992 ). Two main chemical modifications have 
been used: cross-linking and substitution. Starches modified using these two methods will be 
described in the following sections. 
 
 
1.3.2 Cross-linked amylose 
Cross-linked amylose, commercialized as Contramid®, was introduced in the early 
1990s as an excipient for monolithic dosage forms able to control drug-release over an 
extended period of time, ranging between 18 and 24 hours (Lenaerts, Dumoulin et al. 1991). 
This semi-synthetic polymer is produced by the reaction of starch with high-amylose content 
with a cross-linking agent in an alkaline medium, forming a three dimensional structure. The 
agent usually used is epichlorohydrin (Lenaerts, Dumoulin et al. 1991; Moussa and Cartilier 
1996; Moussa and Cartilier 1997; Dumoulin, Alex et al. 1998; Lenaerts, Moussa et al. 1998; 
Moussa, Lenaerts et al. 1998; Dumoulin, Cartilier et al. 1999), though trisodium 
trimetaphosphate, adipic-acetic anhydride and phosphorus oxychloride have also been 
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mentioned (Dumoulin, Carriere et al. 1998). 
Different degrees of cross-linking can be obtained by varying the ratio of 
epichlorohydrin to amylose in the reaction vessel. It was also found that water absorption, 
degree of swelling and drug-release rate from cross-linked amylose tablets increase with 
increasing cross-linking degree of the polymer (Lenaerts, Dumoulin et al. 1991; Moussa and 
Cartilier 1996). At high degrees of cross-linking, amylose is used as a tablet binder and/or 
disintegrant (Cartilier, Mateescu et al. 1997). However, effective control of the release of 12-
24 hours can be obtained for moderate degrees of cross-linking of the amylose (Lenaerts, 
Dumoulin et al. 1991). 
It was demonstrated that in the dry state, there was a predominance of the V-type 
single helix arrangement of amylose irrespective of the cross-linking degree. However, upon 
hydration, the polymer with the lower cross-linking degree showed a transition from the V to 
the B-type double helix arrangement whereas the polymer with the higher cross-linking degree 
remains largely in the V form. The V to B transition generated a huge three-dimensional 
network of both chemical and physical links and a relatively tighter network than at a higher 
cross-linking degree. It was hypothesized that at higher cross-linking degrees, the ability of 
amorphous amylose chains to rearrange in double helices is probably hindered by the 
increased density in cross-links and hence a reduced mobility of the amylose chains. 
Therefore, the lower water uptake and drug-release rates with decreasing cross-linking degree 
were attributed to the tighter network obtained with a lower cross-linking degree (Dumoulin, 
Alex et al. 1998; Dumoulin, Carriere et al. 1998; Lenaerts, Moussa et al. 1998). Moreover, 
cross-linking as well as spray drying technique usually applied to dry the polymer, are 
believed to have a negative influence on the development of double helices and, thus, of 
crystalline organization (Guilbault and Mercier 1988).  
Although Contramid® forms a gel membrane at the surface of the tablets within the 
first minutes of hydration (Moussa and Cartilier 1996; Lenaerts, Moussa et al. 1998), this gel 
layer thickens very slowly over time, giving the hydrated matrices of Contramid® a reservoir-
type structure. The control of the release has been attributed only to diffusion of dissolved 
drug through the membrane (Moussa and Cartilier 1996). Therefore, an optimum level of 
chemical cross-linking ensures the integrity of the swollen tablet whose sponge-like structure 
enclosed by the membranous surface is responsible for SR (Le Bail, Morin et al. 1999).  
  
54 
1.3.3 Substituted amylose as a sustained drug-release agent in matrix 
systems 
Substituted amylose was introduced in 1999 as a pharmaceutical excipient for 
sustained drug-release tablets prepared by direct compression (Cartilier, Moussa et al. 1999; 
Chebli, Moussa et al. 1999). The SR properties of this starch derivative are a result of a 
substitution reaction by etherification of hydroxyl groups available in the chains of high-
amylose starch (containing 70% or 60% of amylose).  
Several substitution agents have been proposed and most of the resulting excipients 
showed ability to slow down the release of drug. This family of starch derivatives is referred 
to as SA,R-n where SA refers to Substituted Amylose, R is a code defining the substituent 
used and n is the degree of substitution (DS), expressed as the ratio of moles of substituent per 
kilogram of amylose (Cartilier, Moussa et al. 1999; Chebli, Moussa et al. 1999). 
This SR vehicle presents advantages at an economic level, since the production of 
matrix tablets with this new excipients is simple and easy, consisting of dry mixing of drug 
and SA polymers followed by compression, which is the easiest way to manufacture an oral 
dosage form. 
 
 
1.3.3.1 Synthesis at laboratory scale and general characteristics 
The process to synthesize substituted amylose at laboratory scale can be summarized 
as follows (Cartilier, Moussa et al. 1999; Chebli, Moussa et al. 1999): 
1) Reaction between high-amylose corn starch and a substituting agent in alkaline media 
(NaOH, 1N) at 50°C, in a Hobart planetary mixer at its slowest speed. The alkaline pH 
assures the activation of the reactive sites (positioned at C-6, C-2 and C-3) of the amylose 
chains. Different DS can be obtained by varying the substituent/amylose ratio (mole of 
substituent/kg of amylose). 
2) Neutralization of the well-mixed mass by adding, first, distilled water (heated to 50ºC), 
followed by the necessary volume of acetic anhydride to obtain a pH of 7.0. The 
homogenization was continued for an additional time at the same speed. 
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3) Filtration of the resultant gel through a Büchner funnel, and its dehydration by successive 
washings with water and acetone or ethanol to recover the excipient in the form of a nearly 
dry powder. The powder product was exposed overnight to air at room temperature, which 
was sufficient to produce a powder ready to be compressed. 
 
 
Figure 1.14 General representation of the synthesis of SA polymers at laboratory scale. 
 
 
Since amylose contain reactive hydroxyl groups, being the one positioned on C-6 the 
most reactive, followed by hydroxyl groups on C-3 and finally C-2, it is possible to use a 
substituting agent and chemically modify these hydroxyl groups by an etherification process, 
resulting in substituted amylose (SA). A range of substituents such as 1,2-epoxypropanol (or 
glycidol = G), 1,2-epoxybutane, 1,2-epoxydecane and 1-chlorobutane, were investigated. 
However, the SA,G-n polymers showed the most interesting properties in terms of good 
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compression behaviour and sustained drug-release (Cartilier, Moussa et al. 1999; Chebli, 
Moussa et al. 1999).  
Sustained drug-release matrix systems based on SA,G-n technology presented large 
ranges for drug loading, drug solubility and tablet weight (TW) (Cartilier, Moussa et al. 1999; 
Chebli and Cartilier 2000). In vitro dissolution release times of 95% of the drug ranged from 9 
to 20 hours for all DSs studied for 400-mg matrices containing 10% of acetaminophen 
(Cartilier, Moussa et al. 1999; Chebli, Moussa et al. 1999). Moreover, DSs ranging from 0.4 to 
3.4 had no significant effect on the release of acetaminophen but exerted a significant 
influence on the water uptake of SA,G-n polymers, i.e., increasing the DS resulted in 
increased in hydrophilicity. However, beyond these values, the release properties decreased 
because of excessive water absorption, which led to the erosion of the system (Cartilier, 
Moussa et al. 1999; Chebli, Moussa et al. 1999). In contrast to pregelatinized starches known 
for their poor binding properties (Hancock, Carlson et al. 2001; Rahmouni, Lenaerts et al. 
2002), the tablets produced with SA,G-n polymers presented very high crushing strength 
values, comparable to those of microcrystalline cellulose tablets, a reference among 
binders/fillers (Cartilier, Moussa et al. 1999; Chebli, Moussa et al. 1999). In addition, a study 
showed no significant influence of CF ranging from 0.5 to 5.0 tons/cm2 on the release 
properties of SA,G-n polymers, with a DS greater than 1.5 (Chebli and Cartilier 2000). These 
features help ensure high reproducibility of batch performance and versatility despite possible 
variations during industrial production. It was also demonstrated that the importance of the 
relaxation of chains and erosion in the mechanism of drug-release increases with the DS, 
being diffusion the dominant drug transport mechanism for low DSs (Chebli, Moussa et al. 
1999). Finally, a study on the release of rhenium (VII) oxide from SA,G-n matrix tablets in the 
presence or the absence of α-amylase enzymes revealed only a slightly faster SR of the drug 
from SA,G-2.7 matrix systems in the presence of the α-amylase enzyme in the dissolution 
medium and no significant influence on the release properties when DS was increased to 4.0, 
showing that increasing the DS made the matrix less accessible to the enzymes (Chebli, 
Cartilier et al. 2001). This finding confirmed the value of this polymer for SR applications, 
since systems based on starch are normally susceptible to biodegradation by α-amylase. 
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1.3.3.2 Performance of amylose substituted by 1,2-epoxypropanol (SA,G-2.7) 
Of all SA,G-n polymers, SA,G-2.7 was the one which demonstrated the best 
performance as an excipient for sustained drug-release systems. SA,G-2.7 polymeric matrices 
obtained by direct compression allowed nearly constant drug-release (Figure 1.15) (Cartilier, 
Moussa et al. 1999; Chebli, Moussa et al. 1999; Chebli and Cartilier 2000). Such a release 
profile is unusual for a hydrophilic matrix system where a Fickian release, i.e. a first-order 
kinetics, is expected. Moreover, a study revealed that release time was directly proportional to 
TW for tablets containing 10% of acetaminophen (Chebli and Cartilier 2000), showing that 
TW can be used as a formulation tool, independently of CF. It was also demonstrated that 
SA,G-2.7 matrices could be employed for a wide range of model drugs, independently of their 
nature, solubility, and concentration (Chebli and Cartilier 2000). Indeed, their release 
properties were maintained for both slightly soluble drugs (theophylline) and freely soluble 
drugs (chlorpheniramine maleate). Ninety percent of chlorpheniramine maleate was released 
in 11 hours from 500-mg SA,G-2.7 matrices with 10% of drug, whilst concentrations of 
theophylline ranging from 3 to 50% had released times between 8 and 18 hours from 600-mg 
tablets, with a maximum obtained with a concentration of 10% (Chebli and Cartilier 2000). 
The most important aspect of the release mechanism from tablets constituted by SA,G-
2.7 is believed to be related to the ability of this high-amylose polymer to hydrate and form a 
rigid and long-lasting gel on the surface of the tablets in response to water penetration. This 
gel layer acts like a barrier against the fast release of drugs whilst controlling at the same time 
the penetration of aqueous medium and the diffusion of drug. 
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Figure 1.15 Release rate of acetaminophen from SA,G-2.7 matrices (compressed at CF 
between 0.5 and 5.0 tons) as a function of dissolution time, showing a nearly constant drug-
release from approximately 1 h to 6 h, and three different regions for the drug-release rates. 
Figure reproduced from (Moghadam, Wang et al. 2007) with permission of Elsevier Ltd. 
 
 
The drug-release rates from SA,G-2.7 matrix tablets in function of time showed three 
clearly distinguishable regions (Figure 1.15) (Chebli and Cartilier 2000; Moghadam, Wang et 
al. 2007). The first region presented high release rates for all CF, although the initial release 
rate seemed to depend on the CF. This phenomenon, known as “burst effect”, is characteristic 
of hydrophilic matrix systems and is due to the drug dissolution occurring at the surface of the 
tablet, before the polymeric gel membrane forms and hinders drug diffusion outside of the 
matrix (Huang and Brazel 2001). In addition, the burst effect is influenced by the tablet 
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porosity, and thus by the CF applied. The second region, however, was not representative of a 
hydrophilic matrix system as it showed an almost constant release rate, maintained for a few 
hours and independent of the CF, while the third region showed a first-order-like decline of 
the release rate for all tablets. These two regions are more typical of a reservoir system, where 
the drug is released constantly through a membrane until the inner compartment no longer 
contains a drug-saturated solution. This hybrid behaviour, typical of a hydrophilic matrix and 
a reservoir system, can be explained by the sequence of events that follow the immersion of a 
SA,G-2.7 tablet in an aqueous medium (Chebli and Cartilier 2000; Moghadam, Wang et al. 
2007): during the burst effect, the polymer at the surface of the tablet hydrates and the 
hydrated amylose chains associate through hydrogen bonds created between hydroxyl groups 
present on the glucose units (Biliaderis 1991) and form a rigid gel. This external gel 
membrane controls the penetration of aqueous medium towards the core of the matrix and the 
release of drug by diffusion. The slow medium penetration allows the maintenance of a drug-
saturated solution in a core surrounded by a gel membrane that swells gradually, resulting in 
an almost constant drug-release until the internal hydration and the concentration of drug do 
not allow the existence of a drug-saturated solution in the interior of the matrix. 
It was observed that for drug loadings lower than 30% of acetaminophen, the 90% 
release time increased as a function of drug loading (Moghadam, Wang et al. 2007). This 
behaviour was explained considering the continuous membrane-like structure created around 
the tablet and that augmenting the drug concentration resulted in an increase of the drug 
content in the core of the tablet, and thus in an increase of the 90% release time. However, in 
order for this phenomenon to happen, the structure of the external gel membrane has to be 
maintained intact. Thus, for drug loadings larger than 30%, the physical erosion of the 
membrane led to an acceleration of drug-release and to a continuous decrease of the 90% 
release time as a function of the drug loading, which is the typical behaviour of hydrophilic 
matrices. 
High-amylose content was referred to be an essential feature to obtain sustained drug-
release properties from SA,G-2.7 matrices and other starch derivatives (Cartilier, Moussa et al. 
1999). This occurrence can be explained by the creation of a gel network due to the transition 
from an essentially amorphous character in the dry state into A or B crystalline form when the 
tablet is immersed in an aqueous environment. However, this phenomenon will only take 
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place if a critical concentration of amylose is present in the starch material. Common starches, 
i.e. starches presenting high concentrations of amylopectin and low concentrations of amylose, 
do not form a rigid gel allowing drug-sustained release.  
An evaluation of the combined effect of drug loading and TW on the SR properties of 
SA,G-2.7 showed that a minimum weight of 300 mg was required to obtain drug-sustained 
release (Moghadam, Wang et al. 2007). Tablets with lower weights were too thin to be able to 
create an external membrane controlling drug diffusion, because the matrix was fully hydrated 
too quickly.  
The excellent compression behaviour of this polymer was demonstrated by 
measurements of the crushing strengths and the thickness of tablets for different drug 
concentrations and CF (Chebli and Cartilier 2000; Moghadam, Wang et al. 2007). A study 
(Moghadam, Wang et al. 2007) revealed that the relationship between tablet thickness (TT) 
and TW was linear and independent of the CF applied, except for a slight deviation observed 
in the case of the lowest CF (1.5 tons/cm2), and that the densification was the same for all CF, 
indicating that an optimal particle rearrangement occurred and that some peculiar phenomenon 
took place, even at low compressions. Image analysis by scanning electron microscopy was 
used to observe the structure of SA,G-2.7 tablets. The core of these tablets was completely 
melted while the external layer went through densification, deformation and partial melting. 
This melting phenomenon, which is not observable amidst pharmaceutical excipients such as 
HPMC or pregelatinized starches, offered an explanation for the high crushing strength values 
observed for SA,G-2.7 tablets. In addition, a measure of the porosity of these tablets showed 
that the total porosity was very weak, since pores were present in a very low and narrow 
range, i.e., around 12 nm, while HPMC tablets presented an important porosity with large 
pores. This porosity study confirmed that SA,G-2.7 tablets went through an important 
densification process. It was also found that the water uptake values were not affected by CF 
in the range 1.5-5.0 tons/cm2 (Moghadam, Wang et al. 2007), which reinforces the theory of 
an absence of effect of tablet porosity on the drug-release rate after the burst-effect. 
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1.3.4 High-amylose sodium carboxymethyl starch 
Although SA,G-n polymers presented good properties as sustained drug-release 
excipients, the reaction of high-amylose starch with sodium chloroacetate or chloroacetic acid 
(Figure 1.16) instead of nonionic substituents such as 1,2-epoxypropanol (or glycidol) was 
later proposed to obtain a new substituted amylose derivative (Cartilier, Ungur et al. 2005; 
Ungur, Yonis et al. 2005).  
 
Figure 1.16 Reaction of substitution of amylose by sodium chloroacetate. 
 
 
Sodium carboxymethyl starch produced from starch with low-amylose content and 
substituted with sodium chloroacetate has been used as a well-known disintegrant agent in IR 
tablets (Bolhuis, Van Kamp et al. 1986; Edge and Miller 2005) as well as in the food industry 
for decades, and has thereby proven its safety. Therefore, it is more readily acceptable by 
regulatory agencies such as the FDA. This high-amylose sodium carboxymethyl starch was 
first referred to as SA,CA-n, where “CA” stands for chloroacetate and n the DS. 
As the polymer is ionic, the tablets can be formulated with the addition of an 
electrolyte, which allows the integrity of the swollen matrices to be maintained when they are 
immersed in media undergoing pH changes simulating the pH environment along the 
gastrointestinal tract, while allowing controlled and sustained drug-release. This electrolyte 
can be another excipient, a drug or mixture thereof (Cartilier, Ungur et al. 2005; Nabais, 
Brouillet et al. 2007).  
 
  
62 
1.3.4.1 High-amylose sodium carboxymethyl starch produced at laboratory scale 
SA,CA-n was first synthesized at laboratory scale following the same methodology 
used to prepare SA,G-n polymers. SA,CA-n polymers with DSs (also expressed as the number 
of moles of substituent added per kilogram of amylose) ranging from 1.55 to 2.7 were 
produced and the SA,CA-n which presented the closest characteristics to SA,G-2.7 was 
selected. Scanning electron microscopy was used to compare the structures of the granules of 
both polymers. SA,CA-n granules presented the same main characteristics, i.e., an amorphous 
character and a high porosity (Cartilier, Ungur et al. 2005).  
Dissolution studies demonstrated SR of acetaminophen from tablets containing 
SA,CA-n produced at laboratory scale independently of the DS, within the range of DSs used 
to produce these polymers. Indeed, DSs ranging from 1.55 to 2.7 did not significantly 
influence the drug-release profiles in spite of a significant influence on the absorption of 
water, which increased with the number of carboxyl groups. The drug-release rates of SA,CA-
n were, however, slightly faster than for SA,G-n and the release profiles less linear (Cartilier, 
Ungur et al. 2005). 
Initially, for comparison with the SA,G-n polymer, dissolution tests were carried out 
only in a phosphate buffer at pH 7.4. However, compared to glycidol, the new substituting 
agent confers an ionic nature to the SA,CA-n polymer. This had to be taken into account when 
assessing the behaviour of this polymer, given that the pH gradient throughout the digestive 
system can have a significant influence on the behaviour of ionic polymers. For this reason, 
SA,CA-n tablets started being tested in a pH gradient (pH = 1.2 and pH = 7.4) in place of an 
unique phosphate buffer. When using a pH gradient, the same type of sustained drug-release 
profiles was observed (Cartilier, Ungur et al. 2005).  
The release profiles from SA,CA-1.55 matrices with 10% of acetaminophen in a pH 
gradient bore the closest resemblance to the release profiles from SA,G-2.7 matrices. In 
addition, as the residence time in the stomach can vary, studies on the influence of the 
residence time in the acidic medium on the in vitro drug-release from SA,CA-1.55 matrices 
were performed. These studies showed no significant influence of residence times ranging 
from 0.5 to 2.0 hours on the release of acetaminophen and led to the selection of SA,CA-1.55 
as the prototype SA,CA polymer produced at laboratory scale. Although cracks on the surface 
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of the tablets produced with this polymer appeared during the dissolution tests, they did not 
significantly influence drug-release. In addition, the use of a pH gradient instead of a sole 
phosphate buffer delayed the development of cracks (Cartilier, Ungur et al. 2005). 
The performances of this prototype allowed considering a transition to a pilot-scale 
development.  
 
 
1.3.4.2 High-amylose sodium carboxymethyl starch produced at pilot scale 
The first pilot scale batch was obtained from Roquette Frères S.A. (Lestrem, France) 
and consisted of a sodium salt of high-amylose carboxymethyl starch with a DS of 0.05, thus 
referred to as SA,CA-0.05. It is important to point out that the expression of DS employed by 
the company in the fabrication of the polymer is different from the definition used to produce 
SA,G-n and SA,CA-n at laboratory scale. In this case, the DS was expressed as number of 
moles of substituent per number of moles of anhydroglucose (dry weight of starch divided by 
162, the molecular weight of anhydroglucose). For convenience of description, pilot scale 
SA,CA-0.05 was later renamed HASCA in this work, where “HAS” means high-amylose 
starch and “CA” defines chloroacetate. This term will be used hereafter. 
Pilot scale HASCA was produced via an industrial process different from the 
laboratory process, using a drying method without organic solvents. However, this excipient 
was not suitable for tableting by direct compression and sustained drug-release. Therefore, the 
dry powder of pilot scale HASCA was dispersed in hot water, and then precipitated with 
ethanol using the laboratory process, as previously described, though the original process used 
acetone to precipitate SA polymers. The recovered dry powder possessed the required binding 
and SR properties (Cartilier, Ungur et al. 2005; Ungur, Yonis et al. 2005). 
However, as it happened for lab scale SA,CA-1.55, the tablets produced only with the 
new polymer and the drug presented cracks on their surface. To solve this problem several 
associations with additives of different nature, i.e., gelling ionic or nonionic polymers, 
pregelatinized starch, dextrin, soluble and non-ionic diluents or insoluble diluents, were tested 
without success (Ungur, Cartilier et al. 2004; Cartilier, Ungur et al. 2005). Surprisingly, ionic 
soluble compounds, i.e., organic acids and organic bases of low molecular weight, buffering 
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agents and electrolytes, were the substances that added to the tablet formulation led to the best 
results regarding the maintenance of the tablet integrity during the dissolution tests in a pH 
gradient. It was expected that these hydrophilic substances, and in particular the electrolytes, 
would exacerbate the occurrence of cracks by increasing significantly the penetration of water 
into the matrix and, as a consequence, the osmotic pressure inside the matrix. Instead, the 
addition of sodium chloride (NaCl) helped maintain the integrity of the swollen matrix tablets 
without affecting the SR properties of HASCA (Cartilier, Ungur et al. 2005).  
Like the SA,G-n polymers, HASCA revealed to possess numerous qualities as a 
pharmaceutical excipient for SR of drugs (Ungur, Cartilier et al. 2004; Cartilier, Ungur et al. 
2005). Despite their ionic nature, the SR properties of HASCA-based matrix tablets were not 
influenced by residence times in acidic medium ranging from 0.5 to 2.0 hours when the tablets 
were tested in a pH gradient. Besides, even in the presence of NaCl, the release rate of 
acetaminophen from HASCA tablets was not significantly influenced by the CF applied or by 
the addition of magnesium stearate, a well-known table lubricant, to the formulation. HASCA 
tablets were capable of delaying the release of pseudoephedrine hydrochloride, an ionic and 
highly soluble drug, from tablets containing 60% of drug, when they were evaluated in a pH 
gradient, which support the excellent properties of this new excipient. The release time of 
pseudoephedrine hydrochloride increased with an increase in TW, but decreased with an 
increase in drug loading, indicating that both the TW and the drug concentration can be used 
to optimize a formulation containing HASCA as the SR excipient. Moreover, HASCA tablets 
are characterized by the same unusually high crushing strength values observed for SA,G-n. 
 
The characteristics summarized above illustrate the qualities of high-amylose sodium 
carboxymethyl starch as a functional and performing hydrophilic excipient for the formulation 
of SR systems. However, the proposed manufacturing process required very high volumes of 
ethanol to precipitate and recover the final product, which represented a drawback for a 
change in scale from laboratory to industrial production because it limited the economic 
viability of this excipient. In order to prepare the scale-up for easier and more economical 
industrial production of HASCA, Brouillet et al. (Brouillet, Baylac et al. 2010) designed a 
process to transform by spray drying totally amorphous HASCA into an efficient sustained 
drug-release excipient for matrix tablets while decreasing ethanol quantities. The spray drying 
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method has the advantage of being able to produce a fine powder while drying the solid. The 
same methodology was used to prepare the HASCA polymer used in the experiments of the 
present work and will be briefly described in the next section. 
 
 
1.3.4.3 Spray-dried high-amylose sodium carboxymethyl starch 
The process used in this work to produce spray-dried high-amylose sodium 
carboxymethyl starch (SD HASCA) with the required binding and sustained drug-release 
properties was previously developed by Brouillet et al. (Brouillet, Bataille et al. 2010) and 
included the following steps: 
1) Dispersion of pilot-scale HASCA in a solution composed of water and at least one 
pharmaceutically acceptable organic solvent miscible with water and suitable for spray 
drying; In this case ethanol was the chosen organic solvent. 
2) Heating of the dispersion obtained in the first step; 
3) Addition of a second volume of the same organic solvent used in the first solution to the 
heated dispersion to decrease its viscosity to easily process the suspension through the 
spray dryer; and 
4) Spray drying of the final dispersion in order to obtain a dry powder of HASCA comprising 
a major fraction of amorphous form and a minor fraction of crystalline Vh-form. 
 
Because of the presence of its hydroxyl groups, amylose in aqueous solution forms a 
viscous gel through strong hydrogen bonding. The high viscosity of the dispersion of HASCA 
will difficult its process through the spray dryer. In order to limit the formation of a viscous 
starch gel a water/organic solution was used to disperse HASCA (Tijsen, Scherpenkate et al. 
1999; Tijsen, Kolk et al. 2001; Tijsen, Voncken et al. 2001). The organic solvent chosen in 
this process was ethanol, because it is pharmaceutically acceptable, miscible with water and 
compatible with spray drying methods, and it has been tested before for this purpose (Sloan, 
Mehltretter et al. 1962; Thewlis and Albans 1969). It is believed that alcohol disrupts the 
amylose gel structure by bonding to hydroxyl groups on starch molecules. Unlike hydrogen 
bonding between adjacent amylose chains through water molecules, this binding is terminal 
  
66 
and produces no connection between amylose molecules, reducing the apparent viscosity of 
the solution and resulting in amylose precipitation at high alcohol concentrations (McGrane, 
Mainwaring et al. 2004).  
 
After optimization of the process, tablets produced with SD HASCA presented high 
crushing strengths. It was hypothesized that these high values were in part due to the 
decreased particle size of the powder obtained after spray drying. Second, the combination of 
water and ethanol may have a plasticizer effect, causing partial melting of the excipient and 
particle re-arrangement under compression (Brouillet, Baylac et al. 2010) This atypical 
melting process was demonstrated using scanning electron microscope and porosimetry in the 
case of SA,G-2.7 (Moghadam, Wang et al. 2007) as described in a previous section.  
 
 
1.4 Physiological factors influencing oral drug-absorption 
As previously described, the oral route of administration requires an absorption step 
before the drug reaches the systemic circulation. The factors affecting drug absorption depend 
on the physiology of the gastrointestinal tract and on the passage of the drug through the 
gastrointestinal membrane towards the blood circulatory system. 
 
 
1.4.1 Physiology of the gastrointestinal tract 
The gastrointestinal tract is a highly specialized region of the body, which includes 
organs and glands whose primary functions involve: 1) processes of secretion of fluids 
(secreted by the salivary glands, pancreas, liver and the gastrointestinal epithelial cells) 
composed of mainly digestive enzymes, ions, mucus and bile; 2) guiding food as it passes 
through and its digestion, which involves the breakdown of food into smaller components in 
order to permit the extraction and absorption of its nutrients into the bloodstream; 3) passing 
out remaining wastes for elimination.  
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The gastrointestinal tract consists of a muscular tube that stretches from the mouth to 
the anus and consists of four main anatomical areas: the oesophagus, the stomach, the small 
intestine and the large intestine or colon (Figure 1.17) (Ashford 2002; Marieb and Hoehn 
2010). The luminal surface of the tube is not smooth but very rough, thereby increasing the 
surface area for absorption. The different areas of the gastrointestinal tract present their own 
anatomy, physiology and environmental characteristics concerning, for example, the 
composition of gastrointestinal fluids, the type of secretion, the pH value, the nature of 
enzymes and the transit time (Table 1.3). These particularities define the role of each 
anatomical area in the digestive process. However, a certain structural similarity can be 
observed along the length of the wall of the gastrointestinal tract except for the mouth, 
consisting of four principal histological layers, which form the apical surface (lumen) of the 
gastrointestinal tract to the basolateral surface (bloodstream) are (Washington, Washington et 
al. 2001; Ashford 2002; Marieb and Hoehn 2010):  
1. The mucosa, which is essentially composed of three layers. The first layer is the 
epithelium. The epithelium lines the gastrointestinal lumen and is implied in the absorption 
of nutrients and drugs, in the secretion of enzymes and mucus, and in the immune defence 
of the organism and protection of the tissues that lie beneath it. The epithelium lies on a 
layer of mainly connective tissue known as the lamina propria (Figure 1.18), which 
provides structural support and assures the blood supply and lymphatic drainage of the 
epithelium. The lamina propria contains many types of cells, such as lymphocytes, 
macrophages and plasma cells, and it is believed that it has an important role in preventing 
the entry of microorganisms and foreign substances. This layer is followed by the 
muscularis mucosa, a thin layer of smooth muscle that can change the local conformation 
of the mucosa and separates it from the submucosa. 
2. The submucosa, which is a layer of connective tissue containing some secretory tissue. 
The submucosa is richly supplied with blood and lymphatic vessels. A network of nerve 
cells, known as the submucosal plexus (or "Meissner's plexus"), is also located in this 
layer;  
3. The muscularis externa, which consists of an inner circular layer and an outer longitudinal 
layer of smooth muscle, being the outer layer thinner than the inner one. Contractions of 
these muscles provide the forces for movement of gastrointestinal contents; 
  
68 
4. The serosa, also called serous membrane is a membrane formed by a wet thin layer of 
epithelial cells overlying some loose connective tissue. 
The majority of the gastrointestinal epithelium is covered by a layer of mucus, a 
viscoelastic translucent gel composed mostly of water (~95%) and large glycoproteins called 
mucins, which are responsible for its physical and functional properties. Mucus is secreted 
throughout the gastrointestinal tract and acts as a mechanical barrier and a protective layer 
against the proteolytic action of digestive enzymes (Khanvilkar, Donovan et al. 2001; Ashford 
2002). 
 
 
 
 
Figure 1.17 General anatomy of gastrointestinal tract. Figure reproduced from (MacFarlane 
and Stover 2008) with permission of Elsevier Ltd. 
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1.4.1.1 Oral cavity 
The oral cavity or mouth is the point of entry of food into the digestive systems as well 
as of a large number of drugs. The primary function of the mouth is mechanical (mastication). 
The oral mucosa has a protective role during the process of mastication, which exposes the 
mucosa to compression and shear forces. The oral cavity contains a great variety of 
microorganisms, whose entry into the body as well as of any potential toxic waste product is 
limited by the oral epithelium (Washington, Washington et al. 2001). 
The mucus and saliva present in the mouth lubricate its surface and constitute a further 
protection barrier (Marieb and Hoehn 2010). Saliva is composed mainly of water, but also 
contains mucus, proteins, mineral salts and enzymes (Washington, Washington et al. 2001), 
including amylase, which initiates the digestive process of polysaccharides such as starch. 
Following mastication, food mixed with saliva form the food bolus, which is directed to the 
oesophagus. In the case of dosage forms that are not meant to dissolve in the mouth, the 
contact between the dosage form and the oral mucosa is usually brief. 
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Table 1.3 Biological and physical parameters of the human gastrointestinal tract (approximate 
values) (Daugherty and Mrsny 1999; Ashford 2002).  
Segment Surface area Length Residence 
time 
pH  Major catabolic 
activities 
Oral cavity 100 cm2  Seconds to 
minutes 
6.5 Polysaccharidases 
Oesophagus 200 cm2 23-25 cm Seconds 5-6  
Stomach 3.5 m2 
(variable) 
0.25 m 
(variable) 
5 min - 2 h  1-3.5 (fasted 
state) 
Proteases, lipases 
Duodenum 1.9 m2 0.20-0.35 m 0.5-0.75 h 4-5.5 Polysaccharidases; 
oligosaccharidases; 
proteases; 
peptidases, lipases, 
nucleases 
Jejunum 184 m2 2.0-2.8 m 1.5-2.0 h 5.5-7.0 Oligosaccharidases; 
peptidases; lipases 
Ileum 276 m2 3.0-4.2 m 5-7 h 7.0-7.5 Oligosaccharidases; 
peptidases; lipases; 
nucleases; 
nucleotidases 
Colon and 
rectum 
1.3 m2 1.5 m 1-60 h (35 
hours average) 
7.0-7.5 Broad spectrum of 
bacterial enzymes 
 
1.4.1.2 Oesophagus 
Once food or dosage forms leave the oral cavity, they are transported via the 
oesophagus to the stomach by a simple or multiple peristaltic waves. The oesophagus is 
composed of a thick muscular layer whose inner surface is covered with a well-differentiated 
squamous epithelium of non-proliferative cells. The epithelial cells provide a tough 
impermeable lining which resists the abrasive nature of food boluses and its mucus protects 
the lower part of the oesophagus from gastric acid (Ashford 2002). The function of the 
oesophagus is purely mechanical and no activity related to digestion or absorption occurs at 
this point of the gastrointestinal tract (Marieb and Hoehn 2010). In the upright position the 
transit of materials through the oesophagus is assisted by gravity.  
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1.4.1.3 Stomach 
The stomach is the most dilated part of the gastrointestinal tract and is composed of a 
thick muscular layer. The main functions of the stomach are to act as a temporary reservoir for 
ingested food, to mix and reduce ingested solids to a semifluid mass, known as chyme, by the 
action of acid and enzymatic digestion, and then emptying these contents at a controlled rate 
into the upper small intestine (duodenum). This enables better contact of the ingested material 
with the mucous membrane of the intestines and thereby facilitates absorption (Ashford 2002). 
The stomach can be divided into three anatomical regions: the fundus, the corpus or body, and 
the antrum. The proximal region, made up of the fundus and corpus, serves as a reservoir for 
ingested material, which gradually presses the gastric contents forward to the distal stomach 
and the duodenum, whereas the distal region (antrum) acts as a gastric homogenizer and 
grinder and it is coordinated with the corpus in the propulsion of gastric contents towards the 
pylorus (Mayersohn 2002). The opening of the stomach to the to the duodenum is controlled 
by the pyloric sphincter, which allows liquids and fractions of chyme to empty while other 
material is retropulsed into the antrum of the stomach and caught up by the next peristaltic 
wave (contraction of the distal stomach) for further size reduction before emptying (Ashford 
2002). 
Each section of the stomach is covered with a mucous membrane with a variety of 
secretory glands located beneath the epithelium and whose distribution varies from one region 
to another (Washington, Washington et al. 2001). The gastric secretions include (Washington, 
Washington et al. 2001; Ashford 2002):  
• acid (HCl) secreted by the parietal cells, which maintains the pH of the stomach between 1 
and 3.5 in the fasted state;  
• gastrin, a hormone that stimulates gastric acid production and aids in gastric motility. The 
release of gastrin is stimulated by peptides, amino acids and distension of the stomach;  
• pepsins, which are proteases whose precursor, pepsinogen, is released by the gastric chief 
cells (or peptic cells). Pepsins break down proteins into peptides at low pH. The low 
gastric pH produced by the HCl leads to the hydrolysis of pepsinogen into pepsin; Pepsins 
are more efficient in cleaving peptide bonds between hydrophobic and preferably aromatic 
amino acids. 
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• and mucus, which is secreted by the surface mucosal cells and lines the gastric mucosa. 
The mucus protects the gastric mucosa from the combination of acid and the proteolytic 
action of pepsin. 
 
Very little nutrient and drug absorption occurs in the stomach due to its small surface 
area compared to the small intestine. The rate of gastric emptying can be a controlling factor 
in the onset of drug absorption from the major absorptive site, which is usually the small 
intestine (Ashford 2002). 
 
 
1.4.1.4 Small intestine 
The small intestine is the longest and most complex organ of the gastrointestinal tract, 
extending from the pyloric sphincter of the stomach to the ileocaecal junction, where it joins 
the large intestine. Its main functions are to mix food with enzymes and other intestinal 
secretions to facilitate digestion and absorption, and to propel the unabsorbed materials in an 
aboral direction. Although drugs may be absorbed by passive diffusion or by other absorption 
mechanisms from all parts of the gastrointestinal tract, for most drugs, the optimum site for 
drug absorption after oral administration is the small intestine. It is the region of the digestive 
system that presents the vastest surface area for drugs to diffuse passively (Table 1.3). In 
addition, the wall of the small intestine has a rich network of both blood and lymphatic 
vessels. The lymphatic system is important in the absorption of fats from the gastrointestinal 
tract. Its surface area is increased immensely, by about 600 times that of a simple cylinder, to 
approximately 200 m2 in an adult, by the ensemble of three distinctive structures, which render 
the small intestine such a good absorption site: the folds of Kerckring, the villi and the 
microvilli (Ashford 2002). The folds of Kerckring increase the surface of absorption by 3 
times and consist of submucosal coarse folds. These folds are several millimetres in depth and 
extend circularly most of the way around the intestine, being particularly well developed in the 
duodenum and jejunum. The villi (Figure 1.18) amplify the surface of absorption by 30 times 
and are finger-like longitudinal projections into the lumen (approximately 0.5-1.5 mm in 
length and 0.1 mm in diameter). They are covered with an epithelium consisting of a mixture 
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of absorptive cells (enterocytes), mucous cells (caliciform cells) and endocrine cells and are 
well supplied with blood vessels. About 600-1000 of brush-like structures called microvilli 
(~1 µm in length and 0.1 µm in width) cover each villus, providing the largest increase in 
surface area. The microvilli are covered with the glycocalyx, a fibrous substance consisting of 
a mixture of proteins, cholesterol and glycoproteins, and together they form the so-called 
“brush border”, which constitutes an important physical barrier with a powerful enzymatic 
activity (Washington, Washington et al. 2001; Ashford 2002). 
 
 
 
Figure 1.18 Epithelium, lamina propria and villi in the jejunal mucosa. Figure reproduced 
from (Moghaddami, Cummins et al. 1998) with permission of Elsevier Ltd. 
 
 
The small intestine is divided into the duodenum, the jejunum, and the ileum (Figure 
1.17). These regions are not anatomically distinct, although there are differences in villus 
height, absorptive capability, specificity and secretion. The duodenum constitutes the first 20-
35 cm and receives the chyme from the stomach. The duodenum wall contains duodenal 
digestive glands and Brunner's glands. Brunner's glands are only found in the submucosa of 
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the duodenum and they produce a protective, bicarbonate rich, alkaline secretion that 
neutralizes the acidic content from the stomach and provide an alkaline environment for the 
intestinal enzymes to be active. The jejunum is the main area for the absorption of nutrients 
and drugs from the gastrointestinal tract into the systemic circulation. It is thicker walled and 
more vascular than the duodenum and has larger and more numerous villi than the ileum 
(Washington, Washington et al. 2001; Ashford 2002). In the ileum, the Peyer’s patches are 
larger and more numerous than elsewhere in the intestine. The Peyer’s patches are areas of 
lymphoid tissue close to the epithelial surface, which play a key role in the immune response 
as they transport macromolecules and are involved in antigen uptake (Ashford 2002). 
The ileocaecal junction divides the terminal small intestine from the caecum. Its 
function seems to be to retain chyme in the small intestine until digestion is largely complete 
and then to empty its contents into the large intestine. The ileocaecal junction also serves to 
prevent the spread of the colonic bacteria into the small intestine (Melia, Washington et al. 
1994). 
 
The process of digestion depends on the proper functioning of other organs that release 
their secretions into the small intestine, i.e., the liver and the pancreas. These two organs 
produce the elements necessary to the degradation and absorption of lipids, carbohydrates and 
proteins. The role of the liver in the digestion is the production of bile, a complex aqueous 
mixture of organic solutes (bile acids, phospholipids, cholesterol and bilirubin) and inorganic 
compounds (plasma electrolytes, sodium and potassium). Bile is stored in the gallbladder and 
when a meal is ingested, the gallbladder contracts and bile is secreted into the duodenum 
where it emulsifies dietary fat by the formation of micelles, promoting its efficient absorption 
(Ashford 2002; Marieb and Hoehn 2010). In the case of the pancreas, this large gland 
produces and secretes pancreatic juice, which major components are sodium bicarbonate and 
enzymes. The enzymes consist of proteases, mainly trypsin, chymotrypsin and 
carboxypeptidases, which are secreted as inactive precursors or zymogens and converted to 
their active forms in the lumen by the enzyme enterokinase. The pancreatic juice also contains 
amylase, lipase, esterases, and nucleases. The bicarbonate component is largely regulated by 
the pH of chyme delivered into the small intestine from the stomach (Washington, Washington 
et al. 2001; Ashford 2002). 
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1.4.1.5 Large intestine 
The large intestine (or large bowel) is the last section of the digestive system and it is 
about 1.5 m long. It extends from the ileocaecal junction to the anus and consists of the 
caecum, colon, rectum, and anal canal. The colon is, in turn, composed of the ascending colon, 
the hepatic flexure, the transverse colon, the splenic flexure, the descending colon, and the 
sigmoid colon (Washington, Washington et al. 2001; Ashford 2002). The ascending and 
descending colons are relatively fixed, since they are attached via the flexures and the caecum. 
The transverse and sigmoid colons, however, are much more flexible (Ashford 2002). 
The main difference between the structure of the mucosa in the large and small 
intestine is that the first one is devoid of villi. However, the irregularly folded mucosa, the 
microvilli of the absorptive epithelial cells and the presence of crypts, termed crypts of 
Lieberkühn, increase the surface area of the colon by 10-15 times that of a simple cylinder of 
similar dimensions (Washington, Washington et al. 2001; Ashford 2002). Nonetheless, the 
surface area remains approximately 1/30th that of the small intestine (Ashford 2002). An 
important number of mucous cells are dispersed within the colonic mucosa, which is thicker 
and tighter than the mucosa of the small intestine (Marieb and Hoehn 2010).  
One of main functions of the colon is the absorption of sodium ions, chloride ions and 
water from the lumen in exchange for bicarbonate and potassium ions. Thus, the colon has a 
significant homeostatic role in the body (Caspary 1992; Ashford 2002). The metabolic activity 
in the colon is carried out by the bacterial microflora and is limited to the fermentation of 
polysaccharides and proteins which have escaped digestion (Caspary 1992). The large 
intestine is also responsible for the formation of a solid stool and the storage of faecal matter 
until it can be discharged. 
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1.4.2 Gastrointestinal transit of pharmaceutical dosage form 
1.4.2.1 Introduction 
The transit time of SR dosage forms through certain regions of the gastrointestinal tract 
may represent a physiological constraint on the use of these pharmaceutical products, given 
that it limits the residence time at the absorption site and, consequently, the maximum period 
of time during which a therapeutic response can be maintained following administration of a 
single dose. If SR drug delivery systems are being designed, it is, thus, important to consider 
their transit times along each area of the digestive system, amid other factors that will affect 
their behaviour, such as the gastrointestinal fluids composition and pH differences. It is also 
important to take into account that certain situations, such as certain disease conditions or the 
presence of some drugs can affect gastrointestinal transit. 
 
 
1.4.2.2 Oesophagus 
Normally, transit through the oesophagus is extremely rapid and dependent upon the 
size, shape and density of the dosage form and the position of the subject. In general, most 
dosage forms, when taken in an upright position, transit through the oesophagus in about 10 to 
15 seconds (Washington, Washington et al. 2001; Ashford 2002). Large oval tablets seem to 
have a shorter oesophageal transit than large round tablets. However, the size and shape of 
formulations have little influence on oesophageal transit compared to the posture of the 
subject. Generally, oesophageal transit is slower in supine patients than upright ones 
(Washington, Washington et al. 2001). Tablets/capsules taken in the supine position, 
especially if taken without water, are likely to lodge in the oesophagus. Adhesion to the 
oesophageal wall can occur as a result of partial dehydration at the site of contact and the 
formation of a gel between the formulation and the oesophagus. The chances of adhesion will 
depend on the size, shape and type of formulation. A delay in reaching the stomach may delay 
the onset of action of the drug or cause damage or irritation to the oesophageal wall, 
depending that damage on the drug (Ashford 2002). 
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1.4.2.3 Stomach and gastric retention and emptying 
The time a non-disintegrating dosage form takes to traverse the stomach is usually 
termed the gastric residence time, gastric emptying time or gastric emptying rate. Gastric 
emptying of pharmaceuticals is highly unpredictable and depends greatly on the type of 
dosage form (size and shape) and the presence (fed state) or absence (fasting state) of food in 
the stomach. Other factors that can influence gastric emptying include the postural position, 
the composition of the ingested food, the effects of the drugs present in the formulation, such 
as possible irritancy of the drug on the mucosa, and disease state.  
 
Gastric emptying: interdigestive and digestive phases 
 
 
Figure 1.19 Schematic representation of the interdigestive motility pattern, frequency of 
contraction forces during each phase and average time period for each phase. Figure 
reproduced from (Prajapati, Jani et al. 2013) with permission of Elsevier Ltd. 
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During the interdigestive phase, the fasted stomach exhibits a cyclic activity called the 
migrating motor complex (MMC) (Figure 1.19), which governs the transit of dosage forms. 
Each cycle can be divided into four phases. Phase I, the most quiescent, develops few or no 
contractions for 30 to 60 minutes. Phase II, which lasts 20 to 40 minutes, is characterized by 
the gradual increase of the incidence of irregular and intermittent sweeping contractions 
simultaneously in the antrum and duodenum, culminating in the onset of phase III. During 
phase III intense bursts of circular peristaltic waves start in the stomach and sweep the residual 
material and bacteria rapidly down the entire small intestine into the colon. These powerful 
peristaltic contractions, which last about 10 to 20 minutes and are often called the housekeeper 
waves, open the pylorus and clear the stomach of any residual material, including existing 
large non-disintegrated tablets and capsules. These waves then subside to phase IV, a short 
transitional period of decreasing activity until next cycle (Kelly 1980; Sarna 1985; Ashford 
2002; Prajapati, Jani et al. 2013). The different phases of the cycle migrate distally from the 
stomach to the duodenum and further proceed from the small intestine through the colon 
(Sarna 1985; Kellow, Borody et al. 1986). The whole cycle repeats itself every 1.5 to 2 hours 
until a meal is ingested, at which stage the MMC cycle is immediately interrupted (Code and 
Marlett 1975; Thompson, Wingate et al. 1980) and the digestive phase initiated (Malmud, 
Fisher et al. 1982). Therefore, the emptying of individual units from the fasted stomach is 
extremely erratic, occurring any time between 10 minutes and 3 hours after administration, 
depending on the occurrence of the next MMC relative to the time of dosing (Melia, 
Washington et al. 1994). 
When food is ingested, the proximal stomach relaxes to receive it and gradual 
contractions of this region move the contents distally. The distal part of the stomach develops 
peristaltic contractions moving as a ring from the mid-stomach toward the antrum to the 
pylorus, which mix and break down food particles and move them towards the pyloric 
sphincter. The pyloric sphincter allows liquids and small food particles to empty, while the 
solids unable to pass forward are retropulsed back into the antrum of the stomach and caught 
up by the next peristaltic wave for further size reduction before emptying (Moes 1993; 
Ashford 2002). Food intake also induces changes in the gastrointestinal environment, 
including lumen content, pH, viscosity, ionic strength, osmolality, secretions (bile salts, 
digestive enzymes, etc.), metabolic enzymes, and transporters (Qiu 2009).  
  
79 
Close parallels are found between the gastric transit of the different food components 
and their pharmaceutical formulation counterparts. In the fed state, liquids, pellets and 
disintegrating tablets will tend to empty with food, whereas large SR dosage forms can be 
retained in the stomach for long periods of time (Melia, Washington et al. 1994; Ashford 
2002). However, there is no certitude regarding the exact size of a dosage form that would not 
be expelled until the MMC arrival. It has been reported that non-disintegrating dosage forms 
up to 7 mm in diameter can still be emptied from the human stomach during the postprandial 
period (Park, Chernish et al. 1984; Khosla, Feely et al. 1989). A non-disintegration dosage 
form greater than 10 mm, on the other hand, will have to wait until the end of digestion before 
it can be cleared from the stomach into the small intestine in association with the phase III 
cleansing contractions of the MMC activity (Smith and Feldman 1986). The cut-off size of 
solids that are retained in a fed stomach is also influenced by the inter-individual variations in 
the diametrical opening of the pylorus and in the pressure force of the propelling waves. In 
addition, gastric emptying is proportional to meal size and composition. Emptying of a large 
single-unit dosage form after a light meal has been reported to happen at 2 to 3 hours after 
administration (Melia, Washington et al. 1994), whilst if the same  dosage form is given with a 
large meal and the subject is fed at regular intervals, the dosage form can remain in the 
stomach for over 16 hours (Mojaverian, Ferguson et al. 1985) owing to prolonged suppression 
of the MMC. The longer gastric residence time will delay drug absorption.  
 
The gastric residence time of non-disintegrating monolithic dosage forms in the fasted 
state is, thus, mainly dependent on the coincidence between dosing time and phase III 
occurrence. The gastric emptying is, however, rather unpredictable and the residence time is 
usually short and highly variable (Moes 1993). Consequently, the fasting mode of 
administration of large SR dosage forms has the disadvantage of offering only a limited period 
of time for effective drug-release in the upper tract. As a result, reduced drug bioavailability is 
likely to occur, particularly if the optimum absorption region is in the small intestine (Welling 
and Dobrinska 1987). 
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1.4.2.4 Small intestine 
The small intestine is the main site of absorption in the gastrointestinal tract for most 
drugs. Therefore, small intestinal transit time is an important parameter as the extent of drug 
absorption from the small intestine is directly related to the length of time that the drug 
remains in contact with the absorptive epithelium. 
The average small intestine transit duration is approximately three hours (Davis, Hardy 
et al. 1986; Davis, Hardy et al. 1986; Khosla, Feely et al. 1989; Ashford 2002). Studies on 
whether the presence of food influences intestinal transit times have been contradictory, with 
some authors reporting variations depending on whether the subject has eaten and the size of 
the meal (Read and Sugden 1988; Melia, Washington et al. 1994) and others stating that, in 
contrast to the stomach, the small intestine does not discriminate between solids and liquids, 
and hence between dosage forms (e.g. solutions, pellets and single units) or between the fed 
and the fasted state (Davis, Hardy et al. 1986; Khosla, Feely et al. 1989; Moes 1993; Ashford 
2002).  
The discrimination between the fed and the fasted state and dosage forms can be 
explained based on the fed and fasted patterns of motility in the small intestine. The fasting 
motility pattern is a continuation of the MMC initiated in the stomach. For most of the fasting 
period the majority of the small intestine is at rest. At approximately 90-120 minute intervals, 
an intense contraction sweeps from the duodenum to the ileum, taking approximately 90 
minutes to complete its journey. As one contraction ends, another begins. These contractions 
serve to sweep the stomach and small intestine of material that has no nutritional value, 
quickly moving it to the colon. The fed pattern of motility is random and consists of segmental 
and peristaltic contractions, with the segmental contractions being the most frequent. The 
segmental motility is characterized by reversible contractions of adjacent segments of the 
bowel, less than 2 cm in length. This type of motility mixes chyme by continually moving it in 
the lumen and increasing the contact with the absorbing surface. Since there are less frequent 
segmental contractions aborally than orally, there is a net movement of chyme towards the 
large intestine. This movement is enhanced by peristaltic contractions that occur less 
frequently than segmental contractions and each of them move the chyme a few centimetres 
(Melia, Washington et al. 1994). Therefore, there are two main types of intestinal movement, 
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propulsive and mixing. The propulsive movements primarily determine the intestinal transit 
rate and, consequently, the residence time of the drug or dosage form in the small intestine 
(Melia, Washington et al. 1994; Ashford 2002).  
The physical and chemical nature of the food determines the number of small intestinal 
contractions and, thus, the transit through the small intestine. For example, large amounts of 
unabsorbable carbohydrate or a large amount of fluid accelerate transit and could, therefore, 
reduce the degree of absorption from a SR formulation taken with the meal (Read, Miles et al. 
1980). The presence of fat in the distal small intestine, on the other hand, prolongs transit time 
and may, therefore, increase the degree of absorption from SR dosage forms by increasing 
their residence time in the upper gastrointestinal tract. However, unlike the stomach, the 
intestine does not appear to discriminate between liquids and small solid particles (Melia, 
Washington et al. 1994). Small intestinal residence time is particularly important for SR 
dosage forms, because when administered after a light breakfast, for example, these dosage 
forms can reach the large intestine after 4-6 hours. The motor activity of the upper small 
intestine also differs from that in the ileum. The luminal contents travel rapidly through the 
jejunum to the ileum, where they may remain until transported gradually into the colon (Read, 
Al-Janabi et al. 1986). 
Non-disintegrating matrices may remain at the ileocaecal junction for some time. 
Times ranging from 2-20 hours in the ileocaecal region have been reported (Marvola, Aito et 
al. 1987). 
 
 
1.4.2.5 Large intestine 
The transit time of dosage forms through the large intestine, in particular through the 
colon is long and variable, ranging from anything between 2 and 48 hours, and depends on the 
type of dosage form, diet, eating pattern and disease state (Ashford 2002). The colonic transit 
is mainly aboral and is characterized by short bursts of activity followed by long periods of 
stasis. The contractile activity in the colon can be divided into propulsive contractions or mass 
movements, which are associated with the aboral movement of contents, and segmental 
contractions, which serve to mix the luminal contents and result in only small aboral 
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movements. Segmental contractions are caused by contraction of the circular muscle and 
prevail, whereas the propulsive contractions are due to contractions of the longitudinal muscle 
and occur only 3-4 times daily in normal individuals (Ashford 2002). 
As a result of the usually long transit time through the colon, a SR dosage form is 
likely to spend a long time, if not most of its time, within the large intestine. Therefore, transit 
through the colon is an important parameter in optimizing delivery of drugs by SR dosage 
forms for prolonging drug absorption.  
It is expected that absorption of most drugs from the colon, by comparison with that in 
the small intestine, will be slower, because the colonic mucosa has a much lower and more flat 
surface area, with fewer folds and without villi. In addition, the lumen of the colon is wider, 
the movement more sluggish and the volume of dissolution fluid available is low. Apart from 
transit constraints, drugs also encounter transverse resistance to absorption in the colon (Melia, 
Washington et al. 1994). However, many drugs appear to be well absorbed from the colon as 
the low surface area is balanced by the prolonged residence time in this region. In fact, studies 
have demonstrated that the model drugs used in the studies of the present thesis, 
acetaminophen (Ishibashi, Ikegami et al. 1999) and tramadol hydrochloride (Lintz, Barth et al. 
1998) are quickly and well absorbed from the colon. This is important because it enhances the 
likelihood of a complete absorption of these drugs from the developed dosage form. 
 
 
1.4.3 Barriers to drug absorption 
The mechanisms necessary for the digestion of food and the absorption of nutrients, 
and for the protection of the intestinal membrane represent potential barriers to the passage of 
exogenous molecules into the systemic circulation. Next, a description of some physiologic 
parameters that may influence intestinal drug absorption is given.  
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1.4.3.1 The environment within the lumen 
In general, a drug substance must be in solution form before it can be absorbed through 
the absorptive epithelia of the gastrointestinal tract into the body fluids. Besides, it cannot 
become bound to food or other material within the gastrointestinal tract, and it needs to be 
chemically stable in the pH gradient and resistant to enzymatic degradation along the 
gastrointestinal tract (Ashford 2002). The gastrointestinal pH may influence the chemical 
stability of the drug in the lumen, its dissolution or its absorption, if the drug is a weak 
electrolyte. The digestive enzymes found in the gastrointestinal tract may degrade drugs or 
dosage forms that resemble nutrients (Ashford 2002), as it is the case of the degradation of 
peptide drugs by pepsin and proteases, or of starch-based dosage forms by amylases. In 
addition, the intestinal microflora can metabolize a wide variety of pharmacological agents 
resulting in production of metabolites required for the physiological activity of these agents or 
conversely in the inactivation of these agents (Goldin 1990). The presence of food in the 
gastrointestinal tract can also influence the rate and extend of absorption via a variety of 
mechanisms, some of which, such as the modification of the gastric pH and emptying time and 
the stimulation of gastrointestinal secretions, were described in previous sections. Other 
mechanisms include competition between food nutrients and drugs with a similar chemical 
structure for specialized absorption mechanisms, or the irreversible complexation of drugs 
with food components as, for example, tetracycline and calcium (Ashford 2002). 
 
 
1.4.3.2 Mucus 
The gastrointestinal epithelium is covered by a continuous layer of protective mucus 
gel that a drug must first diffuse through before it can be absorbed across the epithelium 
(Thomson and Dietschy 1977). In performing its functions, mucus may adversely affect the 
absorption of drugs administered by the oral route. The diffusion coefficient of a drug through 
mucus depends on the relative size of the drug molecule, the effective mesh size of the 
mucous gel formed by the association of the mucin macromolecules, and any interactions 
between the drug and the mucous components. For example, an inverse relationship between 
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molecular weight and diffusion coefficient of the drug has been observed. In addition, the 
permeability of small, uncharged molecules appears to not be as significantly affected by a 
mucous barrier as larger or charged (cationic) molecules, which can form ionic bonds with 
negatively charged mucins (Khanvilkar, Donovan et al. 2001). 
 
 
1.4.3.3 Gastrointestinal membrane and drug transport mechanism 
The gastrointestinal membrane separates the lumen of the stomach and the intestines 
from the systemic circulation, and is the main cellular barrier to the drug absorption. As for all 
other cell membranes, the plasma membrane in the intestinal epithelial cells consists of lipids, 
proteins, lipoproteins and polysaccharides. The elemental structure of the membrane, usually 
known as the fluid mosaic model (Figure 1.20), is the phospholipid bilayer, which forms a 
stable barrier between two aqueous compartments, i.e., the inside and the outside of the cell. 
The barrier has the characteristics of a semipermeable membrane, allowing the rapid transit of 
some materials and restraining the passage of others. Proteins embedded within the 
phospholipid bilayer carry out the specific functions of the plasma membrane, including 
selective transport of molecules (Cooper 2000; Ashford 2002). 
 
 
Figure 1.20 Fluid mosaic model of cell membranes (epithelial and other cell membranes) with 
the integral and peripheral proteins embedded in the phospholipid bilayer. Figure reproduced 
from (Fry 2007) with permission of Elsevier Ltd. 
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Absorption across the gastrointestinal epithelium is mediated by transcellular (across 
the cells) and paracellular (through the intercellular spaces) mechanisms. The transcellular 
pathway (Figure 1.21) involves passive or active movement across cell membranes and is 
divided into passive transport (simple diffusion and diffusion via pores in the plasma), carrier-
mediated transport (facilitated diffusion and active transport), and endocytosis (Ashford 2002). 
Paracellular transport (Figure 1.22) involves the movement of drugs between cells also by 
passive diffusion (Thummel, Kunze et al. 1997). Endocytosis is a process by which cells 
absorb molecules by incorporating them into the interior of vesicles resulting from the 
invagination of the cellular membrane. After detachment from the membrane, the vesicles fuse 
with the lysosomes, which, more often than not, lead to the degradation of the drug (Hillery, 
Lloyd et al. 2001).  
 
 
 
Figure 1.21 Passive transport (simple diffusion or diffusion via pores) and carrier-mediated 
transport (facilitated diffusion and active transport) across the plasma membrane. Figure 
reproduced from (Baynes and Riviere 2010) with permission of Elsevier Ltd. 
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Figure 1.22 Pathways of epithelial permeability. Transcellular permeability is associated with 
solute or water movement through intestinal epithelial cells. Paracellular permeability is 
associated with movement in the intercellular space between epithelial cells and is regulated 
by tight junctions (one of the components responsible for the contact between epithelial cells 
and for the regulation of transport between extracellular and intracellular space). Figure 
reproduced from (Groschwitz and Hogan 2009) with permission of Elsevier Ltd. 
 
 
Passive diffusion is the free diffusion of relatively small lipophilic molecules, and thus 
many drugs, across the lipoidal membrane, from a region of high concentration in the lumen 
(apical side) to a region of lower concentration in the blood (basolateral side). Blood flow and 
a rapid distribution of the drug maintain a lower concentration at the basolateral side than at 
the absorption site. The rate of transport is determined by the physicochemical properties of 
the drug, the nature of the membrane and the concentration gradient of drug across the 
membrane (Ashford 2002). The rate of diffusion can be determined mathematically by Fick’s 
law of diffusion (Hillery, Lloyd et al. 2001): 
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€ 
dQ
dt =
D.k.A.ΔC
h        Equation 10 
 
where dQ/dt represents the rate of drug diffusion across a membrane; D, the diffusion 
coefficient and k, the partition coefficient of the drug in the membrane; h, the membrane 
thickness; A, the surface area available for absorption; and ΔC, the concentration gradient 
between the two sides of the membrane. 
 
Facilitated diffusion is as well a passive mechanism. However, it implies the link 
between the drug and a membrane transport protein, and thus it is reserved to the molecules 
that present a strong structural homology with the receptor substrate (Hillery, Lloyd et al. 
2001). The movement occurs down a concentration gradient and, just as passive diffusion, it 
does not require an input of chemical energy. In contrast, active transport moves subtracts 
against a concentration gradient and, therefore, uses cellular energy, such as from adenosine 
triphosphate (ATP) hydrolysis.  
 
Drug transporters can be generally separated into two major classes – uptake and 
efflux transporters. Uptake transporters act by facilitating the transfer of drugs into cells. By 
contrast, efflux transporters transport drugs from the intracellular to the extracellular milieu, 
often against high concentration gradients (Ho and Kim 2005).  
Targeted localization of transporter proteins is involved in the intestinal absorption 
process as well as in the urinary or biliary excretion of many drugs. These drug transporters 
tend to be multifunctional and often have normal physiologic roles in terms of transporting 
endogenous substances such as sugars, lipids, and hormones. They are an important class of 
proteins for regulating cellular and physiologic solute and fluid balance (Ho and Kim 2005). 
Both carrier-mediated transport processes are saturable, and can be inhibited and induced. 
Induction as well as inhibition of carriers involved in drug transport may lead to diminished or 
enhanced absorption of drugs with affinity for these carriers (Wagner, Spahn-Langguth et al. 
2001).  
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In the small intestine, enterocytes possess a number of transporters essential for 
absorption of dietary constituents and drugs. However, among these proteins there is an efflux 
transporter which can actively pump drugs back into the intestinal lumen and which has been 
determined to be particularly important in effectively limiting the extent of drug absorption 
(bioavailability). This multidrug resistance 1 gene (MDR1) product, known as P-glycoprotein 
(Pg-p), is a transmembrane efflux protein which was first described in tumour cell lines 
displaying cross-resistance to various anticancer agents (Juliano and Ling 1976). It acts as an 
ATP-dependent pump that expels drugs out of cells (Chin, Pastan et al. 1992). In addition to 
tumour cells, Pg-p is present in normal tissues (Thiebaut, Tsuruo et al. 1987; Cordon-Cardo, 
O'Brien et al. 1990), such as on the apical (luminal) side of the epithelial cells in the intestine, 
liver, kidney and pancreas (Thiebaut, Tsuruo et al. 1987). Therefore, it plays a significant role 
in regulating absorption, excretion, and tissue distribution of many drugs, as well as in 
detoxification processes (Wacher, Salphati et al. 2001).  
Substrates for Pg-p cover a broad range of structures with diverse therapeutic 
indications (Benet, Izumi et al. 1999). For example, studies have indicated that 
acetaminophen, one of the model drugs used in the present study, is a Pg-p substrate and, 
therefore, Pg-p is involved in acetaminophen transport (Manov, Bashenko et al. 2006). 
However, reports on the functional interaction of Pg-p and tramadol, the second model drug 
used in the study, have been contradictory, with some authors suggesting that tramadol is not a 
Pg-p subtract (Kanaan, Daali et al. 2009; Hamidi, Sheikholeslami et al. 2012) and others 
pointing out that tramadol is one of the Pg-p substrates (Slanar, Nobilis et al.). However, both 
drugs are mainly absorbed by passive diffusion and, therefore, the physicochemical aspects 
related to drug bioavailability are the most important to take into account.  
 
 
1.4.3.4 First-pass metabolism 
In addition to the physical barrier consisting of mucus and the cellular membrane, a 
myriad of enzymes also represent a barrier to drug absorption. Orally administered drugs and 
other xenobiotics can be metabolized by different enzymes in the enterocytes or during their 
passage through the liver. In general, drug-metabolizing enzymes protect the body against the 
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harmful exposure to xenobiotics as well as certain endobiotics (Niwa, Murayama et al. 2009). 
Together, these metabolic processes that the drug undergoes before reaching the systemic 
circulation constitute the first-pass metabolism, also known as first-pass effect (Thummel, 
Kunze et al. 1997).  
First-pass metabolism of drugs and other exogenous compounds involves sequential 
reactions occurring in two phases. Phase I reactions are broadly grouped into three categories, 
oxidation, reduction, and hydrolysis, though oxidation by the cytochrome P450 (CYP) 
superfamily of microsomal enzymes is the most common phase I reaction. These reactions aim 
to increase the polarity of the compound. They are followed by phase II reactions in which the 
metabolite resulting from phase I is conjugated to a polar ligand. In general, conjugation with 
phase II enzymes further increases hydrophilicity, and thereby enhances excretion in the bile 
and/or the urine and, as a result, a detoxification effect (Schuetz, Beck et al. 1996; Xu, Li et al. 
2005).  
The CYP superfamily of enzymes can be classed in families (e.g., CYP2) and 
subfamilies (e.g., CYP2D), which include numerous isoenzymes or isotypes (e.g., CYP2B6, 
CYP3A4) (Thummel, Kunze et al. 1997; Xu, Li et al. 2005). In the digestive system, CYP 
enzymes are found mostly in the hepatocytes (Wacher, Wu et al. 1995; Wacher, Salphati et al. 
2001). However, it was demonstrated that enzymes of the CYP3A subfamily – considered the 
major phase I drug-metabolizing enzymes in humans (Wacher, Wu et al. 1995) – are 
expressed at high levels in the mature villus enterocytes of the small intestine (Kolars, Lown et 
al. 1994; McKinnon, Burgess et al. 1995), and thus have an essential role in the absorption 
process. CYP3A comprises 30% (Shimada, Yamazaki et al. 1994) and 70% (Watkins, 
Wrighton et al. 1987; Kolars, Lown et al. 1994) of total CYPs in the human liver and intestine, 
respectively. Among the CYP3A subfamily, CYP3A4 is the most abundant and most 
important enzyme in human drug metabolism (Benet, Izumi et al. 1999; Wacher, Salphati et 
al. 2001; Zhang and Benet 2001). Indeed, immunohistochemical studies suggest that the major 
CYP3A protein present in the liver, jejunum, colon and pancreas is CYP3A4 (Zhang and 
Benet 2001).  
CYP3A4 substrates include a large number of structurally diverse drugs, covering a 
wide therapeutic range (Smith and Jones 1992). Two examples of CYP3A4 substrates are the 
model drugs used in this study, acetaminophen and tramadol. 
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Figure 1.23 Main metabolic pathways of tramadol. The main compounds responsible for 
tramadol analgesia are marked in bold. Figure reproduced from (Leppert 2011) with 
permission of Karger Publishers. 
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Tramadol undergoes biotransformation in the liver, first by the phase I reactions 
(mainly O- and N-demethylation), followed by the phase II reactions (mainly conjugation of 
O- and N-demethylated compounds) to form glucuronides and sulfates (Figure 1.23) (Lintz, 
Erlacin et al. 1981). The O-demethylation of tramadol leads to the formation of its main 
metabolite, O-desmethyltramadol (M1), which shows potent analgesic activity, and the N-
demethylation to N-desmethyltramadol (M2). Multiple CYP enzymes are involved in the 
metabolism of tramadol to both M1 and M2. CYP2D6 appears to be primarily responsible for 
M1 formation, whereas M2 formation is catalyzed by CYP2B6 and CYP3A4 (Subrahmanyam, 
Renwick et al. 2001). M1 and M2 may then be further metabolized to secondary metabolites, 
including O,N-didesmethyltramadol (M5), which exhibits analgesic activity but weaker than 
M1. All other metabolites are pharmacologically inactive (Leppert 2011). 
Regarding the metabolism of acetaminophen, the principle routes of elimination are 
glucuronidation and sulfation in the liver although oxidation also occurs (Bessems and 
Vermeulen 2001). Glucuronidation accounts for about 45-55% of acetaminophen dose 
(Bessems and Vermeulen 2001; Kiang, Ensom et al. 2005). Glucuronidation is an important 
conjugation reaction that increases the water solubility of endogenous and exogenous 
compounds (drugs and their metabolites) and enhances their excretion via urine or bile. This 
step can be catalyzed by a series of UDP-glucuronosyltransferases (UGTs), which are 
responsible for the process of glucuronidation, a major part of phase II metabolism. Examples 
of UGTs implied in the metabolism of acetaminophen are UGT1A1 and UGT1A6 in the liver 
(Court, Duan et al. 2001; Kiang, Ensom et al. 2005) and UGT1A10 in the intestine (Kiang, 
Ensom et al. 2005). About 30-35% of metabolism of acetaminophen occurs via sulfation, 
another phase II enzyme reaction. In adult human liver, sulfation of acetaminophen is 
catalyzed by sulfotransferases (SULT), such as SULT1A1 and SULT1A3 (Kiang, Ensom et al. 
2005).  
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1.5 Considerations in the selection of drug candidates for 
incorporation in sustained drug-release dosage forms 
Both the drug-release pattern from a dosage form and the performance of the dosage 
form in the body are a function of the physicochemical and the biological properties of the 
drug. Therefore, a number of drug characteristics have to be considered when evaluating drug 
candidates for oral SR dosage forms. Although, for the purpose of this discussion, the 
properties of a drug will be described as being either physicochemical or biological, it is 
important to keep in mind that the biological properties of a drug are a function of its 
physicochemical properties. For example, the physicochemical properties of drug substances 
influence greatly their passage into solution and their transport across biological membranes, 
and thus have a major impact on their bioavailability. Therefore, it is often necessary to 
consider the various properties as combined factors in order to determine the viability of a 
candidate drug for a SR product. 
 
 
1.5.1 Physicochemical properties of drugs influencing their viability as 
candidates for sustained drug-release dosage forms 
1.5.1.1 Aqueous solubility and dissolution rate 
As a drug must be in solution to be absorbed, drugs that possess very low aqueous 
solubility usually experience oral bioavailability problems, even from IR systems. They may 
suffer inconsistent drug absorption caused by difficulty in achieving adequate solubility at or 
above their main absorption sites along the gastrointestinal tract. A second issue that these 
drugs create in the formulation of oral SR dosage forms where the release mechanism is 
diffusion is that, in this case, the concentration in aqueous solution is the driving force for 
gradual dissolution and release of the drug from the dosage form along the gastrointestinal 
tract (Langer and Wise 1984; Li, Robinson et al. 1987). The choice of release mechanism for a 
SR dosage form is, therefore, conditioned by the aqueous solubility of the drug. In addition, 
drugs with limited aqueous solubility, which have their absorption limited by their dissolution 
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rate, do not usually require any additional control over their dissolution rate. These drugs may 
be good candidates for CR systems designed to make their dissolution rate more uniform 
rather than reducing it (Langer and Wise 1984; Gupta and Robinson 1992). 
The most widespread and effective strategy used to increase solubility and dissolution 
rates of acidic and basic drugs is salt formation (Morris, Fakes et al. 1994; Serajuddin 2007). 
Another technique is the design of bioreversible, more water-soluble derivatives of drugs with 
low solubility, generally called prodrugs (Stella and Nti-Addae 2007; Jana, Mandlekar et al. 
2010). For some drugs, solubility and dissolution may be increased in the fed state because of 
the presence of micellar solubilizers (Luner, Babu et al. 1994). 
Effective SR of drugs with very high aqueous solubility, such as greater than 1 g/10 
mL, may also be very difficult to achieve. Efficient control of the release of such drugs over 
an extended period of time will depend on the dosage form approach chosen. For example, 
when such drugs are incorporated in matrix systems, a high proportion of polymeric matrix to 
drug may be required to produce the SR effect (Langer and Wise 1984). Accordingly, the best 
candidates for SR dosage forms are considered to be drugs that have good but not too great 
aqueous solubility. 
When formulating SR dosage forms, it is also important to take into consideration that 
some drugs which have reasonably good to excellent aqueous solubility may present very low 
dissolution rates, and thus lead to dissolution-limited drug absorption (Langer and Wise 1984; 
Li, Robinson et al. 1987). 
Another very important factor related to aqueous solubility, which is essential to 
consider when formulating new SR dosage forms, is that of pH-dependent solubility. For 
example, drugs that are highly soluble in the acidic pH of the stomach but have a considerably 
reduced solubility at pH 5 or higher may have a limited period of time to dissolve before 
reaching their main absorption site (Langer and Wise 1984). The bioavailability of such drugs 
may be improved by dosage form design approaches such as gastro-retention or formulation of 
the drug together with an acid (if the drug is a weak base) or with a base (if the drug is a weak 
acid) in order to make solubility higher and independent of the external environment (Li, 
Robinson et al. 1987). 
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Other factors affecting the solubility of a drug include crystal polymorphism and the 
capacity of the compound to form hydrogen bonds (Higuchi, Lau et al. 1963; Dresse, Gerard 
et al. 1978). 
In dissolution theory, it is assumed that an aqueous diffusion layer or stagnant liquid 
film of thickness h exists at the surface of a solid undergoing dissolution. This thickness h 
represents a stationary layer of solvent in which the solute molecules exist in concentrations 
from Cs to C. Beyond the static diffusion layer, at x greater than h, mixing occurs in the 
solution and the drug is found at a uniform concentration, C, throughout the bulk phase. The 
dissolution of the drug can be described by the Noyes-Whitney equation: 
 
€ 
dM
dt =
D.A Cs −C( )
h        Equation 11 
 
where, dM/dt is the rate of dissolution of the drug particles; A, the effective surface area of the 
drug particles in contact with the gastrointestinal fluids; D, the diffusion coefficient of the 
drug in solution in the gastrointestinal fluids; h, the thickness of the diffusion layer around 
each drug particle; Cs, the saturation solubility of the drug in solution; and C, the concentration 
of the drug in the gastrointestinal fluids.  
 
The dissolution rate of a drug under sink conditions, according to the Noyes-Whitney 
equation, is directly proportional to its intrinsic solubility in the diffusion layer surrounding 
each dissolving drug particle, Cs. 
 
 
Different levels of approximate solubilities have been described, and are shown in 
Table 1.4 (Aulton 2002). 
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Table 1.4 Levels of approximate solubilities. 
Solubility description Approximate weight of solvent (g) 
necessary to dissolve 1 g of solute 
Very soluble < 1 
Freely soluble Between 1 and 10 
Soluble Between 10 and 30 
Sparingly soluble Between 30 and 100 
Slightly soluble Between 100 and 1000 
Very slightly soluble Between 1000 and 10 000 
Practically insoluble > 10 000 
 
 
Regarding the drugs used in the present study, acetaminophen solubility in water varies 
from sparingly soluble to soluble at 37ºC, with pH-independent solubility at physiological 
values (from 1 to 8.5) (Forrest, Clements et al. 1982), and tramadol hydrochloride is freely 
soluble in water and in ethanol (http://chemicalland21.com/lifescience/phar/TRAMADOL 
HCl.htm, last visited on 20th December 2013). 
 
 
1.5.1.2 Partition coefficient and molecular size 
Following administration, the drug must penetrate a variety of membranes to gain 
access to the site of action. The partition coefficient and the molecular size of a drug are 
essential in determining its feasibility as a candidate for SR products because these properties 
influence both the penetration of the drug across biological membranes and its diffusion across 
a rate-controlling membrane or matrix in the SR system itself (Langer and Wise 1984; Li, 
Robinson et al. 1987). 
The partition coefficient of a drug describes the ratio of the concentrations of that drug 
distributed between two immiscible solvents at equilibrium, and is usually expressed as 
concentration in oil or water-immiscible non-polar solvent/concentration in water (Langer and 
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Wise 1984). Therefore, this coefficient is a measure of the lipid solubility of a drug and 
influences greatly its absorption characteristics. Drugs with very high partition coefficient, i.e., 
very oil-soluble, promptly penetrate the membranes, but will preferably remain in the lipid 
phase rather than pass into the blood circulation. Drugs with extreme aqueous solubility, i.e., 
low oil/water partition coefficients, on the other hand, can hardly penetrate the membranes. 
Therefore, a balanced partition coefficient is mandatory to attain optimum drug diffusion 
across both biological membranes and rate-controlling polymeric membranes or matrices 
(Langer and Wise 1984; Li, Robinson et al. 1987). 
One of the water-immiscible solvents most extensively used in the prediction of drug 
absorption is the fatty alcohol, octanol. In this case, octanol represents the lipophilic phase 
because it is assumed to have a degree of lipophilicity comparable to that of a cell membrane 
(Artursson, Palm et al. 2001). According to octanol/water partitioning coefficient (Poct), the 
permeability in the intestinal epithelium increases approximately with the lipophilicity of the 
drug molecule until a log Poct value of about two is reached, when the absorption is considered 
maximal in humans. A log Poct value > 3-4 is associated with a decrease in permeability, given 
that very hydrophobic drugs usually have low aqueous solubility and will tend to pass at a 
slower rate from the lipophilic cell membranes to the aqueous extracellular fluids (Varma, 
Khandavilli et al. 2004). In the case of ionizable drugs, the apparent distribution coefficient at 
pH 7.4 (Doct) is often used instead of Poct (Artursson, Palm et al. 2001). 
 
Drugs with large molecular sizes also produce erratic drug absorption across the 
intestinal membrane, which will make the design of an oral SR dosage form of that drug 
difficult. Therefore, in order to consider drug diffusion through a polymeric membrane or 
matrix as the rate controlling mechanism for a SR dosage form, the candidate drug must have 
a molecular size and a partition coefficient which will allow it to rapidly penetrate and diffuse 
through membranes (Langer and Wise 1984). 
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1.5.1.3 Biopharmaceutical Classification System 
For many oral dosage forms, the main parameters controlling the extent and rate of 
drug absorption are its aqueous solubility and gastrointestinal permeability (Amidon, 
Lennernas et al. 1995). Therefore, a classification system categorizing drug molecules into 
four classes according to their solubility along the gastrointestinal pH range and their 
permeability across the gastrointestinal membrane was proposed. This classification is 
presented in Table 1.5 (Amidon, Lennernas et al. 1995): 
 
Table 1.5 Biopharmaceutical Classification System (BCS). 
 High permeability Low permeability 
High water solubility Class I Class III 
Low water solubility Class II Class IV 
 
 
A drug is considered to be highly soluble when the maximal dose strength available is 
soluble in 250 mL or less of water or a buffer over a large pH range (1-8), and highly 
permeable when the fraction of absorbed dose in humans is expected to be greater than 90% 
(Ashford 2002). 
 
The BCS was introduced as a useful tool for the replacement of certain in vivo 
bioequivalence studies with accurate in vitro dissolution and permeability studies. These in 
vitro studies are expected to be capable of predicting in vivo performance of a drug (Galia, 
Nicolaides et al. 1998). According to this model, all drugs except the ones belonging to the 
Class I will lead to unreliable intestinal absorption and low bioavailability. It is desirable that 
candidates to SR dosage forms belong to Class I drugs, so that drug-release from the dosage 
form is the rate-limiting step and the drug is rapidly and reliably transported across the 
gastrointestinal wall. 
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1.5.1.4 pKa (logarithmic measure of the acid dissociation constant) 
Once in solution, the absorption of a drug is also influenced by its dissociation 
constant, Ka, and the pH at the absorption site. The pKa of a drug is an important 
physicochemical consideration in the formulation of SR dosage forms, because it indicates the 
fraction of the drug that will be ionized and/or unionized at different pH values. Acidic drugs 
with low pKa values will have a higher fraction of uncharged species in the low pH of the 
stomach and first section of the small intestine. However, they may be nearly completely 
ionized in the mid to lower small intestine where the pH increases to 7 and above. Basic drugs, 
on the other hand, have higher pKa values and will be more soluble in the acidic pH of the 
stomach, where they are mostly ionized, but may be almost entirely in their uncharged form 
under the conditions of the higher pH in the mid to lower small intestine. Most drugs are 
preferentially absorbed in their unionized form, as only this form can diffuse readily across the 
cell membranes. Therefore, the pKa of a drug provides a good indication of the main site of 
absorption of the drug along the gastrointestinal tract as well as indicate possible problems 
with the local absorbability (Langer and Wise 1984). 
 
The extent to which a weakly acidic or basic drug ionizes in solution in the 
gastrointestinal fluid can be calculated using the appropriate form of the Henderson-
Hasselbalch equation. For example, for a weakly basic drug possessing a single ionizable 
group the equation takes the form of:  
 
€ 
log BH
+[ ]
B[ ]
= pKa − pH        Equation 12 
 
 
1.5.1.5 Drug stability 
As described before, regardless of the type of dosage form employed, an orally 
administered drug will be exposed to the luminal contents of the gastrointestinal tract (pH 
range, ionic environment, enzymes and flora) before it is absorbed. For this reason, the 
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stability of a drug in the gastrointestinal environment is another decisive physicochemical 
factor to be considered when determining the viability of designing a SR dosage form 
containing that drug, or when considering dosage forms design approaches (Langer and Wise 
1984; Li, Robinson et al. 1987). By gradually releasing the drug to solution in an environment 
in which it is unstable, a SR dosage form will cause the destruction of just about the entire 
drug amount. For example, drugs that undergo extensive metabolism along the intestinal tract 
and in the gastrointestinal membrane may be poor candidates for SR dosage forms. Releasing 
such drugs in low concentrations as they transit along the small intestine will increase the 
fraction of the drug that is metabolized (Langer and Wise 1984). In addition, if some degree of 
colonic absorption is expected, stability to the metabolizing effect of the colonic bacterial 
population is also required (Gupta and Robinson 1992). Typically, the drug must be stable in 
the pH range of 1 to 8 to be considered viable in SR systems (Gupta and Robinson 1992).  
Regarding the drugs used in the present study, the first drug, acetaminophen, has pH-
independent solubility at physiological values (from 1 to 8.5). Hence, this drug is not 
considered to ionize in the physiological pH range (Forrest, Clements et al. 1982). Tramadol 
hydrochloride, the second model drug, has been found to be stable under extreme conditions 
of pH (1N-HCl and 1N-NaOH) for at least 4 weeks (Zaghloul and Radwan 1997). 
Acetaminophen is not subject to any significant enzymatic or bacterial degradation in 
the gastrointestinal lumen (Mattok and McGilveray 1973). The fact that after oral 
administration, nearly all tramadol hydrochloride is absorbed from the gastrointestinal tract 
(Grond and Sablotzki 2004), suggests that this drug is also stable in the gastrointestinal tract 
fluids. Although, the bioavailability of tramadol after a single administration is 70% due to 
extensive first-pass metabolism (Malonne, Sonet et al. 2004), the bioavailability of a SR 
dosage form at steady state is 100% relative to an IR formulation (Raber, Schulz et al. 1999). 
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1.5.2 Biological and pharmacological properties of drugs influencing their 
viability as candidates for sustained drug-release dosage forms 
1.5.2.1 Size of dose, biological half-life and duration of action 
The size of a drug dose is a major factor determining the feasibility of a candidate drug 
for oral SR. When considering the dose of drug to be incorporated into a SR dosage form, it is 
as well necessary to take into consideration the biologic or elimination half-life of that drug 
(generally referred to as t1/2), as these two aspects are related. The t1/2 is the period of time 
required for any specific concentration of a drug in the body to decrease by one-half following 
completion of the absorption phase. It gives an index of the residence time of that drug in the 
body as well as of its duration of action. Therefore, t1/2 also plays a key role in the process of 
deliberating if a drug is suitable for oral SR dosage forms. Factors influencing the t1/2 of a drug 
include its elimination, metabolism, and distribution patterns (Langer and Wise 1984; Li, 
Robinson et al. 1987; Gupta and Robinson 1992).  
Drugs with very short t1/2 require frequent dosing in order to minimize fluctuations in 
blood levels accompanying conventional oral dosage regimens. Therefore, it would appear 
that SR is an advantageous approach for delivering such drugs. However, the formulation of 
SR dosage forms containing these drugs poses some difficulties. First, their elimination rate is 
quite high, and for the required period of time during which the drug is to be released in order 
to achieve the desired duration and intensity of effect, this high elimination rate may, in turn, 
lead to a prohibitively large total dosage for the SR product, especially when the usual 
conventional single dose is already relatively big. This large quantity of drug added to the 
quantity of excipients required to retard its release may exceed that which can be easily 
swallowed in a single solid dosage form. This situation applies particularly to drugs with an 
t1/2 of less than 2 hours, as well as those that are administered in large doses (Gupta and 
Robinson 1992; Kumar, Bhowmik et al. 2010). Besides, the quantity of polymer necessary to 
efficiently retard the release of drug from matrix dosage forms often equals or surpasses the 
quantity of drug being retarded. Moreover, it is mandatory to develop a “fail-safe” dosage 
form that will not allow dumping of all the dose in the product at one time caused by failure of 
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the dosage form or by exposure to a combination of physiological factors (Langer and Wise 
1984), in particular for high dosages and/or drugs with a narrow therapeutic window. 
Drugs with long elimination half-lives of eight hours or more are, on the other hand, 
commonly sufficiently sustained in the body when administered in conventional dosage forms. 
Hence, SR dosage forms are generally not necessary in such cases (Gupta and Robinson 1992; 
Kumar, Bhowmik et al. 2010). 
Therefore, the best candidates for SR systems are usually drugs with relatively short, 
but not very short, biological half-lives, which require frequent administration of a 
conventional dosage form to provide therapeutic drug levels (Langer and Wise 1984).  
Relatively to the drugs used in the present work, the reported values for the plasma 
mean t1/2 of acetaminophen, the first model drugs used, are about 1 to 4 hours (Cao, Choi et al. 
2005). Therefore, this drug was replaced by tramadol hydrochloride, which has a mean t1/2 of 
about 5 to 6 hours (Raffa, Nayak et al. 1995). 
 
 
1.5.2.2 Absorption properties 
As a rule, for SR formulations, the rate-limiting step is the rate of drug-release from 
the dosage form. Therefore, it is desirable that drug absorption from the gastrointestinal tract 
be faster than drug-release from the dosage form. For this reason, efficient drug absorption is a 
requirement for a drug to be considered as candidate for oral SR applications (Gupta and 
Robinson 1992). 
Although, it would be preferable to have a complete absorption of the released drug, 
variation in both the extent and rate of drug absorption can take place due to the multiplicity of 
factors already described in a previous section, such as hydrolytic degradation by digestive 
enzymes, physical loss, metabolism by the intestinal flora or during transit across the 
gastrointestinal membrane. In addition, the diverse absorptive capacity of the different 
segments of the gastrointestinal tract can also influence the amount and rate of absorption for 
some drugs. However, as long as the variations in drug absorption are not very significant, a 
successful SR dosage form can be produced (Li, Robinson et al. 1987). 
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For drugs that are absorbed by passive diffusion, as it is the case of the model drugs 
used in the present study, the permeation across the gastrointestinal membrane usually shows a 
consistent pattern, even though the rate of drug absorption may decline progressively. But, for 
drugs that are absorbed by means of specialized transport mechanisms, such as active 
transport, and/or at restricted areas along the gastrointestinal tract, absorption from the 
gastrointestinal lumen may not be consistent, which limits their suitability for SR applications 
(Langer and Wise 1984; Li, Robinson et al. 1987; Gupta and Robinson 1992).  
Another important aspect of the absorption process via the oral route is the magnitude 
of the absorption rate constant. Drugs with very low absorption rate constants are poor 
candidates for SR products because the desired release rate constant from the dosage form 
would have to be even lower. Besides, as the gastrointestinal transit time is restricted, a SR 
dosage form containing a drug with a very low absorption rate constant will generally have 
poor drug bioavailability (Li, Robinson et al. 1987).  
In literature, it is stated that following oral administration tramadol is rapidly and 
almost completely absorbed by passive diffusion. Its bioavailability of 70% after a single 
administration can be attributed entirely to extensive first pass metabolism (Grond and 
Sablotzki 2004; Malonne, Sonet et al. 2004; Mattia and Coluzzi 2005). Acetaminophen is also 
rapidly absorbed by passive diffusion, its systemic bioavailability being dose-dependent and 
ranging from 70 to 90%. Its rate of oral absorption is predominantly dependent on the rate of 
gastric emptying and on the factors and drugs that influence it. Acetaminophen is also well 
absorbed from the rectum (Forrest, Clements et al. 1982). 
 
 
1.5.2.3 Distribution 
Although having as much information as possible on the disposition of drugs within 
the body would be advantageous for the development of new SR products, usually, decisions 
are made using only a few pharmacokinetic parameters as a guide (Li, Robinson et al. 1987). 
One of these pharmacokinetic parameters is the apparent volume of distribution of a drug, Vd, 
which is frequently used to describe the magnitude of distribution, including binding to 
various tissues and plasma proteins in the body. However, this parameter does not have a 
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precise physiological meaning. Conceptually, Vd is rather considered a proportionality 
constant relating the drug concentration in the plasma to the total amount of drug in the body, 
either circulating in the blood or in target tissues (Li, Robinson et al. 1987; Shargel, Wu-Pong 
et al. 2004).  
The distribution of a drug to the diverse tissues in the body and its binding to plasma 
proteins can influence the duration of action of that drug. This is because the fraction of drug 
and/or active metabolite(s) that is bound can be considered to be inactive and unable to cross 
further membranes to reach sites of action and elimination organs (Langer and Wise 1984; Li, 
Robinson et al. 1987). Accordingly, the extent and rate at which the drug is bound, and the 
extent and rate at which is subsequently unbound will affect the duration of drug action, even 
when the rate of elimination of the unbound fraction is relatively rapid (Langer and Wise 
1984). At high binding, prolonged drug action may take place (Langer and Wise 1984; Li, 
Robinson et al. 1987). 
Tramadol is rapidly distributed in the body and has a plasma protein binding of about 
20% (Grond and Sablotzki 2004). The volume of distribution of tramadol has been reported to 
be 2.7 L/kg in humans (Lewis and Han 1997). Acetaminophen also distributes rapidly and 
evenly throughout most tissues and fluids and has a volume of distribution of approximately 
0.9L/kg. The fraction of the drug bound to red blood cells is 10 to 20% (Forrest, Clements et 
al. 1982; Morris and Levy 1984).  
 
 
1.5.2.4 Metabolism 
Metabolism can either transform active drugs into inactive metabolites or inactive 
drugs into active metabolites.  
Some drugs are significantly restricted from SR product design because of their 
metabolism. First, when the drug is metabolized during its passage through the intestinal 
membrane or through the liver, dose-dependent bioavailability generally occurs. Since both 
intestinal and hepatic metabolism are saturable processes, the fraction of drug lost due to 
metabolism is dose-dependant and a significant reduction in bioavailability would be 
predictable if a drug is gradually released over a prolonged period of time. However, the 
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design of oral SR dosage forms for drugs that are widely metabolized is possible, even though 
difficult, as long as the rate and extent of metabolism are predictable and the rate constants for 
the process are not too large (Li, Robinson et al. 1987). 
 
Tramadol is also widely metabolized in the liver with a first-pass effect of up to 30%, 
its main metabolite being O-desmethyltramadol (Grond and Sablotzki 2004). However, both 
tramadol enantiomers and their metabolites contribute to the analgesic activity by means of 
different mechanisms (Raffa, Friderichs et al. 1992). Acetaminophen is extensively 
metabolised, predominantly in the liver, the major metabolites being the sulphate and 
glucuronide conjugates (Forrest, Clements et al. 1982). The metabolism of both drugs was 
detailed in section 1.4.3.4. 
 
 
1.5.2.5 Safety margin and side effects of the drug 
A key aspect of the choice of drug candidates for SR products is their safety and side 
effects in the administered doses. For some drugs, the incidence of side effects can be 
minimized by controlling the plasma drug concentration for the duration of the therapy, and 
thus SR dosage forms can offer a solution to this problem. 
Tramadol, one of the drugs used in the present work, is an example of a drug whose 
toxic effects can be reduced by the use of SR dosage forms. Indeed, the lower incidence of 
adverse effects with SR tramadol has been demonstrated, presumably because high peak 
concentrations did not occur (Hummel, Roscher et al. 1996; Radbruch, Grond et al. 1996).  
 
The therapeutic index, as defined by the following equation, has been widely used as a 
crude estimation of the relative margin of safety of a drug and its balance safety-efficacy:  
 
Therapeutic index = TD50/ED50      Equation 13 
 
where TD50 is the toxic dose of drug for 50% of the population and ED50 is the minimum 
effective dose for 50% of the population. 
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SR dosage forms containing drugs with narrow therapeutic indices must generate a 
precise and reproducible drug-release pattern in order to attain plasma concentrations within 
the therapeutically safe and effective window. Besides, it is necessary to take into 
consideration other factors which can potentially influence the plasma drug concentrations 
attained, such as patient physiological variability, drug accumulation upon multiple dosing, 
concurrent disease states or eventual drug interactions (Langer and Wise 1984; Li, Robinson et 
al. 1987). All these factors can make the design of SR products for drugs with narrow 
therapeutic indices difficult. Yet, when properly prepared, oral SR formulations are valuable 
for maintaining plasma levels within a narrow therapeutic window, even for drugs with a 
narrow therapeutic index such as tramadol (Overholser and Foster 2011), the second model 
drug of this study, or theophylline (Glynn-Barnhart, Hill et al. 1988; Devarajan, Sule et al. 
1999). 
 
 
1.5.2.6 Therapeutic goal, disease state and circadian rhythm  
When considering the design of a new SR dosage form for a particular drug, the 
desired outcome of the therapy should be defined, as in certain health conditions this type of 
products may not be the desirable or rational choice. For example, oral SR dosage forms are 
contraindicated for antibiotics whose effectiveness is related to high spike blood levels on 
repeated administration, or in situations where a rapid onset of action is expected, such as a 
cardiac emergency, an asthmatic attack or an angina attack. However, SR products may be 
useful in the prevention of some of these situations as, for example, angina pectoris (Langer 
and Wise 1984). 
While disease state and circadian rhythm are not drug properties, in some cases, they 
are just as important as drug properties when considering a drug for SR (Li, Robinson et al. 
1987). Indeed, some physiological processes and disease states follow circadian rhythms, 
reaching peak or valley effects at specific times of the day. Examples are blood pressure, 
which is characterized by a nocturnal fall and a diurnal rise (Imai, Abe et al. 1990) and asthma 
episodes, which occur most often at night-time or early-morning for most asthmatics 
(Goldenheim, Conrad et al. 1987). SR products may be the best treatment approach for these 
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conditions, since they can better assure maintenance of prophylactic blood or tissue 
concentrations, and thus be a better choice in their prevention or control. 
Maintenance of some prophylactic blood or tissue levels may be also required to 
control symptoms of a disease, such as pain caused by certain forms of cancer or rheumatoid 
arthritis, which can be controlled by oral administration of tramadol SR formulations. 
 
 
1.6 Pharmacokinetic considerations and analysis in the design of 
dosage forms 
1.6.1 Importance of biopharmaceutics, pharmacokinetics and 
pharmacodynamics 
When considering strategies for the design of a new oral dosage form for a particular 
drug, it is essential to take into account the sequence of events that precedes or concurs the 
induction of a pharmacologic response upon reaching minimum effective drug concentrations 
at the site(s) of action. These events include administration, drug-release from the dosage 
form, absorption of the drug molecules from the absorption site to the blood, distribution of 
drug molecules from blood to tissues, and elimination via metabolism and/or via the passage 
of drug molecules from the blood to the exterior of the body through urine, bile or other 
routes. The physicochemical properties (and interrelated biological properties) of a drug, the 
dosage form used to administer it and the route of administration significantly influence this 
sequence of events, and are thus decisive determinants of the in vivo performance, safety and 
therapeutic efficacy of that drug.  
 
Biopharmaceutical, pharmacokinetic and pharmacodynamic studies of drugs and drug 
products are usually carried out to understand this interrelationship between the 
physicochemical properties of the drug, the route of administration, the dosage form in which 
the drug is administrated and the pharmacological effect produced by the drug. 
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Biopharmaceutics is essentially related to all the factors that are fundamental to ensure 
that the drug is delivered to the correct part of the body, in the right concentration and at the 
right rate, i.e., the aspects that determine its bioavailability. Therefore, biopharmaceutics 
includes the study of the factors that influence the stability of the drug in the dosage form and 
in the gastrointestinal environment, the release of the drug from the dosage form, the rate of 
dissolution of the drug, and its absorption into the systemic circulation.  
Pharmacokinetics, usually abbreviated as PK, is the study of the time course of drug 
absorption, distribution, metabolism and excretion (Shargel, Wu-Pong et al. 2004). It describes 
the drug concentration-time courses in the body fluids, resulting from administration of a 
specific dose of the drug being studied (Meibohm and Derendorf 1997). Pharmacokinetics 
allows the description in quantitative terms of not only the kinetics of the active drug but also 
of its metabolites. The processes of drug absorption, distribution, metabolism and excretion 
are often abbreviated in pharmacokinetics as ADME, or LADME if liberation from the dosage 
form is also to consider (Shargel, Wu-Pong et al. 2004). In addition, the description of drug 
distribution and elimination is often termed drug disposition. 
Another important element for understanding the factors inducing a pharmacological 
or toxicological response is pharmacodynamics. This discipline, which can be referred to as 
PD, studies the relationship between a certain drug concentration and the response obtained. 
As the same dose of drug can result in different concentrations, it is important to study this 
link between drug concentrations at the site of action (receptor), if possible, or in the blood 
plasma or serum and the pharmacological or toxicological effects.  
Finally, pharmacokinetic/pharmacodynamic (PK/PD) modeling builds the bridge 
between the concentration-time profile resulting from the administration of a certain dose, as 
assessed by pharmacokinetics, and the intensity of the observed response, as quantified by 
pharmacodynamics (Derendorf, Lesko et al. 2000). Thus, the resulting so-called integrated 
PK/PD-models allow the establishment and evaluation of dose-concentration-response 
relationships, and describe the effect-time courses resulting from a drug dose (Meibohm and 
Derendorf 1997; Derendorf, Lesko et al. 2000).  
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1.6.2 Experimental approaches of pharmacokinetics 
1.6.2.1 Measurement of drug concentrations 
The measurement of the amounts or concentrations of drugs and metabolites in body 
fluids or tissues at different times after the administration of a dosage form gives much 
information on drug absorption, distribution and elimination and is, therefore, a fundamental 
element in the determination of individual or population pharmacokinetics. Although, 
concentrations can be measured from different body fluids, e.g., plasma, urine, saliva and 
milk, or even from biological tissues, the biological samples most frequently used for 
assessing the pharmacokinetics of a drug and its metabolite(s) in the body are concentration 
(levels) in blood plasma or serum. Urine may also be sampled to assess the drug amounts 
excreted unchanged. 
The main components of whole blood are red blood cells, white blood cells, and 
platelets (which release the clothing factors), suspended in plasma (which contains proteins, 
such as albumin and fibrinogen, hormones, minerals and vitamins, among other constituents). 
Serum is prepared by obtaining a blood sample, followed by blood clot formation and removal 
of the clot using a centrifuge to obtain the supernatant. To obtain plasma, an anticoagulant, 
such as heparin, is added to the blood sample to prevent the clot formation, and then the 
plasma is obtained from the supernatant after centrifugation. Therefore, the main difference 
between the two lies in their protein content. Plasma still contains clotting factors, whereas 
serum has had the clothing factors removed. 
The number of blood samples should be large enough and the timing appropriate to 
allow an adequate determination of the absorption, distribution and elimination phases. 
Ideally, the target tissue should be sampled and the concentrations of drug that reach it 
measured instead of plasma concentrations. However, this is impractical in most situations. 
Therefore, as plasma perfuses all the tissues of the body and assuming that there is a dynamic 
equilibrium between drug in the plasma and drug in the tissues, then, changes in plasma drug 
concentrations are considered to reflect changes in tissue drug concentrations (Shargel, Wu-
Pong et al. 2004). 
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Since very important decisions in drug development and dosage form development are 
based on diverse studies, including bioavailability, pharmacokinetic and pharmacodynamic 
studies using data obtained from analytical results, it is imperative that the analytical methods 
for the measurement of drugs and metabolites be selective, accurate, and sensitive (Braggio, 
Barnaby et al. 1996). As a rule, these measurements in biological materials are validated so 
that accurate and reliable information is generated. Among the various methods that permit 
drugs and their metabolites to be separated, indentified and quantitatively assayed, 
chromatography is the most frequently employed (Hirtz 1986), in particular liquid 
chromatography (LC) coupled to different detectors such as mass spectrometer (MS) or UV 
detector. Indeed, the LC-MS methods are considered as most appropriate for determination of 
drugs and their metabolites and are also best suited for high throughput analysis (Roškar and 
Lušin 2012).  
In the first article of this research (Nabais, Brouillet et al. 2007), acetaminophen 
plasma concentrations were analyzed by high-performance liquid chromatography (HPLC) 
coupled to UV-Vis spectrophotometric detector. The development and validation of LC/MS 
methods for quantification of tramadol, the second drug used in this study, and for its active 
metabolite O-desmethyltramadol in human plasma have also been described and successfully 
applied to both pharmacokinetic and bioequivalence studies (Vlase, Leucuta et al. 2008; Patel, 
Sharma et al. 2009). 
 
 
1.6.2.2 Plasma drug concentrations as a function of time 
The most important source of information in pharmacokinetics is the plasma drug 
concentration versus time curve. The pharmacokinetic parameters, which pharmacokinetic 
studies are based on, are derived from these curves. 
A description of the plasma concentration versus time curves obtained after 
administration of an oral dosage form and after administration of an intravenous bolus, the two 
forms of administration used in the in vivo studies performed in the scope of the present thesis, 
is given next. 
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Plasma concentration-time curve following a single oral dose 
The typical plasma concentration-time curve following a single oral dose of a drug 
administered in a IR dosage form is characterized by a gradual rise up to a maximum as the 
drug reaches the systemic circulation, usually called absorption phase, followed by a gradual 
decline due to the removal of drug by distribution and elimination, usually called elimination 
phase.  
Initially, the rate of drug absorption exceeds the rate at which the drug is being 
removed from the systemic circulation. As a result, the segment of the curve corresponding to 
the absorption phase is more steep that the segment corresponding to the elimination phase. 
However, the elimination of a drug initiates as soon as it appears in the plasma. At the peak 
(the highest concentration of drug achieved in plasma), the rate of drug absorption equals the 
rate of drug removal. During the first segment of the elimination phase, the rate of drug 
removal from blood becomes more rapid than the rate of absorption because the amount of 
solubilized drug existing at the absorption site declines progressively. However, here, the 
processes of absorption into the systemic circulation, distribution into all the tissues within the 
body, and elimination by excretion (through urine, bile or other routes), metabolism or a 
combination of both, happen simultaneously. After the end of absorption, the rate of drug 
elimination continues to decline until complete elimination from the body. 
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Figure 1.24 Typical plasma drug concentration versus time after oral administration of a 
conventional dosage form, representing the maximum concentration in plasma, Cmax, the time 
to reach the maximum concentration, Tmax, the therapeutic range, the MTC and the MEC, the 
onset time and the duration of action. 
 
 
The already mentioned maximum drug concentration in the plasma or peak 
concentration (Cmax) and the period of time required to achieve that same peak concentration 
of drug after administration of a single dose (Tmax) (Figure 1.24) are two pharmacokinetic 
parameters that can be directly obtained from the curve. The area under the plasma 
concentration-time curve, usually known as AUC (Figure 1.24), a parameter calculated using 
drug concentration-time data from the curve is also shown. These pharmacokinetic parameters 
will be described in a following section. Other important information that can be obtained 
directly from the curve is the onset time, that is, the time required to achieve the minimum 
concentration following administration, and the duration of drug action (Figure 1.24), which 
represents the difference between the onset time and the time for the drug to decline back to 
the minimum effective concentration; in other words, the period of time during which the 
concentration of drug in the plasma surpasses the minimum effective concentration. 
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Plasma concentration-time curve following an intravenous bolus injection 
 
 
Figure 1.25 Plasma concentration versus time profile of acetaminophen in one volunteer after 
an intravenous single dose. Figure reproduced from (Ing-Lorenzini, Desmeules et al. 2009) 
with permission of Elsevier Ltd. 
 
 
 
As explained before, when a drug is delivered by an intravenous bolus, the entire 
administered dose is introduced directly into the systemic circulation, and thus it does not have 
to pass any absorption barriers. Therefore, the dose is considered to be totally bioavailable. 
The maximum plasma concentration is achieved at time zero and is followed only by the 
gradual decline attributed to the removal of drug from the plasma by distribution and 
elimination (Figure 1.25).  
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1.6.3 Theoretical aspects of pharmacokinetics 
1.6.3.1 Development of pharmacokinetic models 
Living organisms are complex biologic systems in which it is difficult to establish 
quantitative relationships between a specific drug dose, the route of administration used to 
give it, the concentration of drug in different anatomical locations, the pharmacological effect 
achieved and the elapsed time. With the aim of obtaining an adequate description of the time 
course of drug concentrations within the body, different mathematical methods were proposed. 
These methods include compartmental pharmacokinetic analysis, physiological models and 
non-compartmental models based on statistical moment theory. Within the scope of the 
research performed in this work, only pharmacokinetic compartmental analysis was used and, 
therefore, it will be the only methodology described herein. 
In order to develop a pharmacokinetic model, simplifying hypotheses regarding the 
movement of the drugs within the body are made. The hypotheses or ‘models’ are conceived 
using mathematical terms, which describe quantitative relationships concisely. These 
mathematical models make it possible to develop differential equations that express the rates 
of the processes of absorption, distribution and elimination, and allow obtaining equations that 
describe and predict the quantity and concentration of drug in the body in function of time 
(Shargel, Wu-Pong et al. 2004). To develop these equations, a set of independent and 
dependent variables, known as experimental data, are needed. Usually, the independent 
variable is time and the dependent variable is the plasma drug concentration described above. 
A mathematical equation relates an independent variable to a dependent variable often 
through the use of pharmacokinetic parameters. Thereby, the concentration-time relationship 
is defined by pharmacokinetic parameters. A pharmacokinetic parameter is a constant for the 
drug, which is estimated by fitting the equation to the experimental data. In other words, a 
mathematical procedure called ‘fitting’, is used to find the best curve fitting to a given set of 
experimental concentration-time data through an equation that describes that curve and which 
incorporates the pharmacokinetic parameters. The best fitting of that equation to the data will 
allow the estimation of the parameters, which will define the model. Computer programs are 
commonly used to facilitate curve fitting and parameter estimation. The model equation is 
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then used to predict plasma drug concentrations versus time. Various mathematical models 
can be created to simulate the rate processes of drug absorption, distribution, and elimination.  
Pharmacokinetic models can be used to evaluate differences in bioavailability between 
equivalent dosage forms (relative bioavailability and bioequivalence), to compare the 
bioavailability resulting from different routes of administration (absolute bioavailability), or 
from different dosage forms. In the in vivo studies carried out in this research, 
pharmacokinetics was used to compare a SR dosage form and an IR dosage form. Besides, 
pharmacokinetic models are used to predict plasma, tissue, and urine drug concentrations with 
any dosage regimen, correlate drug concentrations with pharmacologic or toxicologic activity, 
describe how changes in physiology or disease affect the absorption, distribution, or 
elimination of the drug, explain drugs interactions, evaluate food effects in single or multiple 
dose administration, among other applications (Urso, Blardi et al. 2002; Shargel, Wu-Pong et 
al. 2004). 
 
 
1.6.3.2 Compartmental pharmacokinetic models 
Compartmental models provide a very simplified kinetic approach to describe drug 
absorption, distribution, and elimination. These models group by affinity different anatomical 
and physiological areas of the body into one or more compartments. These open compartments 
communicate reversibly with each other, i.e., a particular amount or concentration of drug is 
exchanged between two compartments per unit time, including to and from the plasma 
compartment, also called central compartment.  
A compartment is not a real physiologic or anatomic region but is considered as a 
tissue or group of tissues or organs with similar kinetic properties, i.e., with similar blood flow 
and drug affinity. Within each compartment it is assumed that the drug is rapidly and 
homogeneously distributed. Thereby, the drug concentration represents an average 
concentration, and each drug molecule has an equal probability of leaving the compartment. 
Rate constants are used to represent the overall rate processes of drug entry into and exit from 
the compartment. Compartment models are based on linear assumptions using linear 
differential equations (Shargel, Wu-Pong et al. 2004). 
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Although compartment models are usually regarded as somewhat empirical and 
lacking physiologic relevance, they present the advantage of permitting a description of the 
time course of drug within the body with a limited amount of data (Shargel, Wu-Pong et al. 
2004). 
 
The simplest compartment model is the one-compartment model (Figure 1.26), which 
considers the drug to be distributed instantaneously and uniformly into a unique compartment 
in the body, usually called the central compartment or plasma compartment, from where the 
drug is eliminated. The central compartment represents the blood, extracellular fluid and 
highly perfused tissues that rapidly equilibrate with drug, such as the organs involved in drug 
elimination. However, drugs that exhibit a slow equilibration with peripheral tissues are best 
described with two-, three- (Figure 1.26) or multi-compartment models. In a two-compartment 
model, drug can move between the central to and from the so-called tissue or peripheral 
compartment, which represents the tissues in which the drug equilibrates more slowly. The 
more compartments the model has, the more different equilibrium rates between tissues are 
considered. Drug tissue concentration is assumed to be uniform within a given compartment. 
The compartmental models are particularly useful when little information is known about the 
tissues (Shargel, Wu-Pong et al. 2004).  
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Figure 1.26 Schematic representations of one-, two-, and three-compartment models. 
 
 
1.6.3.3 Pharmacokinetic parameters 
As mentioned above, only through pharmacokinetic models it is possible to define a set 
of pharmacokinetic parameters that give a simplified description of drug absorption, 
distribution and elimination. 
The first step in the analysis of pharmacokinetic data is usually the estimation of Cmax, 
Tmax, and AUC, which were described above. The t1/2 may also be estimated. These four 
parameters can well represent the data without the need of any complex mathematical model 
(Urso, Blardi et al. 2002). As described before, the t1/2 is the period of time required for the 
amount or concentration of a drug to decrease by one-half. This parameter is used to describe 
the decay of the drug concentration in the terminal phase and may be determined by means of 
the following equation: 
 
  
117 
€ 
t1/ 2 =
ln2
k         Equation 14 
 
The Cmax is related to the dose, the absorption rate constant (ka), and the elimination 
rate constant of the drug (k). Cmax provides indications that the systemic drug absorption was 
sufficient to provide a therapeutic response or that toxic concentration may have been 
achieved. Although Cmax is not a unit for rate, it can be used as a surrogate measure for the rate 
of drug bioavailability (Shargel, Wu-Pong et al. 2004). The Tmax is a rough indicator of the 
average rate of drug absorption and can also be used to assess that rate (Ashford 2002; 
Shargel, Wu-Pong et al. 2004). The AUC is a parameter related to the total amount of drug 
absorbed into the systemic circulation following the administration of a single dose and to the 
ability that the system has to eliminate the drug (clearance). Changes in the AUC reflect 
changes in the total amount of drug absorbed and/or modifications in the kinetics of 
distribution, metabolism and excretion (Ashford 2002). Therefore, this parameter can be used 
to measure the drug amount absorbed and the efficiency of physiological processes that 
characterize the drug elimination (Urso, Blardi et al. 2002). 
 
 
The AUC can be calculated using the trapezoidal rule (Figure 1.27). This simple 
numerical method considers the area between time intervals as the area of a trapezoid and uses 
the following equation to calculate it: 
 
€ 
AUC[ ]tn
tn+1 =
Cn + Cn+1
2 tn+1 − tn( )     Equation 15 
 
where tn represents the time of observation of drug concentration, Cn, and tn+1 is the time 
corresponding to the following observed drug concentration, Cn+1. 
To obtain the total AUC all individual areas between two consecutive time intervals 
are summed. The residual AUC between the last measurable concentration and the complete 
removal of drug from the plasma can be calculated by extrapolation to time equal to infinity 
(∞), as follows: 
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€ 
AUC[ ]tn+1
∞
=
Cf
k        Equation 16 
 
where Cf is the last observed plasma concentration at tn+1 and k is the slope obtained from the 
terminal portion of the curve and represents the overall drug elimination first-order rate 
constant. 
 
Therefore, the full trapezoidal rule to calculate the AUC from time 0 to complete 
removal of drug can be expressed as follows: 
 
€ 
AUC[ ]0
∞
= AUC[ ]tn
tn+1 +
Cf
k∑       Equation 17 
 
 
 
 
Figure 1.27 Graphical illustration of the application of the trapezoidal rule to numerically 
estimate the AUC for first-order absorption data. Figure reproduced from (Byers and Sarver 
2009) with permission of Elsevier Ltd. 
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After oral administration, Cmax and Tmax are dependent on the extent and rate of drug 
absorption and on the disposition profile of the drug. Consequently, they may characterize the 
properties of different formulations in the same subject (Urso and Aarons 1983).  
The Cmax, Tmax, and AUC were determined in the in vivo studies performed in this 
research and used to compare a HASCA SD SR formulation and a commercialized IR one. 
  
There are other pharmacokinetic parameters which may be important in 
pharmacokinetic studies, such as the apparent volume of distribution (Vd), a parameter 
essential to estimate the amount of drug in the body from a certain concentration of drug, and 
the clearance of drug elimination from the body (CL), which can be easily defined using 
compartmental models. However, these parameters are out of the scope of this work. 
 
 
1.6.3.4 Estimation of the cumulative relative fraction of drug absorbed after oral absorption 
Pharmacokinetic models also provide an easy way to obtain an estimate of the 
cumulative relative fraction of drug absorbed versus time after a single oral dose of a drug. 
This estimation was part of the treatment of the in vivo data made in the present research, and 
was obtained using an equation proposed by Wagner-Nelson (Wagner and Nelson 1963; 
Wagner and Nelson 1964): 
 
€ 
Ab
Ab∞ =
Cp + k AUC[ ]0
t
k AUC[ ]0
∞       Equation 18 
 
where Cp is the plasma concentration at time t; Ab is the percentage of drug absorbed at time t 
and Ab∞ is the total amount of drug absorbed. 
 
 
 
 
 
  
120 
1.6.3.5 Statistics in pharmacokinetic studies 
Statistics are used to obtain a valid analysis of experimental data. The objective of data 
analysis is to obtain as much information about the population as possible based on the sample 
data collected. 
All measurements have some degree of error. An error is the difference between the 
true value and the observed value. Errors in measurements may be determinate (systematic) or 
indeterminate (random, accidental). Determinate errors are known and controllable errors, 
such as instrumental errors or personal errors. These errors may be minimized in analytical 
procedures by using properly calibrated instrumentation, standardized chemicals, and 
appropriate blanks and control samples, and a more precise manipulation. Indeterminate errors 
are more difficult to control and are, in some cases, unknown errors (Shargel, Wu-Pong et al. 
2004). Examples are limitations of reading balances and electrical “noise” in instruments. In 
addition, when two or more samples or subjects in a group are measured, there is generally 
variation due to individual differences. For example, the weight of each volunteer in the in 
vivo study performed for this research was widely different. 
For practical purposes, a few measurements of a given sample are usually performed, and the 
result averaged.  
 
Common standard statistical calculations in pharmacokinetic studies include (Shargel, 
Wu-Pong et al. 2004): 
1) The mean or average, which represents the sum of the observations divided by the 
number, n, of observations, and is a frequently used term in statistics to generalize 
the nature of the data and provide a measure of central tendency. 
2) The mean ± standard deviation (SD). The standard deviation gives an indication of 
the spread of data points around the mean. A standard deviation relative to the 
mean value is indicative of good consistency and reproducibility of the 
measurements. A large standard deviation indicates poor consistency and data 
fluctuations. 
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3) The relative standard deviation (RSD), or coefficient of variation (CV) expressed 
as a percentage, represents the ratio of the standard deviation to the mean. It is a 
way of expressing variability on a percent basis and is useful for comparing the 
degree of variation from one set of measurements or calculations to another when 
the means are different. 
4) Other descriptive terms used to give a measure of central tendency are the median, 
which is the middle value of the observations between the highest and lowest value, 
and the mode, which represents the most frequently occurring value.  
5) The term range is used to describe the dispersion of the observations and is the 
difference between the highest and lowest values. For data that are distributed as a 
normal (or Gaussian) distribution (i.e., the bell-shaped curve which describes the 
distribution of the frequency of the measurements drawn randomly from a 
population when data tends to be around a central value) the mean, median, and 
mode have the same value. 
6) Analysis of Variance (ANOVA) is a method used to test differences between two 
or more means. An ANOVA on two groups is similar to the t-test, which tests 
whether the means of two groups are statistically different from one another. 
ANOVA methods can estimate the variance among different subjects (intersubject 
variability), groups, or treatments. 
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1.7 In vitro-in vivo correlations  
1.7.1 Importance of in vitro-in vivo in the development and optimization of 
dosage forms 
A key goal in the development of pharmaceutical dosage forms is a good prediction of 
their in vivo performance. Until the early 1960s, disintegration tests were the only official in 
vitro tests used by major pharmacopoeias all over the world as a means of predicting in vivo 
drug-release and behaviour. However, because of the critical importance of drug dissolution 
and release from a dosage form under physiological conditions, especially for drugs that are 
highly absorbed or for SR dosage forms, in vitro dissolution is more relevant than 
disintegration as a way to describe what will possibly happen in vivo. In the 1970s, a series of 
studies showed that the mean dissolution time resulting from IR tablets could be related to 
pharmacokinetic parameters such as the rate and extent of drug absorption, thus establishing a 
correlation between in vivo and in vitro performance (Johnson, Greer et al. 1973; Lindenbaum, 
Butler Jr et al. 1973; Shaw, Raymond et al. 1973). These results supported the incorporation of 
dissolution tests and specifications into the United States Pharmacopeia (USP) General 
Chapters and monographs on solid oral dosage forms, which substituted disintegration tests as 
the official methodology (Jorgensen and Bhagwat 1998). In the following years, dissolution 
equipment was improved and standardized, and calibration tests were instituted. This led to 
the inclusion of dissolution tests in all monographs for solid oral dosage form and their use as 
a good means of ensuring the uniformity of IR dosage forms (Cohen, Hubert et al. 1990). In 
the early 1980s, the USP addressed the dissolution of extended-release dosage forms 
(‘sustained-release’ herein). Since then, with the advancement of technology, progress in drug 
delivery research and a crescent emphasis on the predictability of in vivo behaviour of dosage 
forms by means of in vitro tests, dissolution tests have gained more popularity (Zahirul and 
Khan 1996). It was, therefore, necessary to further develop a technique to reliably correlate in 
vitro and in vivo drug-release data, known as in vitro-in vivo correlations (IVIVC). 
The term correlation is employed in this context to express the relationship between 
appropriate in vitro release characteristics and in vivo bioavailability parameters. Various 
definitions of IVIVC have been proposed. The FDA has defined an IVIVC as “a predictive 
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mathematical model describing the relationship between an in vitro property of a dosage form 
and a relevant in vivo response”. Usually, the in vitro property is the rate or extent of drug 
dissolution or release while the in vivo response is the plasma drug concentration or amount of 
drug absorbed (Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral 
Dosage Forms. FDA. (1997)). The United States Pharmacopoeia (USP) Subcommittee on 
Biopharmaceutics defines IVIVC as “the establishment of a rational relationship between a 
biological property, or a parameter derived from a biological property produced by a dosage 
form, and a physicochemical property or characteristic of the same dosage form” (US 
Pharmacopeial Convention, 2013). Typically the parameter derived from the biological 
property is the AUC0-∞ or Cmax, while the physicochemical property is the in vitro dissolution 
profile. 
IVIVC has different applications in the pharmaceutical industry, regulatory agencies 
and academia. The main objective of IVIVC is to serve as a surrogate for in vivo 
bioavailability data. Thus, it is used to support the request of waivers of in vivo bioavailability 
and bioequivalence studies (biowaivers) from regulatory authorities. Besides, IVIVC can be 
used in the early stages of the development of new dosage forms to reduce the number of 
studies in human volunteers during formulation development. Likewise, IVIVC are applied in 
certain scale-up and post-approval changes (SUPAC), for example, to optimize formulations 
or to change manufacturing processes or equipment, as these changes may also require human 
studies to prove that the new formulation is bioequivalent with the old one. Therefore, IVIVC 
can significantly reduce the time and cost associated with both development and optimization 
of formulations by avoiding lengthy and expensive clinical trials. Also, IVIVC can be 
employed to establish meaningful dissolution specifications and to support and/or validate the 
use of dissolution methods specifications. A validated in vitro test that is discriminative and 
correlated with the in vivo performance is usually used in quality control to assure that each 
batch of the same product will perform identically in vivo (Guidance for industry. Extended 
release oral dosage forms: development, evaluation and application of in vitro/in vivo 
correlations. FDA. (1997)).  
The BCS has been referenced as a guideline for determining the conditions under 
which IVIVC are expected on the basis of the solubility and gastric permeability of drugs. 
According to the BCS, IVIVC is generally anticipated for IR products containing Class II 
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drugs (low solubility and high permeability). It may also be possible for Class I drugs (high 
solubility and high permeability). However, in the case of Class I drugs, a correlation is only 
possible if the dissolution rate is slower than the gastric emptying rate (Amidon, Lennernas et 
al. 1995). 
Compared to IR dosage forms, an IVIVC is, in general, more easily established for SR 
dosage forms where dissolution and not absorption is the rate-limiting phenomena in the 
absorption process (Demirturk and Öner 2003). Depending on the design of the SR product, 
the apparent absorption takes place in the small intestine, ascending colon and/or throughout 
the large intestine (Shameem, Katori et al. 1995). A longer absorption phase over a prolonged 
period of time makes it easier to develop Level A, B, C or Multiple Level C IVIVC models. 
However, the feasibility of an IVIVC for a SR dosage form depends on drug properties, 
delivery technology, and formulation design (Qiu 2009).  
Because of the importance of IVIVC in the development of dosage forms, the ability to 
predict in vivo dissolution/absorption characteristics from dissolution data of SR dosage forms 
has become one of the most important aspects of developing SR products. The use of in vitro 
dissolution to evaluate and predict in vivo performance of SR drug products through IVIVC 
was supported by the publication of a guidance on IVIVC by the FDA in 1997 (referred to as 
‘modified release’ in this document) (Guidance for industry. Extended release oral dosage 
forms: development, evaluation and application of in vitro/in vivo correlations. FDA. (1997)).  
Regulatory flexibility for certain formulation and process changes regarding SR 
products is allowed when a direct correlation between the in vitro drug-release and in vivo 
absorption exists (Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage 
Forms. FDA. (1997)).  
Another link between in vitro drug product performance and in vivo drug product 
biopharmaceutical and pharmacokinetic performance reported in the literature is the in vitro-in 
vivo relationship (IVIVR). IVIVR is a more general term, which comprises the broad range of 
activities involved in relating in vitro dissolution to in vivo absorption and non-linear 
relationships. The most simple and appropriate relationships to consider first is the linear 
relationship, nonetheless non-linear correlations, even if uncommon, might be appropriate in 
some cases (Emami 2006). 
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Generally, when the dissolution profile is not affected by factors such as pH, 
surfactant, ionic strength, enzyme, osmotic pressure, agitation intensity, a set of dissolution 
data obtained from one formulation is correlated with the corresponding in vivo response in 
order to develop a correlation. When the dissolution rate depends on those factors, the 
dissolution profiles from formulations with different in vitro release rates as, for instance, 
slow, medium and fast (Figure 1.28 (A)), should be determined using a discriminating in vitro 
test methodology. The in vitro release rates, as measured by cumulative percentage of drug 
dissolved for each formulation studied, should differ adequately (e.g., by 10%) (Guidance for 
industry. Extended release oral dosage forms: development, evaluation and application of in 
vitro/in vivo correlations. FDA. (1997)). The corresponding in vivo response can be plasma 
concentrations or, more frequently, the amount of drug released and/or absorbed in vivo. The 
latter is obtained from the observed plasma concentration-time curve by deconvolution. The 
resulting in vivo profiles should show a comparable difference, i.e., a 10% difference in the 
pharmacokinetic parameters of interest between each formulation (Guidance for industry. 
Extended release oral dosage forms: development, evaluation and application of in vitro/in 
vivo correlations. FDA. (1997)). These data may derive from studies at early or late stages of 
dosage form development, such as bioavailability studies conducted in the formulation 
screening stage or an in vivo study specifically designed to explore IVIVC (Mojaverian, Rosen 
et al. 1997; Dutta, Qiu et al. 2005). 
 
 
1.7.2 Correlation levels 
The publication in 1997 of the FDA’s Guidance for Industry: Extended Release Oral 
Dosage Forms: Development and Application of In Vitro/In Vivo Correlations formalized the 
classification of the IVIVC levels into Levels A, B, C, and Multiple C, depending upon the 
type of data used to establish the relationship and the ability of the correlation to predict the 
entire plasma profile of a dosage form.  
Level A correlation (Figure 1.28) is a point-to-point relationship between the in vitro 
release time course and the in vivo response time course (e.g., the time course of plasma drug 
concentration or amount of drug absorbed) and represents the highest category of correlation 
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(US Pharmacopeial Convention, 2013). To develop such a correlation all of the dissolution 
and plasma concentration data available are used, and the mathematical description for the in 
vitro dissolution and in vivo input rate is the same. This direct relationship permits the 
determination of the in vivo drug-release rate of the dosage form using the measurement of in 
vitro dissolution rate alone. Therefore, an in vitro dissolution curve can serve as a surrogate 
for in vivo performance (Emami 2006).  
 
 
 
Figure 1.28 Example of Level A IVIVC. (A) In vitro dissolution profiles of slow (:), 
medium (:), and fast (:) drug formulations. (B) In vivo studies provide plasma drug 
concentration of each formulation (gray lines), which can be converted to fractional absorption 
profile (black lines) by deconvolution. (C) Level A IVIVC can be derived from the fractional 
dissolution in vitro and the fractional absorption in vivo. Figure reproduced from (Lu, Kim et 
al. 2011) with permission of Elsevier Ltd. 
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A Level A correlation is typically attempted for SR dosage forms (Long and Chen 
2009). A validated Level A IVIVC can be used to obtain waivers of bioequivalence studies, 
set dissolution specifications, and form the basis for justifying scale-up and post-approval 
manufacturing changes (Long and Chen 2009). The percentage of drug absorbed may be 
calculated by means of model dependent techniques such as Wagner-Nelson procedure or 
Loo-Riegelman method or by model-independent numerical deconvolution. 
 
 
 
Figure 1.29 Example of Level B (A) and Level C (B) IVIVC. Figure reproduced from (Lu, 
Kim et al. 2011) with permission of  Elsevier Ltd. 
 
 
Level B correlation (Figure 1.29 (A)) is a relationship between the mean in vitro 
dissolution time (MDTvitro) of the product and the mean in vivo dissolution time (MDTvivo) or 
the mean in vivo residence time (MRT), each obtained by application of statistical moment 
analysis to the full release profile. Although a Level B correlation uses all of the in vitro and in 
vivo data it is not considered to be a point-to-point correlation because it does not reflect the 
actual in vivo plasma concentration curve and a number of different in vivo curves can 
generate similar MRT values (Guidance for industry. Extended release oral dosage forms: 
development, evaluation and application of in vitro/in vivo correlations. FDA. (1997)). 
Therefore, it is not possible to rely only on a Level B correlation to justify modifications, such 
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as formulation and excipient source. In addition, in vitro data from such a correlation could 
not be used to justify the extremes of quality control standards (US Pharmacopeial 
Convention, 2013). 
Level C correlation (Figure 1.29 (B)) is a level for which a particular element of the 
dissolution profile (e.g., the cumulative dissolution in vitro at day 21, or the time required for 
dissolution of a certain amount, such as t50%) is related to a single mean pharmacokinetic 
parameter (e.g., AUC, Tmax or Cmax). Therefore, it does not reflect the entire shape of the 
plasma drug concentration curve, which is an essential factor to evaluate the performance of 
SR products. This is the weakest level of correlation as only partial relationship between 
absorption and dissolution is established. Consequently, the usefulness of a Level C 
correlation in predicting in vivo drug performance as well as formulation and manufacturing 
changes is limited. Biowaiver is generally not possible using this correlation level (Guidance 
for industry. Extended release oral dosage forms: development, evaluation and application of 
in vitro/in vivo correlations. FDA. (1997)). Besides, just as level B, this level of correlation is 
not useful in justifying the extremes of quality control standards (US Pharmacopeial 
Convention, 2013). However, Level C correlation can be useful in early stages of formulation 
development when pilot formulations are being selected (Qiu 2009). It can also be used for IR 
products, where the time course for absorption is of short duration, and obtaining a sufficient 
number of data points in the in vivo profile for a Level A IVIVC is more difficult (Long and 
Chen 2009).  
The utility of a Level C correlation can be strengthened by using information from 
multiple time points, and creating a Multiple C correlation (Long and Chen 2009). This type 
of correlation relates the amount of drug dissolved at several time points of the dissolution 
profile to one or several pharmacokinetic parameters of interest (Cmax, AUC, or any other 
suitable parameters). As opposed to level B and level C, a multiple point Level C correlation 
may be used to justify a biowaiver, provided that the correlation has been established over the 
entire dissolution profile with one or more pharmacokinetic parameters of interest (Emami 
2006). A multiple C correlation should be based on at least three dissolution time points 
covering the early, middle, and late stages of the dissolution profile. If such a multiple Level C 
correlation is achievable, then the development of a Level A correlation may also be possible 
(Emami 2006).  
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1.7.3 Considerations in dissolution test method development for IVIVC 
1.7.3.1 Importance of dissolution testing 
Dissolution testing is essential in all stages of drug product development. In the early 
stages of formulation design and optimization, in vitro dissolutions are performed to support 
the choices made between different formulation candidates. These choices are based on 
critical information on possible risks such as dose dumping, food effects, the interaction of 
drug substances with other formulation components, and other important parameters for 
formulation performance. At these stages, dissolution testing also helps to understand the 
drug-release mechanism. Evaluation and analysis of drug-release should not only include 
quantitative evaluations using HPLC or spectrophotometry but also visual observations of the 
performance of dosage forms. Mathematical models, such as the Peppas et al. model, can be 
used to indentify formulations design variables and dissolution method parameters which can 
significantly influence drug-release (Long and Chen 2009). The development process is then 
characterized by further cycles of formulation optimization and performance testing, both in 
vivo and in vitro, during which IVIVC are established. These cycles culminate in the 
determination of the final formulation. Since there is no other in vitro performance test with 
such a close link to in vivo performance, dissolution and drug-release studies are a regulatory 
requirement for the development, and final approval of all solid oral dosage forms (US 
Pharmacopeial Convention, 2013). After product approval, dissolution testing is used to assess 
product quality and to evaluate formulation and manufacturing changes (Guidance for 
Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms. FDA. (1997)).  
Although dissolution tests have been successfully implemented on IR dosage forms by 
regulatory authorities, there have been great difficulties in standardizing dissolution test 
conditions and parameters for testing SR oral dosage forms. These difficulties are mainly due 
to the fact that these dosage forms are usually designed for prolonged residence time in the 
gastrointestinal tract and, therefore, the drug-release profile will be more susceptible to the 
variabilities in the in vivo conditions (e.g., presence and nature of food in the gastrointestinal 
tract or time of the day the dosage form is administered), which are, in turn, very difficult to 
simulate. However, the creative use of dissolution techniques can speed the early stages of 
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formulation development, particularly in the case of SR products. Therefore, even dissolution 
methods which fail to meet compendial requirements may still provide advantages in product 
development (Jorgensen and Bhagwat 1998). 
Through the use of dissolution tests it is possible to obtain a measure of the extent and 
rate of drug-release from a dosage form into an aqueous medium under a set of specific test 
conditions. The drug-release profile is the result of a combination of factors, in particular, the 
physicochemical properties of the drug, the formulation design and manufacturing process, 
and the chemical and mechanical conditions of the test method selected to investigate drug-
release. Therefore, the development of a dissolution test method must include an evaluation of 
the contribution and influence of these factors to drug-release (Long and Chen 2009). In the 
particular case of a new SR dosage form, the development of a test method should also 
involve an assessment of the physiological conditions the dosage form will encounter 
throughout its total residence time in the body, so that the release profile of the drug is tested 
in an environment closely related to the actual in vivo conditions. This assessment is 
particularly important for dosage forms that will have different release/absorption profiles at 
distinct physiological conditions of the gastrointestinal tract. The more information that is 
available, the easier it is to design an initial set of dissolution test conditions (Bowker 1996; 
Zahirul and Khan 1996; Zahirul and Khan 1996). However, while it is possible to have, 
nowadays, a certain control of the drug-release profiles of a dosage form in vitro, it is not 
always possible to obtain the desired drug-release and therapeutic plasma concentrations in 
vivo. 
The key considerations in dissolution test method development are the apparatus type 
employed, along with its associated operating parameters, and the medium composition. A 
brief description of these aspects will follow. 
 
 
1.7.3.2 Dissolution apparatus selection 
The type of dosage form under investigation is the primary consideration in apparatus 
selection. The USP Chapter <711> describes four types of dissolution apparatus used in 
dissolution studies (US Pharmacopeial Convention, 2013) and has been harmonized with the 
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European and the Japanese Pharmacopoeias. These apparatuses are also recommended in the 
FDA Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms (Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms. FDA. (1997)). Guidance for the development and application of dissolution testing is 
also provided by the International Pharmaceutical Federation (FIP) (International 
Pharmaceutical Federation. FIP guidelines for dissolution testing of solid oral products, Final 
draft (1996)). These apparatuses will not be discussed in detail in this thesis. For detailed 
descriptions of the apparatuses, the reader is referred to a book by Dressman J. (Dressman 
2005). Apparatus 1 (rotating basket) and Apparatus 2 (paddle assembly) (Figure 1.30) are the 
most widely used for dissolution testing of solid dosage forms (IR as well as SR products), 
mostly because they are simple, robust, and adequately standardized apparatus designs, and 
are supported by a wider experience of experimental use than the other types of apparatuses 
(Dressman 2005). Apparatus 3 (reciprocating cylinder) and 4 (flow-through cell) were added 
to the USP in 1990 for the convenience of European companies that were using them to 
evaluate MR products. Three other apparatus have been described. Apparatus 5 (paddle over 
disk), 6 (rotating cylinder) and 7 (reciprocating holder) have been used mainly for transdermal 
dosage forms. Apparatus 7 has also been used for oral MR dosage forms using osmotic pump 
technology (Long and Chen 2009). 
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Figure 1.30 Schematic representation of Apparatus 1 (rotating basket) and Apparatus 2 
(paddle assembly) dissolution vessels. 
 
 
Both Apparatuses 1 and 2 use single hemispherical bottom vessels with a centred 
spindle. The vessels contain the dissolution medium, typically 500–1000 mL with 900 mL 
most frequently used. The vessels are fitted with covers containing sampling ports and 
immersed in a water bath kept at a constant temperature as a means of controlling the 
temperature of the media in the vessels. The major difference between the two Apparatuses 
relate to how the dosage form is placed inside the vessel. For Apparatus 1, the dosage form is 
placed in a basket attached to the end of the spindle, while for Apparatus 2 the dosage form is 
dropped directly into the vessel. Apparatus 1 induces agitation by rotating the basket and 
apparatus 2 by using a rotating paddle. When the dosage form floats (e.g., capsules), 
Apparatus 1 can be used. Alternatively, sinkers designed to enclose the dosage form can be 
used with Apparatus 2. However, for hydrophilic matrix systems that swell during dissolution, 
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USP Apparatus 1 may not be appropriate because the matrix can obstruct the holes in the 
basket, disrupting the hydrodynamics and slowing dissolution. In addition, the basket may 
entrap the swelling matrix and damage its structure. The same trouble was demonstrated for 
dosage forms placed inside sinkers used in apparatus 2 (Soltero, Hoover et al. 1989). 
Sampling from Apparatuses 1 and 2 can be accomplished either manually or 
automatically, with filtration to eliminate undissolved particles. 
For any selected apparatus, concentration of each sample is measured by a suitable 
analytical method. The concentration of each sample is then converted to the amount of drug 
released using an algorithm, taking into account the sampling method and whether 
replacement of media occurred. The most common test methods use either UV/visible 
spectrophotometry or HPLC with UV detection (Long and Chen 2009). Measuring absorbance 
at UV or visible wavelengths requires minimal to no sample preparation, which is an 
advantage. However, when using spectrophotometry there is the possibility of assay 
interference by excipients that absorb in the same wavelength region or by any undissolved 
excipients that may scatter light and affect the results. These interferences can be eliminated 
by using a baseline normalization approach or by using second derivatives of the absorbance 
profile (Perkampus 1992). This interference is less problematic when using HPLC because of 
its improved specificity resulting from the chromatographic separation. However, HPLC is a 
technique that requires large amounts of organic solvents, and thus it is more expensive and 
bad for the environment. 
 
 
1.7.3.3 Dissolution test media and methods 
Evaluation of the appropriate testing media begins by considering the in vivo transit of 
an oral dosage form. However, there is no in vitro test that can physically reproduce the in 
vivo release environment given the complex nature of the gastrointestinal tract, the factors that 
affect its activity and the diverse mechanisms employed to achieve sustained drug-release 
(Qiu, Garren et al. 2003). Nevertheless, it is possible to develop a predictive dissolution test 
when in vivo drug-release is the chief controlling factor in the rate of appearance of the drug in 
the blood (Qiu 2009), which is the case with SR dosage forms.  
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Media and test conditions for SR products should be able to tackle at least some of the 
variables encountered in vivo. They should try to simulate 1) the pH range throughout the 
gastrointestinal tract; 2) the approximate time the SR dosage form remains at each pH in the 
digestive system; 3) food induced physiological changes, or at least in part, that occur in the 
gastrointestinal tract; and 4) the motility pattern and other mechanical forces encountered by 
the dosage form in the gastrointestinal tract. Therefore, an IVIVC for a SR product should be 
developed on a case-by-case basis (Qiu 2009). Contrariwise, for IR dosage forms, a lower pH 
medium simulating the conditions in the stomach is more appropriate because these products 
are designed to release drug rapidly, usually in less than an hour.  
Water is not the most preferred medium because water has no buffering capacity. The 
use of buffered media is even more important when the dissolution of either the drug or 
excipients is pH-sensitive. In unbuffered media, dissolution of ionizable species may create a 
pH-microclimate where the pH at the surface of the particles or dosage form is different from 
the bulk solution pH. In addition, the dissolution of an ionizable drug from a dosage form 
containing a high drug loading may create changes of the pH of the bulk medium throughout 
the duration of the test. In either case, these changes in pH add an uncontrolled variable to the 
events taking place during dissolution, and may complicate the interpretation of results (Long 
and Chen 2009). It has also been demonstrated that an improvement of the correlation can be 
attained when the in vitro test is done in a pH gradient instead of distilled water (Ranade 
1991). The typical pH range for dissolution testing is from pH 1 (representing gastric pH) to 
pH 7.5 (representing intestinal pH) (Long and Chen 2009). 
 
There have been many attempts to simulate food affects in vitro – for example, 
surfactants have been added to the dissolution media (Qiu, Cheskin et al. 1997; Dressman, 
Amidon et al. 1998; Galia, Nicolaides et al. 1998), dosage forms have been pre-soaked in 
peanut oil or placed in continuous oil contact to mimic the presence of a high fat meal (Mu, 
Tobyn et al. 2003), or tested in different dissolution apparatuses under varied hydrodynamic, 
mixing conditions to examine the effects of mechanical destructive forces on drug-release 
from MR dosage forms (Shameem, Katori et al. 1995). These methods are, however, only 
capable of imitating one or two aspects of physiological conditions. A very complicated in 
vitro model has been described, which consists of a multi-compartment dynamic computer-
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controlled system designed to simulate the human stomach and small intestine (TIM-1), and 
large intestine (TIM-2), respectively, and intended for studying the behaviour of oral drug 
dosage forms under various physiological gastrointestinal conditions (Minekus, Smeets-
Peeters et al. 1999; Blanquet, Zeijdner et al. 2004). 
Surfactants in dissolution media have been used not only during early formulation 
development to simulate the intestinal state or for correlation with in vivo studies but also to 
increase drug solubility of poorly soluble drugs, because the solubility in buffer solutions may 
be insufficient to allow for the use of a practical volume of medium (Shah, Konecny et al. 
1989; Abrahamsson, Johansson et al. 1994). This approach is not far from real physiological 
conditions, since bile salts and lecithin are natural surfactants present in intestinal fluids and 
bile, and are responsible for solubilizing poorly soluble nutrients before absorption (Hörter 
and Dressman 2001).  
Sink conditions during a dissolution experiment are usually required to obtain in vitro 
dissolution curves representing the biopharmaceutical properties of the drug product under 
investigation with minimal effects due to the influence of solubility (Emami 2006). The term 
‘sink conditions’ denotes a state in which the concentration of the drug in a solubilizing 
medium is very low compared with that of a saturated solution of the drug in the same 
medium (Pillay and Fassihi 1998). According to the USP, sink conditions are achieved when 
the saturated solubility of the drug in the dissolution medium is at least three times the 
concentration of a completely dissolved tablet in the volume of media used in the test. Thus, 
sink conditions are achieved depending on the solubility of the drug in the medium, the drug 
dose, and the selected volume. 
Since the human body temperature is about 37ºC, standard dissolution testing is carried 
out at this temperature with an acceptable variation of ± 0.5 ºC in most pharmacopoeias. 
Another important consideration is drug stability during the dissolution test. A typical 
dissolution test at 37ºC for SR dosage forms runs 12-24 h or more, and quantification of the 
samples can take additional time. Therefore, the stability of the drug in the medium at 37°C 
and as a function of pH should be evaluated (Jorgensen and Bhagwat 1998). Susceptibility to 
light or oxidation should also be evaluated for additional precautions. 
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When choosing the dissolution test conditions that are appropriate for a certain SR 
dosage form, it should also be taken into consideration that the release characteristics of many 
SR products show some pH dependence and may be affected by the physicochemical 
properties of the drug and by the excipients in the formulation to varying degrees depending 
upon the dissolution test conditions. For example, the swelling of polymers used as rate-
controlling agents can be affected by medium pH, ionic strength, surfactants, and even 
counterion composition (Long and Chen 2009). 
Although it is important that in vivo hydrodynamic conditions are simulated during 
dissolution testing, the variability in motility patterns of the gastrointestinal tract in fasted and 
fed objects complicates the task of setting a unique agitation condition during in vitro testing 
(Zahirul and Khan 1996). However, in the case of SR products, the release is typically 
controlled by polymers. Since polymer behaviour, such as swelling or entanglement, may be 
sensitive to pH or ionic strength, the medium composition will usually play a greater role than 
the hydrodynamics in influencing drug-release (Long and Chen 2009).  
In conclusion, a dissolution methodology that is able to discriminate between the study 
formulations with different release patterns and best reflects the in vivo behaviour should be 
used to establish an IVIVC (Emami 2006). It is generally easier to obtain a good IVIVC with 
SR dosage forms that are essentially unaffected by variables such as pH, agitation or ionic 
strength (Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms. 
FDA. (1997)). 
 
In the development of a Level A IVIVC, the in vitro test conditions, such as the 
agitation rate, choice of apparatus and pH and temperature of the medium, may be modified in 
order to alter the dissolution profile and facilitate the establishment of a correlation. The shape 
of the in vivo profile can then be used as a target for the in vitro data to match. Statistics and 
the tools for profile comparisons, which will me discussed in the next section, facilitate 
efficient development (Qiu 2009). However, once a discriminating system is developed, 
dissolution conditions should be the same for all formulations tested in the study and should 
remain unchanged before further steps towards correlation evaluation are undertaken 
(Guidance for industry. Extended release oral dosage forms: development, evaluation and 
application of in vitro/in vivo correlations. FDA. (1997)). 
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1.7.3.4 Statistical comparison of dissolution profiles 
Model-dependent and model-independent methods can be used to quantitatively 
compare dissolution profiles in order to evaluate sameness (Sathe, Tsong et al. 1996; Pillay 
and Fassihi 1998; Yuksel, Kanık et al. 2000; Costa and Sousa Lobo 2001). The model-
dependent methods rely on selecting the proper mathematical model and comparing the 
goodness of fit and changes in fitted parameters. The mathematical models are fitted to 
individual dissolution data using non-linear regression, resulting in the estimation of the model 
parameters with their standard errors and descriptive statistics of regression for each model. 
These estimations allow the determination of the suitable mathematical models to describe the 
dissolution profiles. Common statistical tools, such as t-tests or ANOVA, can be used to 
demonstrate sameness of the fitted parameters (Long and Chen 2009). Model-independent 
approaches also use the dissolution data in their native form. These methods provide a direct 
comparison of a test profile against a reference profile without any transformation to another 
mathematical expression. Calculations that can be made include the area under the curve of 
the percent released versus time profile or the amount released at a particular time point or 
time points (Tsong, Hammerstrom et al. 1996; Yuksel, Kanık et al. 2000). Although there 
measurements may demonstrate the equivalence of the amount of drug released, they will not 
necessarily indicate whether the shape of the profile is similar (Long and Chen 2009). 
The most commonly used model-independent approach is the fit factors, which were 
introduced by Moore and Flanner (Moore and Flanner 1996) and consist of the difference 
factor, f1, and the similarity factor, f2. The f2 is more frequently reported than the f1. The f2 is a 
logarithmic transformation of the average sum squared error and is given by the following 
equation: 
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where Rt and Tt are the mean percent dissolved of the reference and test products at each time 
point t, and n is the number of time points in the profile. 
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Two dissolution profiles are similar if f2 is between 50 and 100, according to the FDA 
and the European Agency for the Evaluation of Medical Products (EMEA). However, the 
closer to 100 (%) f2, the more similar the dissolution profiles are. If f2 is 100, the two profiles 
are identical. An f2 of 50 indicates there is a 10% difference between profiles (Shah, Tsong et 
al. 1998). 
The f1 provides the mean percent difference between two curves and is calculated as: 
 
€ 
f1 = Rt −Tt( )
t=1
n
∑
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ Rt
t=1
n
∑
⎧ 
⎨ 
⎩ 
⎫ 
⎬ 
⎭ 
×100      Equation 20 
 
Identical profiles will have an f1 equal to zero and a value less that 15% is commonly 
taken to indicate sameness of profiles (Long and Chen 2009). 
ANOVA-based methods have also been applied to compare dissolution profiles. These 
methods use the dissolution data in their native form or as simple transform and the analysis is 
capable of showing differences between profiles in level and shape. The latter characteristic is 
particularly important to identify differences in the dissolution mechanism (Yuksel, Kanık et 
al. 2000). 
 
 
1.7.4 Bioavailability studies for development of IVIVC 
Bioavailability is a measure of systemic availability of a drug and reflects the rate and 
extent at which the drug is absorbed from a drug product and becomes available to the site of 
action (Shargel, Wu-Pong et al. 2004). In the development of an IVIVC, a bioavailability 
study should be performed to characterize the plasma concentration versus time profile for 
each formulation (Uppoor 2001). 
A bioavailability study protocol in humans consists of several elements. For example, 
the study design should include test and reference products, dosage regimen, blood sampling 
times, fasting/meals schedule and analytical methods. In addition, the information on 
volunteer selection includes inclusion/exclusion criteria and medical history as well as 
physical examination. For example, the study might exclude any volunteers who have known 
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allergies to the drug, are overweight, or have taken any medication within a specific period 
(often one week) prior to the study. It is also important to refer in the protocol some ethical 
considerations, such as informed consent, side effect risks and physiological effects, and 
emergency procedures. A section relative to data analysis should also be part of the protocol, 
among others (Shargel, Wu-Pong et al. 2004). 
The number of subjects in a typical bioavailability study will depend on the expected 
inter-subject and intra-subject variability (Shargel, Wu-Pong et al. 2004). However, according 
to the FDA guidance (Guidance for industry. Extended release oral dosage forms: 
development, evaluation and application of in vitro/in vivo correlations. FDA. (1997)), 
bioavailability studies for IVIVC development should be performed in humans with enough 
subjects to adequately characterize the absorption profiles of the drug products. 
Both the parent drug and its major metabolites are generally measured using a 
selective, accurate and precise analytical method. Studies on the influence of food are 
generally carried out using meal conditions that are expected to provide the greatest effects on 
gastrointestinal physiology in order to induce the utmost effects on systemic drug 
bioavailability (Shargel, Wu-Pong et al. 2004). 
Crossover studies, in which each volunteer receives all treatments that are being 
investigated in a randomized order and at different times, are preferred to establish a IVIVC, 
since they reduce inter-subject variability. However, parallel studies or cross-study analyses 
may also be acceptable. The reference product can be an intravenous solution, an aqueous oral 
solution or an IR product of the drug. In addition, IVIVC are usually developed in the fasted 
state. When a drug is not tolerated in the fasted state, studies may be conducted in the fed state 
(Guidance for industry. Extended release oral dosage forms: development, evaluation and 
application of in vitro/in vivo correlations. FDA. (1997)). 
The in vivo release/absorption profile from plasma concentration–time data is obtained 
using an appropriate deconvolution technique. Subsequently, in the development of a Level A 
IVIVC, the calculated percentage absorbed or released in vivo is correlated with the 
percentage released in vitro using a basic linear model with intercept (a) and slope (b):  
 
(% absorbed)in vivo = a x b (% released)in vitro    Equation 21 
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Ideally, the relationship should be linear.  
The deconvolution technique can be model-dependent or model-independent. Two 
commonly used model-dependent deconvolution techniques for estimating the apparent in vivo 
drug absorption profiles following oral administration of a dosage form are Wagner–Nelson 
(Wagner and Nelson 1963; Wagner and Nelson 1964) and Loo–Riegelman (Loo and 
Riegelman 1968) methods. These approaches are based on mass balance. The Wagner–Nelson 
technique is derived from a one-compartment model while the Loo–Riegelman technique is 
used for a two-compartment model. In 1983, Wagner published an Exact Loo–Riegelman 
method for absorption analysis of one- to three-compartment models, which contrarily to the 
Wagner–Nelson method requires intravenous data for the calculation of absorption profiles 
(Wagner 1983). The model-independent techniques include convolution and deconvolution 
methods used in linear system analysis (Qiu 2009). For a detailed description of model-
dependent and model-independent techniques and their respective equations, the reader is 
referred to a publication by Emami J. (Emami 2006). In actual applications, software products 
are frequently used to execute deconvolution and convolution procedures and IVIVC analysis. 
 
 
1.7.5 Evaluation of predictability of IVIVC 
Following the establishment of a Level A IVIVC model, it is necessary to demonstrate 
that predictability of in vivo performance of a drug from its in vitro dissolution characteristics 
is accurate and consistent, i.e., is maintained over a range of in vitro dissolution release rates 
and manufacturing changes. The FDA guidance suggests evaluating the goodness of fit by 
estimating the prediction error (PE), i.e., differences between observed and predicted values 
over a range of in vitro release rates. Depending on the intended application of the IVIVC and 
the therapeutic index of the drug, the approaches to validate the model may be internal and/or 
external. Internal validation is based on the initial in vitro release data used to define the 
IVIVC model, while external validation requires additional data sets that were not used in the 
development of the IVIVC (Guidance for industry. Extended release oral dosage forms: 
development, evaluation and application of in vitro/in vivo correlations. FDA. (1997)). The 
external validation demonstrates the robustness of the IVIVC. 
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Chapter 2. Objectives 
2.1 General objective 
Oral solid dosage forms that prolong the drug-release rate have proven to be 
advantageous in the delivery of certain drugs, improving their therapeutic efficacy while 
preventing the occurrence of toxic and/or subtherapeutic plasma drug concentrations. 
Biodegradable and abundant hydrophilic excipients, such as modified starches, are interesting 
excipients for sustained drug-release. SD HASCA was proposed as an innovating hydrophilic 
excipient for oral SR matrix tablets produced by direct compression. Previous studies 
involving this new excipient focused on the development and optimization of the production 
of SD HASCA and the study of formulation parameters. However, further studies aimed at the 
development and optimization of SD HASCA SR matrix tablets in view of their ultimate use 
as dosage forms for oral administration, were necessary to demonstrate the usefulness of this 
polymer for the production of efficient and advantageous sustained drug-release delivery 
systems. 
The general objective of this thesis was to develop, optimize and evaluate in vitro and 
in vivo SR matrix tablets for oral administration using SD HASCA as the only sustained drug-
release excipient. 
 
 
2.2 Specific objectives 
In the first place, the drug-release properties of different formulations containing a 
compressed blend of acetaminophen, sodium chloride and SD HASCA were evaluated in a 
series of dissolution media simulating the pH gradient in the gastrointestinal and its variations 
in the presence of food. The research performed in this section aimed to: 
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1) Select an optimized formulation taking into account the best SR profiles of the 
formulations tested and their physical integrity when immersed in the simulated 
gastrointestinal pH gradient. 
2) Study the influence of simulated fasting and food-induced gastric pH values and 
residence times in each acidic pH on the drug-release characteristics of the optimized 
SD HASCA formulation. 
 
Following the selection of the most appropriate SD HASCA SR formulation, an 
exploratory clinical study in healthy human volunteers was carried out. The objectives of this 
section of the study were to: 
 
1) Explore the aptitude of this formulation to extend the absorption of drug after oral 
administration. 
2) Evaluate the resistance of this formulation to mechanical stresses and hydrolysis by α-
amylase in the gastrointestinal tract. 
 
This clinical study confirmed that SD HASCA matrix tablets are able to extend drug-
release and absorption and that the structure of the swollen matrices is strong enough for oral 
administration. 
 
The following work focused on development of SD HASCA SR formulations with 
clinical relevance. The specific objectives of this part of the research were to:  
 
1) Develop once-daily and twice-daily SD HASCA tablets containing two common 
dosages of tramadol hydrochloride (100 mg and 200 mg), a model drug with clinical 
relevance in sustained drug-release. 
2) Assess the robustness and drug-release characteristics of one of the developed 
formulations in a 40% ethanol medium, since tramadol hydrochloride may lead to side 
effects if released as a bolus. 
3) Investigate the influence of compression force (CF) on the in vitro drug-release rate. 
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Subsequently, the research focused on studying in vitro the influence of the most 
pertinent physiological condition of the gastrointestinal tract taking into account the amylose-
based nature of SD HASCA, i.e., biodegradation by α-amylase enzymes, on the presystemic 
metabolism of SD HASCA SR matrix tablets. It was also hypothesized that that variations in 
gastric residence time of non-disintegrating SD HASCA SR tablets may affect their α-
amylase-catalyzed erosion. Thus, the final section of the research aimed to: 
 
1) Investigate in vitro the influence of α-amylase on the drug-release characteristics and 
mechanisms of SD HASCA SR formulations. 
2) Evaluate in vitro the influence of the residence time in acidic medium on the α-
amylase-catalyzed erosion of SD HASCA SR formulations. 
3) Investigate the contribution of the Fickian diffusion and the erosion mechanisms to the 
overall drug-release rate from SD HASCA SR formulations through the application of 
a two-component model, with and without α-amylase. 
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3.1 Presentation of the article and contribution of the authors 
This article presents the results obtained during the development and optimization of a 
SD HASCA SR formulation containing acetaminophen as the model drug, and sodium 
chloride as the swollen matrix-stabilizing agent. The first part addresses the study of the 
influence of acidic pH value or acidic medium residence time on the in vitro drug-release from 
an optimized SD HASCA formulation. Thereafter, the results of the clinical study are 
reported. The citation for this article is: 
Nabais, T., F. Brouillet, et al. (2007). "High-amylose carboxymethyl starch matrices 
for oral sustained drug-release: In vitro and in vivo evaluation." European Journal of 
Pharmaceutics and Biopharmaceutics 65(3): 371-378. 
 
The contribution of each author to the publication was the following: 
Teresa Nabais – Execution of all dissolution testing; analysis of data resulting from dissolution 
testing; analysis of data resulting from the clinical study in healthy volunteers; writing of the 
article, except introduction. 
Fabien Brouillet – Spray drying of the SD HASCA used to manufacture the tablets used in the 
study; technical support during the first experiments using the dissolution and other 
apparatuses. 
Soula Kyriacos – Execution of clinical studies. 
Mohammad Mroueh – Coordinator of the work of Soula Kyriacos. 
Pedro Amores da Silva – Co-director of this thesis at the time of the publication; revision of 
the article. 
Bernard Bataille – Project coordinator. 
Chafic Chebli - Project coordinator. 
Louis Cartilier – Main project coordinator and director at the time of the publication; writing 
of the introduction of the article; revision of the article. 
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3.2 Abstract 
High-amylose corn starch, that contains 70% of amylose chains and 30% of 
amylopectin, has been used to obtain substituted amylose (SA) polymers. Tablets have been 
prepared by direct compression, i.e. dry mixing of drug and SA, followed by compression, 
which is the easiest way to manufacture an oral dosage form. Until now, their controlled-
release properties have been assessed only by an in vitro dissolution test. Amylose-based 
polymers are normally subject to biodegradation by α-amylase enzymes present in the 
gastrointestinal tract, but matrix systems show no significant degradation of tablets by α-
amylase in vitro. 
High-amylose sodium carboxymethyl starch (HASCA) is an interesting excipient for 
sustained drug-release in solid oral dosage forms. In addition to the easy manufacturing of 
tablets by direct compression, the results show that in vitro drug-release from an optimized 
HASCA formulation is not affected by either acidic pH value or acidic medium residence 
time. In addition, a compressed blend of HASCA with an optimized quantity of sodium 
chloride provides a pharmaceutical SR tablet with improved integrity for oral administration. 
In vivo studies demonstrate extended drug absorption, showing that the matrix tablets do not 
disintegrate immediately and resist enzymatic attack well. Nevertheless, acetaminophen does 
not seem to be the most appropriate drug for this type of formulation. 
 
 
3.3 Introduction 
It is possible to chemically modify the hydroxyl groups of amylose by an etherification 
process, resulting in substituted amylose (SA) [1,2]. These polymers are referred to as SA,R-n, 
where R defines the substituent used, typically 1,2-epoxypropanol (or glycidol=G), and n 
represents the degree of substitution (DS) expressed as the mole ratio of substituent/kg of 
amylose. High-amylose corn starch, that contains 70% of amylose chains and 30% of 
amylopectin (Hylon VII®, Eurylon), has been employed to obtain SA polymers. SA matrix 
tablets have been prepared by direct compression, i.e. dry mixing of drug and SA,G-n, 
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followed by compression, which is the easiest way to manufacture an oral dosage form. Their 
controlled-release properties have been assessed by an in vitro dissolution test. Release times 
of 95% of the drug ranged from 9 to 20 hours for all DSs studied for 400-mg matrices 
containing 10% of a soluble drug [2]. 
Drug transport analysis has revealed that diffusion, relaxation, molecular 
rearrangement and, in some cases, physical erosion, are simultaneously involved in the control 
of drug release. SA,G-2.7 matrices allow nearly constant drug-release [2-4]. Such a release 
profile is unusual for a hydrophilic matrix system where Fickian release, i.e. first-order 
kinetics, is expected. SA hydrophilic matrix tablets sequentially present a burst effect, typical 
of hydrophilic matrices, and near-constant release, typical of reservoir systems. After the burst 
effect, the surface pores disappear progressively by the molecular association of amylose 
chains; this allows the creation of a polymer layer acting as a diffusion barrier and explains the 
peculiar behaviour of SA polymers [5].  
When testing their in vitro resistance to α-amylase enzymatic degradation, SA,G-2.7 
matrix systems and dry-coated tablets maintain their structure, and control the release of 
[186Re], showing no significant degradation of tablets by α-amylase [6].  
High-amylose sodium carboxymethyl starch (HASCA) has been recently proposed as a 
suitable material for oral matrix tablets [7,8]. These tablets can be advantageously improved 
by the addition of electrolytes. Such addition permits the integrity of the swollen matrix tablets 
to be maintained when they are immersed in a medium undergoing pH changes simulating the 
pH evolution of the environment surrounding an oral pharmaceutical dosage form transiting 
along the gastrointestinal tract while allowing controlled and sustained drug-release with a 
remarkable close-to-linear release profile [8].  
Establishing a meaningful relationship between in vitro drug-release and in vivo 
absorption from an extended-release dosage form is an important part of the dosage form 
development process, the ultimate goal of in vitro-in vivo correlation (IVIVC) ideally being 
the application of in vitro data as a surrogate for in vivo evaluation [9]. However, it must be 
understood that "IVIVC is not only a drug-dependent characteristic; it is also a product-
dependent characteristic" [9]. Therefore, the Food and Drug Administration has strictly limited 
IVIVC conditions of use, thereby avoiding overenthusiastic applications [10].  
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The purpose of this study was: 1) to optimize the concentration of sodium chloride in a 
formulation that maintains the integrity of swollen HASCA matrix tablets; 2) to evaluate the in 
vitro drug-release characteristics of an optimized SR formulation containing HASCA, sodium 
chloride and acetaminophen, employing a pH gradient to simulate various pH conditions 
found in the gastrointestinal tract; 3) to demonstrate the extended-release properties of this 
new drug delivery system in vivo by comparing the pharmacokinetic parameters of a SA 
formulation and a commercially-available, immediate-release tablet in healthy volunteers 
under fasting conditions; and 4) to elaborate the relationship between in vitro release and in 
vivo absorption, if any, for this specific SR acetaminophen formulation among healthy 
volunteers under fasting conditions. 
 
 
3.4 Material and methods 
3.4.1 Materials 
HASCA, where “HAS” means high-amylose substituted starch and “CA” defines the 
substituent used, herein chloroacetate, was obtained from Amylose Project Inc. (Beaconsfield, 
Quebec, Canada). Acetaminophen was purchased from Laboratoires Denis Giroux inc. (Ste-
Hyacinthe, Quebec, Canada), and sodium chloride (crystals, lab grade), from Anachemia Ltd. 
(Montreal, Quebec, Canada). Commercially-available, immediate-release Tylenol regular-
strength tablets containing 325 mg of acetaminophen, from McNeil (Guelph, Ontario, 
Canada), were chosen as the reference formulation. All chemicals were of reagent grade and 
were tested without further purification.  
 
 
3.4.2 Preparation of HASCA tablets 
Tablets were prepared by direct compression, i.e. dry mixing of acetaminophen, 
HASCA, and NaCl, followed by compression. HASCA, acetaminophen and NaCl were mixed 
manually in a mortar. No lubricant was added to the formulation. Indeed, it has been 
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demonstrated earlier that magnesium stearate, at standard levels, does not influence the in 
vitro release profile from HASCA matrix tablets containing NaCl as well as their integrity [8]. 
Tablets were prepared on an IR 30-ton press (C-30 Research & Industrial Instruments 
Company, London, U.K.). To evaluate the NaCl percentage in the formulation that maintains 
the integrity of the swollen matrix, tablets of 600 mg containing 40% of acetaminophen as a 
model drug and 17.5%, 22.5% or 27.5% of NaCl, were prepared. On the other hand, 600-mg 
tablets containing 40% of drug and 27.5% of NaCl were produced to investigate the influence 
of acidic pH value and residence time in the acidic medium on the release characteristics of 
HASCA tablets as well as to perform in vivo studies. All tablets were compressed at 2.5 
tons/cm2 for 20 seconds. The diameter of the tablets was 1.26 cm. 
 
 
3.4.3 Drug-release studies 
The drug-release properties of some typical HASCA matrix tablets were assessed by 
an in vitro dissolution test. Since HASCA is an ionic polymer used for oral, sustained drug-
release, the in vitro release experiments were conducted in a pH gradient simulating the pH 
evolution of the gastrointestinal tract to examine the pH-dependency of drug-release 
properties. The tablets were placed individually in 900 mL of a hydrochloric acid medium (pH 
1.2) simulating gastric pH, at 37°C, in U.S.P. XXIII dissolution apparatus No. 2 equipped with 
a rotating paddle (50 rpm). They were then transferred to a phosphate buffer medium (pH 6.8) 
simulating jejunum pH, then finally transferred to another phosphate buffer medium (pH 7.4) 
simulating ileum pH, until the end of the test. The dissolution apparatus and all other 
experimental conditions remained the same. 
The standard pH gradient conditions (A) were: pH 1.2 for 1 hour, pH 6.8 for 3 hours, 
and pH 7.4 until the end of the dissolution test (24 hours). The influence of NaCl percentage in 
the formulation on swollen matrix tablet integrity and drug-release was studied under standard 
conditions. To investigate the influence of pH of the acidic medium and residence time in the 
acidic medium on drug-release from HASCA matrices, different dissolution tests were 
performed, in which both pH of the acidic medium and residence time in the acidic medium 
were varied, as shown in Table 3.1. 
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Table 3.1 pH gradient conditions used to simulate various possibilities of gastric pHs and 
residence times encountered by HASCA matrices during their gastrointestinal transit  
pH value 1.2 3.5 4.5 6.8 7.4 
Conditions A (standard) 1 hr - - 3 hrs Until 24 hrs 
Conditions B 10 min - - 3 hrs Until 24 hrs 
Conditions C - 3 hrs - 3 hrs Until 24 hrs 
Conditions D - - 6 hrs 3 hrs Until 24 hrs 
Conditions E - - - 3 hrs Until 24 hrs 
 
 
The amount of acetaminophen released at predetermined time intervals was followed 
spectrophotometrically (244 nm). All formulations were tested in triplicate. The drug- release 
results are expressed as cumulative % in function of time (hours). 
 
 
3.4.4 Pharmacokinetics in healthy human volunteers 
The pharmacokinetic study, carried out at Notre-Dame de Secours Hospital, Byblos, 
Lebanon, was conducted in 5 healthy volunteers (3 males and 2 females) of mean age 22.6 ± 
1.8 years and mean weight 82.4 ± 24.4 kg. All subjects had a normal medical history, 
medication history, physical examination, and biochemical screening (haematology, blood 
urea nitrogen, serum creatinine, alkaline phosphatase, liver enzymes, and glucose). None of 
them had taken any enzyme-inducing agents for at least 30 days prior to the initiation of this 
study. They were also instructed to abstain from medications and alcohol for at least 1 week 
prior to and during the study period. Informed consent was obtained from all subjects after the 
nature and purpose of the study were explained to them, along with a brief description of the 
drug effect.  
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A single-dose, non-blinded, balanced, 2-way crossover design was adopted using 2 
acetaminophen dosing arms: a commercially-available, immediate-release (IR) dosage form 
(Tylenol containing 325 mg of acetaminophen per tablet) and a SR (SR) formulation 
comprising 240 mg of acetaminophen per tablet (Amylose Project Inc.). All subjects were 
fasted overnight, and in the morning, each of them was given a single oral dose of either a SR 
acetaminophen tablet or an IR Tylenol tablet, as a reference, with 240 mL of water. A 
standardized lunch or snack was served 4 hours after drug administration. A one week 
washout period was allowed before the next treatment to avoid potential carry-over effects. 
Blood samples (9 mL) were collected, in heparinised plastic tubes, at different time intervals 
for each of the 2 products: at 0 (blank), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-
dosing for Tylenol, and at 0 (blank), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 17, 24 and 36 hours 
post-dosing for the SR dosage form. The blood samples were then centrifuged for 5 minutes at 
10,000 rpm, and plasma samples stored in a freezer (-70ºC) until analysis.  
 
 
3.4.5 High-performance liquid chromatography (HPLC) analysis of plasma 
samples 
Acetaminophen plasma concentrations were analyzed by HPLC. The HPLC system 
consisted of a pump (LC-10AD, Shimadzu), a UV-VIS spectrophotometric detector (SPD-
10AVP, Shimadzu) operating at a wavelength of 254 nm, a Rheodyne injector, a reverse-phase 
column (C18, 15 cm × 4.6 mm) and an integrator (C-R 8A Chromatopac, Shimadzu). The 
mobile phase, a mixture of water and acetonitrile (94:6 v/v %), was pumped at a flow rate of 
1.2 mL/min. The lower detection limit of the assay was 0.01 µg/mL of acetaminophen in 
plasma. 
Frozen plasma samples were allowed to reach room temperature. A 200-µL aliquot of 
plasma was placed into a test tube (Eppendorf), to which 70 µL of internal standard 
(theophylline aqueous solution 50 µg/mL for high concentrations [> 0.35 µg/mL] and 5 µg/mL 
for low concentrations [≤ 0.35 µg/mL]) and 430 µL of 10% perchloric acid were added. The 
mixture was vigorously shaken for 5 minutes, then centrifuged for another 5 minutes at 10,000 
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rpm. The supernatant was finally collected, and 50 µL of the filtrate was injected into the 
HPLC system to record either peak areas or heights. 
 
 
3.4.6 Pharmacokinetic data analysis 
Since the 2 formulations presented different doses of acetaminophen, the drug plasma 
concentrations obtained after Tylenol administration were dose-adjusted, i.e. divided by the 
acetaminophen dose in the Tylenol formulation (325 mg) and multiplied by the acetaminophen 
dose in the SR formulation (240 mg), before calculation of the pharmacokinetic parameters. 
Further weight adjustment was performed before plotting the drug concentration-time curves 
to take into account the high weight variation of the volunteers enrolled in the study. 
Maximum plasma concentration (Cmax) and time to reach Cmax (Tmax) after oral 
administration were directly determined from the plasma concentration values. The measured 
plasma concentrations served to calculate the area under the plasma concentration-time curve 
from time zero to the last concentration time point (AUC0-t) and the area under the plasma 
concentration-time curve from time zero to infinity (AUC0-∞). AUC0-t was calculated according 
to the trapezoidal rule, and AUC0-∞ was calculated by the sum of AUC0-t and the last measured 
concentration divided by the elimination constant (Ct/k).  
The Wagner-Nelson method [11] was adopted to calculate the percentages of 
acetaminophen absorbed in function of time for each volunteer enrolled in the study. The 
absorbed percentages were calculated by the following equation:  
 
% Absorbed = [(Ct + k × AUC0-t)/(k × AUC0-∞)] × 100 
 
where Ct is the plasma concentration at time t; k is the elimination rate constant; AUC0-t is the 
area under the plasma concentration-time curve from time zero to time t, and AUC0-∞ is the 
area under the plasma concentration-time curve from time zero to infinity. 
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All the pharmacokinetic parameters were determined for each volunteer, and the 
averages, standard deviations and coefficients of variation calculated. 
No statistical analysis was performed on any of the pharmaceutical parameters because 
this exploratory study was conducted on a very small number of volunteers to evaluate the in 
vitro and in vivo potential of a new SR matrix formulation. 
 
 
3.4.7 IVIVC 
An IVIVC for this specific acetaminophen SR formulation, if any, was explored by 
plotting the point-to-point relationship of the percentage of drug absorbed in vivo vs. the 
percentage of drug released in vitro at the same time, up to the maximum amount of drug 
absorbed in vivo.  
 
 
3.5 Results and discussion 
3.5.1 In vitro drug-release characteristics from HASCA matrix tablets 
Figure 3.1 shows the in vitro release profile of acetaminophen from HASCA SR matrix 
tablets containing NaCl in concentrations ranging from 17.5 to 27.5% w/w. Remarkably, all 
total release times were close to 24 hours for 600-mg tablets containing such large amounts of 
soluble materials, i.e. around two-thirds w/w of each tablet were composed of acetaminophen 
and NaCl.  
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Figure 3.1 Cumulative percent of acetaminophen released in vitro from HASCA matrices 
containing 40% of drug and increasing concentrations of NaCl (: 17.5% of NaCl, : 22.5% 
of NaCl, : 27.5% of NaCl). The number of replicates was three. 
 
Further, an increase in NaCl tablet content did not lead to an increment in the burst-
effect. Only after 2 hours of dissolution could a slight rise in the drug-release rate be observed 
with escalating NaCl concentrations. However, 9 to 12 hours after the beginning of the 
dissolution process, some cracks appeared on the surface of the tablets containing 17.5 or 
22.5% NaCl, leading, at the same time, to an increase in the drug-release rate. This can be 
explained by an augmentation in the tablet diffusion surface as well as by new drug particles 
being directly exposed to the medium for free dissolution, creating a kind of reduced-scale 
burst-effect. Even if these cracks did not lead to a dramatic change in the drug-release rate 
(Fig. 3.1), good mechanical resistance to stress is essential for normal therapeutic use. Indeed, 
when the stomach churns, thereby exerting significant physical force on the formulation, there 
is a strong risk of the tablet breaking apart, which could elicit a burst of drug-release. The 
optimal amount of NaCl found to maintain the integrity of the swollen tablets during the 
totality of the dissolution test was 27.5% for tablets containing 40% of acetaminophen. It has 
been previously reported that adding an optimal percentage of electrolyte to the formulation 
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could maintain the integrity of swollen hydrophilic matrix tablets while allowing controlled 
and sustained drug-release [8]. 
The swelling of SA tablets can be described as moderate when compared to the usual 
hydrophilic matrices such as hydroxypropylmethylcellulose [5]. This is particularly true for 
HASCA tablets, which form a very rigid gel with surprisingly high mechanical strength in the 
swollen state [7,8]. As a consequence, it is possible to create tablets that do not show any 
disintegration, even if mechanical stresses occur, for example, after administration in the 
gastrointestinal tract. However, in the absence of an electrolyte, such swollen HASCA tablets 
show cracks and/or partial or complete separation of the tablet parts, which forbid their normal 
and safe therapeutic use. One possible explanation for the appearance of cracks on the surface 
of the tablets may be that the rigidity of the gel and its tight network hinder water penetration 
into the tablets but, more importantly, strongly decrease diffusion of the dissolved drug out of 
the matrix tablets, thereby tremendously increasing internal osmotic pressure, which in the end 
produces cracks and/or partial or complete separation of the tablet parts to relieve the tablets 
internal stress. Figure 3.1 shows that the addition of an electrolyte like NaCl to the HASCA 
formulation can provide complete stabilization of the swollen matrix structure or at least 
significantly delay apparition of the above-mentioned problems and/or decrease their intensity. 
It is believed that adding an appropriate amount of electrolytes maintains a delicate 
equilibrium between a) hydrogen bonds created, among others, through –COOH associations, 
which enhance gel strength and maintain matrix structure, and b) swelling of the polymer 
chains, increased by their repulsion due to the –COO– groups, which gives the matrix its 
necessary elasticity. The picture is further complicated by other factors, which combine their 
effects to produce complex behaviour: the effect of porosity after dissolution of the drug and 
the electrolyte on gel structure; the effect of NaCl on gel viscosity and, therefore, on drug 
diffusion; the effect of an intramatrix buffer system on gel structure and all other factors 
affecting it, such as the nature and concentration of the drug, electrolytes and other excipients, 
and the pH conditions of the external medium. These results were the opposite of what were 
expected as, indeed, adding an electrolyte to the formulation should pump more water and 
faster inside the tablet, thereby increasing internal osmotic pressure and making the tablet 
present cracks. 
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Figure 3.2 Cumulative percentage of acetaminophen released in vitro from optimized HASCA 
matrices (32.5% of HASCA, 40% of acetaminophen, and 27.5% of NaCl) in pH gradients with 
different acidic pH conditions (: 10 min at pH 1.2, : 1 hr at pH 1.2, : 3 hrs at pH 3.5, : 
6 hrs at pH 4.5, : no acidic medium). The number of replicates was three. 
 
 
Since HASCA is an ionic polymer used for oral, sustained drug-release, the in vitro 
release experiments were conducted in a pH gradient simulating the pH evolution of the 
gastrointestinal tract to study the pH-dependency of the release properties. Because of the 
ionic nature of the HASCA polymer, one would expect immersion in changing pH 
environments to result in differences in the behaviour of the formulation when in contact with 
the various pH mediums, which could lead to a pH-dependent release rate. Fig. 3.2 shows the 
release profiles from HASCA SR matrix tablets containing 27.5% of NaCl in pH gradients 
where both acidic pH value and residence time in the acidic medium varied according to Table 
3.1. No significant differences in the drug-release profiles were observed. The drug-release 
profile from such SR matrix tablets appears to be independent of both the acidic pH value and 
residence time in the acidic medium. Most probably, the combined presence of NaCl and the 
carboxylic groups of the polymer creates a buffered environment in the matrix, allowing it to 
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be insensitive to pH changes of the surrounding medium. This is important considering that 
materials that possess pH-independent release properties are preferable for oral extended-
release formulations, since they are not affected by intra- and inter-subject variations of both 
gastric pH and gastrointestinal transit time [12]. It is expected that this observation will remain 
true as long as the ionization and solubility of other ingredients in the formulation are not 
significantly affected by pH changes in the gastrointestinal tract, as is the case with 
acetaminophen (pKa 9.5) [13].  
 
 
3.5.2 Pharmacokinetics in healthy human volunteers 
The model drug chosen was acetaminophen, a commonly used analgesic and 
antipyretic, which is well absorbed by passive diffusion with high permeability throughout the 
intestinal tract [14]. According to the Biopharmaceutics Classification System [15], 
acetaminophen is classified as a “class I” drug. Its solubility in water varies from sparingly 
soluble to soluble at 37ºC, with pH-independent solubility at physiological values (from 1 to 
8.5). Hence, this drug is not considered to ionize in the physiological pH range (pKa 9.5) [13]. 
The plasma elimination half-life (t1/2) of acetaminophen ranges from 1 to 4 hours [16]. 
Moreover, the drug is safe and non-toxic when doses ranging from 200 to 400 mg are 
administered. Therefore, the chosen dose, i.e. 240 mg, did not represent any risk of toxicity to 
the subjects. In addition, acetaminophen is not subject to any significant enzymatic or bacterial 
degradation in the gastrointestinal lumen. Food reduces the rate of acetaminophen absorption 
but not its extent [17]. Finally, acetaminophen is easily detected, quantified and relatively 
inexpensive. Considering that this was an exploratory in vivo study to evaluate a new drug-
delivery system, it was important to avoid the usual contraindications of a SR dosage form, 
i.e., the risk of dose dumping, as a consequence of tablet rupture or erosion, and accumulation 
in the body. Acetaminophen, at that dosage strength, was thus a safe choice as a model drug. 
Because of the above-mentioned characteristics, the controlled release of acetaminophen from 
numerous formulations has been widely investigated [18-20]. 
The mean drug plasma concentration-time profiles following oral administration of the 
HASCA SR formulation and the commercial IR tablet are illustrated in Figure 3.3. The 
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absence of a burst-effect during the time range between 5 minutes and 2 hours after 
administration of the HASCA SR matrix tablets to fasted, healthy volunteers, which coincides 
with normal gastric residence times for a dosage form given in a fasted state [21], suggests 
that the gel was strong enough to resist the powerful peristaltic contractions normally 
occurring in the fasted state and which open the pylorus and clear the stomach of any residual 
material (sometimes called housekeeper waves). Therefore, the in vivo concentration-time 
profiles show that the tablets maintain their integrity while traversing the stomach. No burst-
effect was also detected during the first 3 to 5 hours after administration of the formulation. 
Considering that residence time in the small intestine is about 3 hours [21], this was the period 
of time where the HASCA polymer was under attack by α-amylase. This absence of burst-
effect whilst the dosage form traverses the small intestine indicates that the HASCA polymer 
resisted α-amylase biodegradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Acetaminophen plasma concentration (expressed in µg/mL/kg) vs. time profiles 
(mean ± SD) following oral administration of the HASCA SR formulation () and the 
commercial IR tablet (). 
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There were large differences in plasma concentrations between the IR and the SR 
dosage forms. Differences in the curves reflected different release rates of the 2 formulations. 
The first portion of the plasma concentration-time curves (Fig. 3.3) showed large differences, 
demonstrating IR for the Tylenol formulation and a SR profile for the HASCA formulation. 
The mean (± standard deviation) pharmacokinetic parameters and their respective coefficients 
of variation (%CV) are listed in Table 3.2. The very rapid drug absorption from the IR tablets 
was confirmed by the Cmax and Tmax values, i.e. 2.90 µg/mL and 45 min respectively. The 
AUCs calculated for HASCA tablets and for Tylenol after dose-adjustment were similar, 
which suggests that the total amount of drug absorbed by the body after administration of 
the same dose was the same for both formulations, irrespective of the absorption rate. 
 
Table 3.2 Pharmacokinetic parameters of acetaminophen (mean ± SD and %CV) following 
oral administration of the HASCA SR formulation and the IR tablet. 
 AUC0-24 hr (µg ×  hr/mL) 
AUC0-∞ 
(µg ×  hr/mL) 
Cmax  
(µg/mL) 
Tmax  
(hr) 
Tylenol 
Mean ± SD 
%CV 
 
11.59 ± 3.13 
27.01 
 
11.76 ± 3.20 
27.24 
 
2.90 ± 0.97 
33.37 
 
0.75 ± 0.50 
66.67 
HASCA 
matrix tablet 
Mean ± SD 
%CV 
 
 
11.14 ± 3.45 
30.96 
 
 
11.24 ± 3.46 
30.82 
 
 
1.32 ± 0.46 
34.95 
 
 
4.40 ± 2.51 
57.05 
 
 
There was relatively high inter-subject variability of the estimated pharmacokinetic 
parameters, particularly for Tmax. A possible explanation for the relatively high inter-subject 
variation of the estimated pharmacokinetic parameters is given by the large differences in 
anatomic characteristics of the volunteers, like their weight, especially for such a small 
number of subjects. 
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Figure 3.4 shows the average cumulative percentage of drug absorbed in function of 
time (hours), calculated by the Wagner-Nelson method. Since the k value in the Wagner-
Nelson calculation has to be obtained after bolus intravenous administration of the drug, we 
used a value from in the literature, i.e. 2.52 h-1 [22]. In vivo absorption appeared to be 
continuous, although its rate decreased strongly after 4 hours and became marginal after 12 
hours. After 4-6 hours, the drug-release rate might well not be able to compensate for the fast 
elimination of acetaminophen, which could explain the decrease in drug plasma concentration 
for the SR curve in Figure 3.3. The high variations observed in Figure 3.4 might be explained, 
among others, by the same factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Cumulative percentage (mean ± SD) of acetaminophen absorbed following the oral 
administration of HASCA SR matrix tablets to 5 healthy volunteers. 
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As suggested by the in vitro release profiles, the results of the in vivo study indicate 
that the HASCA formulation slowed acetaminophen absorption compared to the IR 
formulation, with significant drug-release for up to 12 hours. However, therapeutic blood 
levels were not maintained over a more extended time period due to the high k of 
acetaminophen. Other limitations of this in vivo study include the small number of volunteers 
and, as mentioned above, the high inter-subject anatomic variability. However, our pilot study 
has clearly demonstrated the difference between the IR tablet and the HASCA SR tablet with 
respect to their release mechanisms. Further, the absence of immediate and fast disintegration 
of the HASCA tablets as well as their resistance to enzymatic degradation prove the potential 
of this new excipient as an efficient drug-delivery system. However, it must be remembered 
that ours was a non-blinded study where volunteers were not randomized, as the protocol was 
specific to each drug formulation.  
 
 
3.5.3 IVIVC 
To assess the relationship between in vivo acetaminophen absorption and in vitro 
acetaminophen release from the HASCA matrix tablet formulation, percent drug-release in 
vitro was compared to percent in vivo absorption at given time points. Figure 3.5 presents the 
results for the 5 volunteers and the average mean. Certain deviations from the ideal 1:1 
relationship, which is represented by the straight line with slope = 1 [23], were observed. 
While a linear relationship between the percentage released in vitro and the average 
percentage absorbed in vivo seems to be present for a portion of the curve, it appears that the 
release rate is faster in vivo. At this stage, we do not know if this is due to really faster release 
in vivo or to the fast elimination of acetaminophen, which renders application of the Wagner-
Nelson method difficult and lacking in precision. Moreover, the intercept value should 
approximate zero for a “perfect” IVIVC, i.e. when the percentage absorbed varies in direct 
proportion to the percentage released in vitro. It is possible that in vivo, the matrix system 
takes a little more time to be hydrated enough to trigger burst-release. Finally, the variations 
seen from volunteer to volunteer are large, and volunteers seem to divide into 2 groups, but 
with such a small number of subjects, it is impossible to be sure. It is noteworthy that a poor 
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IVIVC has already been reported for a SR matrix tablet containing similar doses of 
acetaminophen, although these results look more erratic and their dosage forms are more 
subject to pH variations than the present ones [23]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 IVIVC plot for HASCA SR matrix tablets administered to 5 healthy volunteers (: 
volunteer 1, : volunteer 2, ×: volunteer 3, : volunteer 4, : volunteer 5, ⎯⎯: 
average, - - - - -: linear). 
 
 
However, it must be reiterated that the drug and the strength chosen, i.e. 
acetaminophen and 240 mg, were not the most appropriate for evaluating HASCA SR matrix 
tablets, since the drug’s short half-life would require excessively large amounts of drug in 
each dosage unit to maintain sustained effects, forcing the dosage form itself to become 
unreasonably large. In addition, the elimination rate of this drug from the body was too high 
compared to the release rate from the proposed formulation, not allowing therapeutic blood 
levels to be maintained over an extended time period. Again, it must be emphasized that, as 
this was the first time that the new drug-delivery system was administered to human 
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volunteers, their safety was the main concern when choosing the drug and its strength. 
Therefore, further investigations like increasing dosage strength and the release rate, are 
required to obtain a meaningful IVIVC for acetaminophen associated with this formulation. 
 
 
3.6 Conclusion 
HASCA is an interesting excipient for sustained drug-release in solid oral dosage 
forms. In addition to the easy manufacturing of tablets by direct compression, the results show 
that in vitro drug-release from an optimized HASCA formulation is not affected by either 
acidic pH value or acidic medium residence time. In addition, a compressed blend of HASCA 
with an optimized quantity of NaCl provides improved integrity to a pharmaceutical SR tablet 
for oral administration. The in vivo study demonstrates extended drug absorption, showing that 
the matrix tablets do not disintegrate immediately and resisted enzymatic attack well. 
Nevertheless, acetaminophen does not seem to be the most appropriate drug for this type of 
formulation. 
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4.1 Presentation of the article and contribution of the authors 
This article presents a formulation screening carried out in order to select once-daily 
and twice-daily SD HASCA matrix tablets with two common dosages of tramadol 
hydrochloride (100 mg and 200 mg). The results regarding dissolution studies in a 40% 
ethanol medium are also included. This article was submitted to ISRN Pharmaceutics on 
January 22, 2014. 
 
The contribution of each author to the publication was: 
Teresa Nabais – Execution of all dissolution testing; analysis of data resulting from dissolution 
testing; writing of the article. 
Grégoire Leclair – Project coordinator and director at the time of the publication; revision of 
the article.  
 
 
4.2 Abstract 
Substituted amylose (SA) polymers were produced from high-amylose corn starch by 
etherification of its hydroxyl groups with chloroacetate. Amorphous high-amylose sodium 
carboxymethyl starch (HASCA), the resulting SA polymer, was spray dried to obtain an 
excipient (SD HASCA) with the better binding and sustained-release (SR) properties. Tablets 
containing different percentages of SD HASCA and tramadol hydrochloride were produced by 
direct compression and evaluated for dissolution. Once-daily and twice-daily SD HASCA 
tablets containing two common dosages of tramadol hydrochloride (100 mg and 200 mg), a 
freely water-soluble drug, were successfully developed. These SR formulations presented high 
crushing forces, which facilitate further tablet processing and handling. When exposed to both 
a pH gradient simulating the pH variations through the gastrointestinal tract and to a 40% 
ethanol medium, a very rigid gel formed progressively at the surface of the tablets providing 
controlled drug-release properties. These properties indicated that SD HASCA was a 
promising and robust excipient for oral, sustained drug-release, which may possibly minimize 
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the likelihood of dose dumping and consequent adverse effects, even in the case of co-
administration with alcohol. 
 
 
4.3 Introduction 
Starch is a naturally occurring and a biodegradable polymer that is metabolized by the 
human body. Besides being non-toxic, starch is an abundant, cost-effective and renewable 
material [1]. Due to these advantages, starches and modified starches have been widely and 
safely used in the food industry as thickeners, enhancers of organoleptic properties or texture 
modifiers, and in the pharmaceutical industry as fillers, binders, disintegrants [2] and, more 
recently, as hydrophilic excipients for sustained drug-release. Numerous starch-modification 
methods, such as chemical [3], physical (i.e. gelatinization) [4], enzymatic [5], or a 
combination thereof, have been employed to produce new starch products with specific 
properties. Starch is a good candidate for chemical reaction or transformation because it is 
composed of amylose and amylopectin, two glucose polymers presenting three hydroxyl 
groups accessible as chemically active functional entities. Some of the modifications 
commonly employed to prepare starch derivatives are carboxymethylation, ethoxylation and 
oxidation [6]. 
Substituted amylose (SA) has been introduced as a promising pharmaceutical excipient 
for sustained drug-release. SA matrix tablets have been prepared by direct compression, which 
is the easiest way to manufacture an oral dosage form and consists of dry mixing of drug and 
SA polymers followed by compression [7,8]. The first SA polymer showing good properties 
as an excipient for sustained-release (SR) was produced by an etherification process using 
high-amylose corn starch and glycidol as the substituent, and was referred to as SA,G-2.7, 
where G defines glycidol and 2.7 represents the degree of substitution (DS), expressed as the 
ratio of mole of substituent per kilogram of amylose [7,8]. These properties included almost 
constant in vitro drug-release [7-9], no significant influence of compression forces (CF) 
ranging from 0.5 to 5.0 tons/cm2 on the drug-release properties [9,10], large ranges of use for 
drug-loading, drug-solubility, and tablet weight (TW) [7,8], and unusually high crushing force 
values [10].  
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The use of sodium chloroacetate or chloroacetic acid in place of nonionic substituents 
like glycidol has been subsequently proposed to produce an excipient more readily acceptable 
by regulatory agencies for its non-toxicity [11,12]. Sodium carboxymethyl starch with low 
amylose content was already a well-known disintegrant agent in immediate-release (IR) 
tablets [13]. High-amylose sodium carboxymethyl starch (HASCA, where “HAS” means high-
amylose substituted starch and “CA” defines the substituent used, herein chloroacetate), 
contrariwise, has been introduced as a promising pharmaceutical excipient for oral SR tablets 
prepared by direct compression [11,12]. Contramid®, a cross-linked high amylose starch, has 
already been used in tablets as a retarding agent [14].  
After being initially produced on laboratory scale, the polymer was obtained on an 
industrial pilot scale. However, these latter batches of polymer were unsuitable for tableting 
and sustained drug-release due to inadequate physical properties. For this reason, the material 
was spray dried (SD) to obtain a compressible excipient. This procedure, which has been 
described elsewhere [6], resulted in SD HASCA, the polymer used in the current study. 
Studies on the in vitro release characteristics of acetaminophen from tablets composed of SD 
HASCA, drug and sodium chloride have demonstrated the suitability of this polymer as a 
sustained drug-release excipient. No burst-effect was observed, even in the presence of large 
amounts of soluble sodium chloride in the formulation [15-17]. Moreover, the release of 
acetaminophen from optimized SD HASCA formulations is not significantly influenced by the 
variations of pH and residence time in acidic media [17]. These prior results suggest that drug-
release from SD HASCA tablets may not be affected by intra- and inter-subject variations in 
gastric pH or gastric residence time. Acetaminophen (phenol, pKa 9.51) and tramadol 
hydrochloride (tertiary amine, pKa 9.41) are completely non-ionized and completely ionized at 
physiological pH, respectively. Moreover, a first in vivo study where the same optimized SD 
HASCA formulation was administered orally to healthy human subjects has demonstrated 
extended acetaminophen plasma levels, and that the gel formed by the polymer was strong 
enough to resist both the powerful peristaltic contractions normally occurring in the fasted 
state and biodegradation in the intestine [17]. Other features of SD HASCA that confirm the 
potential of this polymer for sustained drug-release include its excellent binding properties in 
the absence of binders, which resulted in very high crushing forces [6,15,16]. A strong 
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dependence of drug-release on TW has also been found, corresponding a TW rise to an 
increased total release time [16].  
Tramadol is a synthetic, centrally acting analgesic agent with a dual mechanism of 
action [18]. It has proven to be effective in the treatment of moderate to moderately severe 
pain without causing severe side effects and organ damages [19]. For the treatment of chronic 
pain, frequent oral administration of IR tramadol is required (at least four times daily) because 
of its mean elimination half-life, which can vary from 5 to 7 h in humans [20]. In adults and 
adolescents, the usual oral dosage regimen is 50 to 100 mg every 4 to 6 hours, with a 
maximum dosage of 400 mg/day [18]. Consequently, oral formulations of tramadol that 
provide a more gradual release of the drug have been developed with the aim of reducing the 
frequency of administration, minimizing acute adverse effects, and thus improving the patient 
compliance [21,22]. After oral administration, tramadol is rapidly and almost completely 
absorbed. Its bioavailability of 70% after a single administration can be attributed entirely to 
extensive first pass metabolism [23]. However, at steady state, the bioavailability of a SR 
formulation has been shown to be 100% relative to an IR formulation [24], which represents 
another advantage of SR formulations of tramadol. Bioequivalence after dose adjustment 
between IR and SR formulations has been demonstrated [20]. Tramadol hydrochloride is 
readily soluble in water and ethanol and hence judicious selection of release retarding 
excipients is necessary to achieve an extended in vivo input rate of the drug. 
SR formulations, especially those designed for once-daily administration, contain 
amounts of drug that can be potentially risky if released as a burst, commonly called dose 
dumping. Tramadol hydrochloride may cause severe side effects if high plasma concentrations 
are reached quickly. Inadvertent or intentional misuse of a SR formulation, with consequent 
dose dumping, may include breaking, crushing tablets and simultaneous co-ingestion of the 
medication with high doses of ethanol. Therefore, the robustness of SD HASCA tablets in an 
ethanolic medium as well as their crushing strength values are important factors to take into 
account. 
In this study, the vitro release characteristics from matrix tablets comprising tramadol 
hydrochloride as the model drug and SD HASCA as the only SR excipient were evaluated in a 
series of buffers simulating the pH of the fluids throughout the gastrointestinal tract. Tablets 
intended to twice-daily and once-daily administration with 100 mg and 200 mg of drug were 
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developed and the dissolution profiles of these tablets were compared with those of marketed 
tramadol hydrochloride SR formulations of same drug content. The resistance of the gel 
formed by SD HASCA to an alcoholic medium was also investigated. 
 
 
4.4 Materials and methods 
4.4.1 Materials 
Amorphous HASCA (Eurylon 6, batch 3910, ref. 799511) was provided by Roquette 
Frères (Lestrem, France) and contained approximately 60% of amylose and 40% of 
amylopectin. The DS was equal to 0.045 (number of moles of substituent/number of moles of 
anhydroglucose) [16]. Tramadol hydrochloride was purchased from Jubilant Organosys Ltd. 
(Nanjangud, Mysore, India). Commercially available tramadol tablets Tridural® 100 mg and 
200 mg, Ralivia® 200 mg, Zytram® XL 200 mg, Topalgic® LP 100 mg and 200 mg as well as 
Contramal® LP 200 mg were purchased from pharmacies in Canada and in France. All 
chemicals were of reagent grade and were used without further purification. 
 
 
4.4.2 Preparation of HASCA tablets 
Amorphous HASCA, as provided by its manufacturer, did not possess the required 
binding and SR properties to be used as a suitable material for SR tablets prepared by direct 
compression. Therefore, this polymer was spray-dried as described by Brouillet et al. [6] by 
first preparing a suspension of HASCA in a mixture of water and ethanol (final water/ethanol 
ratio of 1.33, 4 mL of ethanol/g of HASCA), and then spray drying using a Büchi B-290 Mini 
Spray-Dryer (Flawill, Switzerland).  
Tablets were prepared by direct compression using a 30-ton manual hydraulic press 
(referred herein as HP, C-30 Research & Industrial Instruments Company, London, U.K.) 
equipped with round flat-faced tooling (diameter 12.6 mm) or a single-stroke press machine 
(referred herein as SSP, Manesty F3 Machine, Manesty Machines Ltd., Liverpool, UK) also 
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equipped with round flat-faced tooling (diameter 11.1 mm). In the HP, compression force was 
adjusted to target a specific CF, and in the SSP, compression force was adjusted to target 
specific thickness. SD HASCA tablets of different total weights containing different 
percentages of polymer and drug were produced as described in Table 4.1. 
 
 
Table 4.1 SD HASCA tablets formulation, press used, target CF and thickness and selected 
twice-daily and once-daily tablets. 
TW 
(mg) 
% of drug (w/w) Tablet 
press 
Target CF 
(tons/cm2), HP 
Target thickness 
(mm), SSP 
Selected twice-
daily and once-
daily tablets 
400 12.5 HP 2.5    -   - 
 25 HP 2.5    -   - 
 37.5 HP 2.5    -   - 
 50 HP 2.5   -   - 
 60 HP 2.5    -   - 
450 22.22 HP 2.5    - Twice-daily (not 
selected) 
500 20 HP 2.5    -   - 
 30 HP 2.5    -   - 
 40 HP 2.5    - Twice-daily (not selected) 
 50 HP 2.5    -   - 
 60 HP 2.5    -   - 
700 14.3 HP 1    -   - 
 14.3 HP 1.5    -   - 
 14.3 HP 2    -   - 
 14.3 HP 2.5   - Once-daily (not selected) 
800 12.5 HP 2.5    -   - 
 25 HP 2.5    - Once-daily (not selected) 
 37.5 HP 2.5    -   - 
 50 HP 2.5    -   - 
 60 HP 2.5    -   - 
450 22.22 (100 mg) SSP   - 4.63 Twice-daily 
(Selected) 
500 40 (200 mg) SSP   - 5.15 Twice-daily 
(Selected) 
700 14.3 (100 mg) SSP   - 6.98 Once-daily 
(Selected) 
800 25 (200 mg) SSP   - 7.43 Once-daily 
(Selected) 
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4.4.3 Tablets characterization and in vitro drug-release evaluation 
The crushing forces (Newton) of SD HASCA tablets were measured using a hardness 
tester (Pharma Test Type PTB 301, Hainburg, Germany) and their thickness using an 
electronic caliper (Starrett, 799A Series). 
The in vitro drug-release properties of SD HASCA SR tablets in simulated gastric fluid 
(stage I) and simulated intestinal fluids (stage II and stage III) were assessed using a USP 
apparatus 2 (900 mL, 37°C, 50 rpm) [25]. During stage I, the tablets were exposed to 
hydrochloric acid buffer (pH 1.2), simulating gastric pH (SGF) for 1 h. During stage II, the 
tablets were exposed to phosphate buffer (pH 6.8) simulating jejunum pH (SIF I) for an 
additional 3 h. Finally, the tablets were exposed to a second phosphate buffer (pH 7.4) 
simulating ileum pH (SIF II) until the end of the assay (total time of 24 h). All standard buffer 
solutions were prepared according to the USP. 
In addition, dissolutions tests in a 40% ethanol in water solution were performed to 
assess the release properties of a SD HASCA formulation and a commercial formulation with 
the same drug content and the same frequency of administration. This percentage of ethanol 
was chosen because it represents a standard strength of alcoholic spirits [26]. Tests in alcohol 
were carried out during 7 h.  
To avoid eventual floating to the surface of the medium or adhesion to the vessel, each 
tablet was placed inside a perforated cylindrical plastic cage (Fig. 4.1). The cage had enough 
internal space for drug-release to occur from all sides of the matrix and its perforations were 
big enough not to interfere with the circulation of the medium inside the dissolution vessel but, 
on the other hand, were small enough to keep the tablets inside.  
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Figure 4.1 Plastic cage used in the dissolution experiments to avoid eventual adhesion to the 
vessel or floating. 
 
 
Due to the presence of the cages at the bottom of the dissolution vessel, the paddle 
relative position in the vessel was positioned 5 cm above what it is settled by USP. After each 
sampling, an equivalent volume of fresh medium (10 mL) was added. Each experiment was 
performed in triplicate. The occurrence of macroscopic transformations in the matrix tablets 
and their eventual influence on the release profiles was registered. Samples were filtered 
through syringe filters (0.45 mm, nylon). Tramadol hydrochloride release was followed by UV 
spectrometry (271 nm). A calibration curve was prepared for each of the three mediums (pH 
1.2, 6.8 and 7.4) as well as for the ethanolic medium, and before the measurement of the 
samples resulting from each dissolution test. The drug-release results are expressed as 
cumulative percentage (%) as a function of time (h). 
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The in vitro release properties of twice-daily and once-daily commercial formulations 
with 100 mg or 200 mg of tramadol hydrochloride were also evaluated using the same 
experimental conditions, so as to provide a direction regarding the desired release times. The 
twice-daily dosage forms tested were Topalgic® LP 100 mg, Topalgic® LP 200 mg and 
Contramal® LP 200 mg, and the once-daily dosage forms tested were Tridural® 100 mg, 
Tridural® 200 mg, Ralivia® 200 mg and Zytram® XL 200 mg.  
 
 
4.4.4 Modifications to the United States Pharmacopeia (USP) method 
In the first in vitro studies on the release of tramadol hydrochloride from SD HASCA 
matrix tablets some formulations showed a propensity to float or to adhere to the bottom of the 
vessel. This propensity was higher as the concentration of tramadol hydrochloride increased. 
This situation makes the tablets very susceptible to large variations in hydrodynamic 
conditions that prevail in a dissolution vessel. In addition, the tablets floating at the surface of 
the dissolution medium or adhering to the glass surface had a lower surface area in contact 
with the medium. This situation can affect drug-release from the tablets, as the exposed 
surface area is a major factor determining release kinetics both in erosion-controlled as well as 
diffusion-controlled systems [27]. 
The use of perforated cylindrical plastic cages placed below the paddles in the 
dissolution vessels showed to be successful in preventing adhesion to the vessel and floating. 
This solution was chosen in detriment of the use of USP apparatus I (basket) as the use of this 
apparatus can interfere with the free swelling of the matrix. However, the paddle relative 
position had to be at a higher height compared to what is settled by the USP because of the 
size of the cage. Hence, the influence of the paddle position on drug-release was evaluated. 
The cumulative percentage of acetaminophen released in vitro from 700-mg matrix tablets 
comprising 40% of acetaminophen and 60% of HPMC when the paddle relative position in the 
dissolution vessel was as settled by USP or placed about 5 cm above what it is settled by USP 
was equivalent (f2 equal to 99.77). 
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4.4.5 Statistical analysis and formulations comparison 
The arithmetic average and the standard deviation of the cumulative % of drug 
released at predetermined time intervals were calculated. 
Dissolution profiles were compared using the similarity factor (f2), according to the 
following equation proposed by Moore and Flanner [28]:  
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where Rt and Tt are the percent dissolved of the reference and test products at each time point t 
and n is the number of pool points.  
Two dissolution profiles are similar if f2 is between 50 and 100 according to the Food 
and Drug Administration (FDA) and the European Agency for the Evaluation of Medical 
Products (EMEA). However, the closer to 100 (%) f2, the more similar the dissolution profiles 
are. The dissolution profiles were also compared using the values of the time to release 50% 
(T50%) and to release 90% of drug (T90%). 
 
 
4.5 Results and discussion 
4.5.1 Measurement of tablet crushing strengths in order to guarantee the 
reproducibility of the spray drying method 
The reproducibility of the method used to transform amorphous HASCA into SD 
HASCA was assessed through the evaluation of tablet crushing forces for different batches. 
SD HASCA tablets weighting 200 mg were prepared by direct compression. The excipient 
was compressed at a CF of 2.5 tons/cm2 using a HP using a dwell time of 20 seconds. The 
values of the crushing forces of 200-mg tablets produced from different batches of SD 
HASCA varied between 124.9 ± 10.5 and 148.5 ± 3.2 Newton (arithmetic averages ± standard 
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deviations). Therefore, the crushing forces were considered reproducible. As non-SD HASCA 
particles did not possess any binding properties and the SD procedure resulted in a decrease in 
particle size of the polymer, it has been hypothesized that these unusual high crushing strength 
values are due, in part, to the particle size reduction, which corresponds to a higher surface 
area of the particulate product and provides a higher number of binding points. In addition, it 
is believed that the combination of water and ethanol in the SD process has a plasticizer effect, 
causing partial melting of the polymer and particle re-arrangement under compression [6].  
 
 
4.5.2 Formulation screening and development of twice-daily and once-daily 
SD HASCA formulations with 100 mg and 200 mg of tramadol 
hydrochloride 
The values of the T50% and T90% of tramadol hydrochloride from tablets of different 
total weights and containing different percentages of polymer and tramadol hydrochloride 
(compressed with the HP) are summarized in Table 4.2. Increasing the percentage of tramadol 
hydrochloride in the tablet led to an increase in the drug-release rate for all TWs, which is a 
common observation for hydrophilic matrices. In addition, the total release time increased 
significantly as a function of TW. The T50% was, though, less affected by TW than the T90%.  
When immersed in the dissolution mediums, a very rigid gel layer with high 
mechanical strength in the swollen state formed on the surface of the tablets. This strong gel 
layer, which is formed by hydrogen bonding between the hydroxyl groups of the soluble 
gelled starch chains, has been documented before for SD HASCA [15,16]. In addition, its 
formation has been related to the pH-independent SR behaviour of high-amylose sodium 
carboxymethyl starch produced at low DS, as it is the case of SD HASCA [29]. The gel layer 
formed by SD HASCA showed a lower degree of swelling when compared to the gel layer 
formed by hydroxypropylmethylcellulose (HPMC) (results not shown). The most important 
aspect of the release mechanism from tablets constituted by hydrophilic polymers is known to 
be the formation of a gel layer around the dry core of the matrix in response to water 
penetration. This gel layer hinders fast inward medium penetration and outward drug 
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diffusion. Phenomena that govern gel layer formation and, therefore, drug-release, are 
penetration of the dissolution medium into the matrix, resulting in polymer hydration and 
swelling (relaxation process), drug dissolution and diffusion through the layer of swollen 
polymer, and erosion on the surface of the matrix. The formation of the gel layer is caused by 
the polymer-state transition. The gel layer acts like a barrier against the fast release of drugs 
whilst controlling at the same time the penetration of aqueous medium and the diffusion of 
drug.  
 
 
Table 4.2 Time to release 50% (T50%) and 90% (T90%) of drug from SD HASCA tablets 
with total weights between 400 mg and 800 mg, and % of drug (w/w) between 12.5% and 
60%. 
  % of drug (w/w) 
TW 
(mg) [T50%, T90%] (h) 12.5 14.3 20 22.22 25 30 37.5 40 50 60 
400 T50% 1.8 - - - 1.5 - 1.4 - 1.3 1.1 
 T90% 6.5 - - - 5.3 - 4.5 - 4.6 3.5 
450 T50% - - - 1.9 - - - - - - 
 T90% - - - 6.4 - - - - - - 
500 T50% - - 2.55 - - 2.05 - 1.9 1.75 1.4 
 T90% - - 8.75 - - 7.6 - 6.7 5.9 4.65 
700 T50% - 4 - - - - - - - - 
 T90% - 14.4 - - - - - - - - 
800 T50% 4.9 - - - 4.1 - 3.3 - 2.7 2.5 
 T90% 18.4 - - - 16.4 - 11.5 - 10.25 9.3 
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As the size of the internal dry and/or partially hydrated core of the tablets increases as 
a function of TW for the same concentration of drug, if the core is considered as a drug 
reservoir, the larger is the internal reservoir the longer is the time to empty it, which explains 
the increase of the total release time as a function of TW. Besides, as demonstrated in a 
previous study, augmenting TW heightens the contribution of diffusion to the detriment of 
erosion as the main mechanism controlling drug-release, leading to a decline in the drug-
release rate [16]. Furthermore, a combination of two release mechanisms has been described 
as controlling the kinetics of drug-release from SD HASCA matrices: drug diffusion through 
the gel layer after drug dissolution (Fickian diffusion) and polymer disentanglement and 
erosion (Case-II relaxational release) [16]. Fickian diffusion release occurs by diffusion of 
drug molecules due to a concentration gradient. Case-II relaxational release is the mechanism 
associated with polymer state-transition from the glassy, a solid state (dry polymer), to the 
rubbery state, an expanded and flexible state, which is linked with the polymer swelling 
process [30]. Similar conclusions were reported for the transport of acetaminophen from non-
ionic SA matrices [8,9]. It is known that drug concentration and thickness of the gel layer are 
the factors governing drug-release [31]. At lower drug concentrations, that is, higher polymer 
concentrations, diffusion is the main transport mechanism, and thus the total release time was 
longer. However, as drug concentration increases the drug-release rates also increase. 
Tramadol hydrochloride is freely soluble in water, and thus dissolves quickly in aqueous 
medium. Its high solubility along with an increase in drug loading resulted in higher drug 
concentration in the gel. In addition, the high hydrophilicity of tramadol hydrochloride 
promotes the penetration of the dissolution medium into the matrices. Above a certain drug-
loading threshold, the quantity of absorbed water may be such that the interactions water-
polymer become superior to the interactions polymer-polymer, causing chain disentanglement 
and polymer dissolution [32]. As a result, progressive erosion appears on the surface of the 
tablets, leading to a decrease in the thickness of the gel layer and an increase in the drug-
release rate. Indeed, it has been reported that the gel strength is an essential factor in the 
matrix performance and is controlled not only by the viscosity and chemical structure of the 
rubbery polymer but also by its concentration [31]. Therefore, lower SD HASCA 
concentrations in the tablet led to lower gel strengths, and thus to higher release rates, owing 
to higher erosion. Besides, it can be hypothesized that at certain drug/polymer ratio the release 
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process will become governed mainly by erosion. However, opposite results have been 
observed for tablets containing SD HASCA, acetaminophen and sodium chloride. In this case, 
an increase in drug loading corresponded to an increase in total release time, until a certain 
level where erosion occurred [16]. It is important to take into consideration the higher 
solubility of tramadol hydrochloride compared to acetaminophen. Indeed, when formulating 
SD HASCA matrices, not only the concentration of the components has to be taken into 
account but also their solubility, nature and interactions between them.  
As the values of the time to release 25% of drug (T25%) for different TWs were 
similar, especially for the 400-mg tablets, these values are not presented. The T25% 
corresponds usually to the burst effect and depends on the amount of drug on the table surface 
available for immediate dissolution and release in the medium.  
The formulation screening allowed the investigation of the most adequate total weights 
for four formulations with SD HASCA as the SR excipient: two twice-daily with 100 mg and 
200 mg of tramadol hydrochloride, and two once-daily with 100 mg and 200 mg of tramadol 
hydrochloride. In order to select these formulations, the in vitro drug-release profiles from 
tablets with 100 mg and 200 mg of drug, which were produced using the HP to study the 
influence of drug content and TW on the dissolution rate, for the formulation screening 
described above, were compared to the in vitro drug-release profiles of commercially available 
twice-daily and once-daily tramadol hydrochloride formulations with the same drug content. 
The release profile from the tablets with a total weight of 700 mg, containing 100 mg of drug 
and compressed with the HP at 2.5 tons/cm2 for 20 seconds, which were prepared to study the 
influence of the CF on the release rate, was also compared to the release profile of commercial 
formulations. Figure 4.2 shows the drug-release profiles from the commercial once-daily 
dosage forms. 
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Figure 4.2 Cumulative % of tramadol hydrochloride released in vitro from once-daily 
commercial formulations (: Tridural® 100 mg, : Tridural® 200 mg, : Ralivia® 200 mg, 
: Zytram® XL 200 mg).  
 
 
The values of T50% and T90% for the tablets weighting 500 mg with 200 mg of 
tramadol hydrochloride were 1.9 and 6.7 hours (Table 4.5), very similar to the values for 
Topalgic® LP 200 mg, 2 and 6.9 hours, respectively (Table 4.3). In addition, the f2 resultant 
from the comparison of their profiles resulted in value of 86.54. Consequently, the 500-mg 
tablet with 200 mg of drug was chosen as the twice-daily formulation with 200 mg of drug. 
An evaluation of the release characteristics of a formulation corresponding to a total 
weight of 450 mg with 100 of drug was also performed to determine if its release 
characteristics approached better the ones of the 500-mg tablet with 200 mg. The T50% and 
T90% for this formulation were 1.9 and 6.4 hours (Table 4.5), very similar to values of the 
selected twice-daily SD HASCA formulation with 200 mg, and more similar than the T50% 
and T90% for the 400-mg and 500-mg tablets with 100 mg of drug.  
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Table 4.3 Time to release 50% and 90% of tramadol hydrochloride [T50%, T90%] from 
twice-daily (every 12 hours) and once-daily (every 24 hours) commercially SR formulations 
and SD HASCA formulations (produced with the SSP), with 100 mg and 200 mg of drug. 
Release-times are presented in hours. 
Frequency of administration: twice-daily 
Formulation Commercial     SD HASCA (SSP) 
 Topalgic® 
LP 100 mg 
Topalgic® 
LP 200 mg 
Contramal® 
LP 200 mg 
  100 mg of 
drug (SSP) 
200 mg of 
drug (SSP) 
 [2.15, 7.60] [2.00, 6.90] [2.10, 6.85]   [3.00, 
10.70] 
[3.00, 
10.25] 
Frequency of administration: Once-daily 
Formulation Commercial     SD HASCA (SSP) 
 Tridural® 
100 mg 
Tridural® 
200 mg 
Ralivia® 
200 mg 
Zytram® XL 
200 mg 
 
100 mg of 
drug (SSP) 
200 mg of 
drug (SSP) 
 [6.10, 
15.70] 
[6.00, 
19.50] 
[6.40, 
11.60] 
[7.50, > 24]  [5.20, 
20.40] 
[5.20, 
19.10] 
 
 
In addition, the f2 results also showed that the 450-mg tablet with 100 mg of drug 
presented release characteristics more similar to the selected twice-daily formulation with 200 
mg of tramadol hydrochloride (f2 equal to 89.23) and to Topalgic® LP 100 mg (f2 equal to 
72.71), which led to the selection of the formulation weighting 450 mg as the twice-daily SD 
HASCA formulation with 100 mg. Close similarity between both the twice-daily and the once-
daily developed formulations with different contents of drug was desired. 
Given that SD HASCA formulations were produced for oral administration, the size of 
the tablets had to be taken into consideration when producing once-daily formulations. 
Consequently, an increase in tablet size was not considered and the tablet weighting 800 mg 
with 200 mg of drug was chosen as the once-daily formulation with 200 mg of tramadol 
hydrochloride, even considering that the release rate from this tablet was faster than the rate 
from Tridural® 200 mg (f2 equal to 55.83). In addition, even though the release from the 
tablets weighting 800 mg with 100 mg of tramadol hydrochloride was slower and more similar 
to Tridural® 100 mg (f2 equal to 68.1) than the tablet weighting 700 mg with the same drug-
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content (f2 equal to 53.09), the latter had a profile more similar to the tablet with a total weight 
of 800 mg and 200 mg of tramadol hydrochloride (f2 equal to 82.39), the selected once-daily 
SD HASCA formulation with 200 mg of drug. Therefore, the 700-mg tablet with 100 mg of 
drug was chosen as the optimal once-daily formulation with 100 of tramadol hydrochloride. 
A pH gradient was used instead of a unique buffer or distilled water because it 
provides a more accurate simulation of the environment that an oral dosage form encounters 
when transiting through the gastrointestinal tract. Besides, studies have shown that in vivo-in 
vitro correlations (IVIVC) are improved when the dissolution tests are carried out in a pH 
gradient rather than in distilled water [33].  
Studies have demonstrated that the DS has a significant influence on the structural, 
physicochemical and drug-release properties of high-amylose carboxymethyl starch [29,34]. 
These studies have suggested that high-amylose sodium carboxymethyl starches produced at 
lower DS are preferably suitable for use as an excipient for SR formulations, showing 
extended-release in both acidic and alkaline dissolution media, while high-amylose sodium 
carboxymethyl starch at higher DS (referred to as CM-HAS) can be used as an excipient for 
delayed-release, since the drug-release rate in acidic medium is significantly lower than in 
alkaline medium [29,34]. As a result, the potential of this polymer produced at higher DS as 
an excipient for formulations with gastro-resistant properties of a variety of drugs, including 
bioactive agents, have been investigated [35,36]. The polymer used in this study was produced 
at a lower DS and, therefore, shows SR properties in both acid and alkaline environment. 
 
 
4.5.3 Decrease of the tablet surface area in order to increase the in vitro 
release time of tramadol hydrochloride from twice-daily and once-daily 
SD HASCA matrix tablets 
The comparison between the T50% and T90% from the once-daily SD HASCA 
formulations with 100 mg (4 and 14.4 h) and 200 mg of tramadol hydrochloride (4.1 and 16.4 
h), prepared using a HP (Table 4.5), and the T50% and T90% from Tridural® 100 mg (6.1 and 
15.7 h) and Tridural® 200 mg (6 and 19.5 h), the once-daily commercial dosage forms (Table 
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4.3), show that the release rates from the once-daily SD HASCA tablets were slightly higher 
than the release rates from the commercial tablets. Closer values were, however, found for the 
tablets intended for twice-daily administration. 
The ultimate purpose of the developed SD HASCA SR formulations is oral 
administration in humans. Tablet size, shape and geometry are important factors to take into 
consideration when designing medication to be administered by this route, since they 
determine the level of patient comfort during oral administration, and thus compliance. 
Besides, it has been shown that tablet size, shape, and surface area may affect drug-release 
profiles [37,38] and can, therefore, be used for modulation of drug-release rate. A study on the 
influence of tablet surface area/volume (SA/V) ratio on drug-release from controlled-release 
matrix tablets containing HPMC indicated a direct relationship between SA/V ratios and drug-
release rate. Utility of SA/V to influence drug-release was demonstrated by altering tablet 
shape to adjust SA/V [37]. The importance of this finding is related to the possibility of 
achieving optimal drug-release profiles without further modification of a formulation, by 
simply choosing an appropriate SA/V ratio for a tablet. Based on the higher comfort for the 
patient when swallowing tablets with narrower diameters and the direct link found between 
surface area and drug-release rate, the dimensions of the selected SR SD HASCA formulations 
were changed so as to decrease their diameter, decreasing the tablet SA/V ratio. To achieve 
these changes, the tablets were compressed using a SSP machine instead of the 30-tons 
manual HP. This compressing machine produced tablets with an average diameter of 11.1 mm 
instead of 12.6 mm and, consequently, tablet heights were thicker. 
When using the SSP, the lower plunger nuts was adjusted so as to achieve a target 
average thickness of 7 mm for the once-daily tablet with 100 mg of drug (instead of 4.4 mm of 
the tablets produced with the HP), 7.4 mm for the once-daily with 200 mg of drug (instead of 
4.8 mm of the tablets produced with the HP), 4.6 mm for the twice-daily tablets with 100 mg 
and 5.2 mm for the twice-daily tablets with 200 mg (no thickness measurements had been 
made with the HP). As the number of sample tablets was small, it was not possible to present 
the values of the standard deviations of the tablet thickness. 
The in vitro drug-release characteristics from the tablets produced with the SSP were 
then evaluated under the same pH gradient dissolution conditions. Even though the twice-daily 
SD HASCA formulations presented a release profile close to the profile of the commercial 
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ones, the same changes in surface area were studied so as to develop all the four formulations 
under the same conditions and make them all more easily swallowable. 
 
 
4.5.3.1 Preliminary crushing strengths measurements  
The crushing strengths of 700-mg and 800-mg tablets with 100 mg and 200 mg of 
tramadol hydrochloride, respectively, compressed with the HP were measured. The designed 
procedure was to apply a CF starting at 1 tons/cm2 and to increase it gradually up to 2.5 
tons/cm2. Not even the 700-mg and the 800-mg SD HASCA tablets with 100 mg and 200 mg 
of drug, compressed with the HP at 1 ton/cm2 were breakable. Therefore, no further 
measurements were necessary. The very high crushing strengths found for these tablets 
support the theory, described above, of the occurrence of particle re-arrangement and partial 
melting of the polymer under compression, resulting in the densification of the matrices. The 
high crushing strength values are an advantage when considering industrial manufacture 
because they ensure batch reproducibility throughout the process. 
 
 
4.5.3.2 Influence of CF on tramadol hydrochloride release from SD HASCA tablets  
The influence of CF ranging between 1 and 2.5 tons/cm2 on the drug-release properties 
from SD HASCA matrix tablets weighting 700-mg tablets with 100 mg of tramadol 
hydrochloride, and compressed using a 30-tons manual HP, was also investigated. This range 
of CF was selected because it covers the normal range of CF employed at the industrial level. 
The T50% and T90% for the tested CF and the values of the f2 between tablets compressed at 
different CF are represented in Table 4.4. Between 1 and 2.5 tons/cm2, CF did not 
significantly influence drug-release from SD HASCA matrix tablets. The same results were 
found for 600- and 400-mg tablets containing 32.5% of SD HASCA (with 70% of amylose 
and 30% of amylopectin, and spray-dried with a final ethanol/HASCA ratio w/w of 3.2), 40% 
of acetaminophen and 27.5% of sodium chloride [16].  
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Table 4.4 Time to release 50% and 90% of tramadol hydrochloride [T50%, T90%] for SD 
HASCA tablets compressed at different CF between 1 and 2.5 tons/cm2 and similarity factors 
(f2) between tablets weighting 700-mg tablets with 100 mg of tramadol hydrochloride, 
compressed with a 30-tons manual HP at different CF. 
CF (tons/cm2) [T50%, T90%] (hours) f2 vs. 2.5 tons/cm2 
1 [3.90, 14.25] 90 
1.5 [4.10, 14.50] 89 
2 [4.25, 15.40] 84 
2.5 [4.00, 14.40]  
 
 
These consistent results show that the independence between drug-release from SD 
HASCA matrices and the CF used is not affected by the different composition of the polymer, 
the final ethanol/HASCA ratio and the substitution of sodium chloride for tramadol 
hydrochloride as the electrolyte in the formulation. Ungur et al. [11] have already noted that in 
the case of lab-scale HASCA, CF influenced microporosity but did not alter the drug-release 
rate. A study using formulations composed of SD HASCA, acetaminophen and sodium 
chloride, where the relationship between TW and CF versus TT was investigated to 
understand the good binding properties of SD HASCA, suggested that an intense densification 
of the matrices occurred and was the same for CF ranging from 1 to 2.5 tons/cm2. In this case, 
it was also demonstrated that CF does not considerably influence TT [16]. This peculiar 
mechanism of densification, i.e., sintering by viscous flow and melting under compression, 
has been demonstrated by scanning electron microscopy (SEM) and porosimetry for matrices 
composed of SA,G-2.7 [10]. Such very low porosity might explain why CF does not influence 
the drug-release rate from tablets with SD HASCA or SA,G-2.7 as the SR excipient. As 
opposed to SA,G-2.7, no influence of CF on the amplitude of the burst effect as well as on the 
time-lag has also been observed for SD HASCA tablets. 
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The fact that the CF applied did not significantly influence drug-release is important 
since it indicates that the unknown CF exerted by the SSP machine may not have a significant 
influence on the release of tramadol hydrochloride from SD HASCA tablets compressed with 
this machine. This finding and the very high crushing strengths further illustrate the utility of 
SD HASCA as a directly compressible excipient for oral sustained drug-release and assures 
the reliableness of the SSP. 
 
 
4.5.3.3 In vitro release of tramadol hydrochloride from optimal twice-daily and once-daily SD 
HASCA matrix tablets  
As shown in Figure 4.3, the 700-mg SD HASCA tablets (once-daily) with 100 mg of 
drug compressed with the SSP machine had a slightly lower release than the once-daily 
commercial formulations after 10 hours of release. At this stage of experimentation, this does 
not represent a problem given that one does not know yet how these SD HASCA dosage forms 
will behave in vivo. 
Decreasing the diffusion surface area using the SSP led to a decrease in the release rate 
and consequently to an improvement of the similarity of the 700-mg tablet with 100 mg of 
drug to Tridural® 100 mg, when compared with the same formulation compressed with the HP 
(f2 equal to 70.66 for the SSP vs. 53.09 for the HP). In the same way, the f2 for the 800-mg 
tablet with 200 mg of drug compressed with the SSP machine was relatively higher than the f2 
for the 800-mg tablet with 200 mg of drug compressed with the HP, when both formulation 
were compared to Tridural® 200 mg (f2 equal to 79.80 for the SSP vs. 55.83 for the HP).  
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Figure 4.3 Cumulative percentage of tramadol hydrochloride released in vitro from once-daily 
SD HASCA formulations compressed using a single-stroke press machine (SSP), and once-
daily commercial formulations (: 700-mg tablets with 100 mg of drug, : 800-mg tablets 
with 200 mg of drug, : Tridural® 100 mg, and : Tridural® 200 mg). Tests were performed 
with the tablets placed inside a cage. f2 values: 70.66 between 700-mg tablets with 100 mg and 
Tridural® 100 mg, 79.80 between 800-mg tablets with 200 mg and Tridural® 200 mg, 93.14 
between 700-mg tablets with 100 mg and 800-mg tablets with 200 mg. 
 
The f2 between the once-daily SD HASCA with 100 mg and the once-daily SD 
HASCA with 200 mg formulations compressed with the SSP was 93.14, much superior to the 
value between the commercial formulations, i.e., 69.67. Figure 4.4 shows that the release from 
both the 450-mg tablets with 100 mg of drug and the 500-mg tablets with 200 mg of drug, 
compressed with the SSP, was slower than the release from the commercial formulations with 
100 mg and 200 mg (f2 equal to 54.52 for twice-daily SD HASCA 100 mg and Topalgic® LP 
100 mg; and equal to 52.36 for twice-daily SD HASCA 200 mg and Topalgic® LP 200 mg). 
The f2 regarding the similarity between the twice-daily SD HASCA formulations compressed 
with the SSP (88.01) and the f2 regarding the similarity between commercial formulations 
(85.06) were nearly identical. The differences between the release profiles from the two types 
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of twice-daily formulations, commercial and SD HASCA, were not an issue, since the main 
goal of the present work was essentially to prove the SR properties of the developed SD 
HASCA formulations and to develop once-daily and twice-daily SD HASCA formulations 
with similar release profiles for both dose strengths (100 mg and 200 mg) and type of 
formulation (once-daily and twice-daily). Besides, the commercial formulations were mainly a 
guide to remain within reliable release profiles for the 12 hours and the 24 hours release 
formulations. Therefore, a strict similarity was not required between SD HASCA and 
marketed formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Cumulative percentage of tramadol hydrochloride released in vitro from twice-daily 
SD HASCA formulations, compressed with the single-stroke press machine, and twice-daily 
commercial formulations (: 450-mg tablets with 100 mg of drug, : 500-mg tablets with 
200 mg of drug, : Topalgic® LP 100 mg, and : Topalgic® LP 200 mg). Tests were 
performed with the tablets placed inside a cage. f2 values: 54.52 between 450-mg tablets with 
100 mg and Topalgic® LP 100 mg, 52.36 between 500-mg tablets with 200 mg of drug and 
Topalgic® LP 200 mg, 88.01 between 450-mg tablets with 100 mg and 500-mg tablets with 
200 mg of drug. 
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As it can be observed in Figures 4.3 and 4.4, the release profiles from SD HASCA 
tablets can be divided into two stages, which are typical of hydrophilic matrices. First, a burst 
effect occurs. This burst of drug corresponds to the rapid dissolution and release of drug from 
the tablet surface, whilst the viscous gel layer forms around the dry core of the matrix tablet. 
Thereafter, the release rate decreases gradually until the end of the dissolution process. This 
decrease in release rate corresponds to an increase of the diffusion pathway that drug 
molecules have to traverse, owing to the progressively forming gel barrier. This release 
behaviour is characteristic of a mainly diffusion-controlled mechanism [39]. 
Table 4.5 shows a clear decrease in the rate of drug-release, given by the T50% and T90%, 
from twice-daily and once-daily SD HASCA tablets compressed using the SSP when 
compared to the tablets compressed with the HP. In the same way as it was observed for the 
tablets compressed with the HP, the T50% was less affected by TW than the T90% when the 
tablets were compressed using the SSP. The in vitro release rates from the optimized twice-
daily and once-daily SD HASCA formulations were in agreement with documented preferred 
profiles [40].  
 
 
Table 4.5 Time to release 50% and 90% (hours) of tramadol hydrochloride [T50%, T90%] 
from twice-daily and once-daily SD HASCA tablets with 100 mg and 200 mg of drug, 
compressed using a 30-tons manual hydraulic press at 2.5 tons/cm2 (HP) or a single-stroke 
press (SSP).  
Formulation 
Frequency of 
administration 
100 mg of 
drug (HP) 
100 mg of 
drug (SSP) 
200 mg of 
drug (HP) 
200 mg of 
drug (SSP) 
Twice-daily [1.90, 6.40] [3.00, 10.70] [1.90, 6.70] [3.00, 10.25] 
Once-daily [4.00, 14.40] [5.20, 20.40] [4.10, 16.40] [5.20, 19.10] 
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4.5.4 In vitro release of tramadol hydrochloride from SD HASCA tablets 
under ethanolic conditions  
The results of the in vitro release of tramadol hydrochloride from once-daily SD 
HASCA tablets with 100 mg of tramadol hydrochloride and from Tridural® 100 mg (once-
daily) in a hydro-alcoholic medium with 40% ethanol, performed to address safety issues 
related to simultaneous administration of SD HASCA tablets and ingestion of alcohol, are 
presented in Figure 4.5 The same figure shows the release profiles from the same formulations 
in a pH gradient. The rate of release of tramadol hydrochloride from SD HASCA tablets 
decreased under ethanolic conditions when compared to the rate of release in a pH gradient. 
SD HASCA formed a very hard gel in the hydro-alcoholic medium, which retained SR 
properties independently of the alcoholic environment. The same decline in the rate of release 
was observed for Tridural® 100 mg, having SD HASCA and the commercial formulations 
remarkably similar profiles (f2 equal to 88.51). 
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Figure 4.5 Cumulative percentage of tramadol hydrochloride released in vitro from once-daily 
SD HASCA tablets with 100 mg of drug and once-daily commercial formulations with 100 
mg of drug in a pH gradient versus a 40% ethanol hydro-alcoholic medium (: SD HASCA 
with 100 mg in a pH gradient, : Tridural® 100 mg in a pH gradient, : SD HASCA with 
100 mg in a 40% ethanolic medium : Tridural® 100 mg in a 40% ethanolic medium. f2 
values: 70.66 between 700-mg tablets with 100 mg of drug and Tridural® 100 mg in pH 
gradient, 88.51 between 700-mg tablets with 100 mg of drug and Tridural® 100 mg in a 40% 
ethanol hydro-alcoholic medium. 
 
 
It has been reported that in vitro dissolution experiments in 40% ethanol hydro-
alcoholic mediums over a 2 hours period are expected to be representative of the most extreme 
alcoholic conditions likely to be encountered in vivo, because of to the dilution of the ethanol 
in the gastrointestinal fluids [26]. Yet, the dissolution tests in alcohol were carried out during a 
7 hours period to better distinguish the different drug-release profiles between formulations 
and between dissolution mediums.  
The decline in the release rate may be explained by a possible susceptibility of the 
solubility of SD HASCA, the SR agent in our tablets, and Contramid® (a cross-linked starch), 
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the SR agent in Tridural®, to high-alcohol concentrations. Indeed, it has been shown that in 
heated aqueous solutions containing some alcohols, including ethanol, amylose precipitates 
forming complexes known as Vh-amylose crystals [41]. However, in the same study where 
SD HASCA was designed, it was suggested that the presence of a Vh form of HASCA was 
unnecessary to obtain sustained drug-release and that its concentration did not influence the 
drug-release process, as long as it remained a minor component in a mainly amorphous matrix 
[6]. Further studies on the complex interactions between ethanol and the solubility of the SR 
excipients are required to explain the slower release rate. Although the solubility of tramadol 
hydrochloride is pH-independent, a distinct solubility of tramadol hydrochloride in a pH 
gradient versus in the ethanolic medium, if any, will also influence its release from the 
formulations.  
Tramadol hydrochloride is available from a number of companies as once-daily SR 
formulations in strengths up to 300 mg. The higher dose in SD HASCA formulations is 200 
mg. These amounts of drug can possibly be released as a bolus, known as dose dumping, if 
misuse of the tablets by bisection, breaking, crushing, chewing or simultaneous ingestion of 
alcohol occurs, which could lead to harmful adverse effects like nausea, dizziness, vomiting, 
headache and abdominal pain [42]. Besides, tramadol adverse affects are accentuated in the 
presence of alcohol.  
The influence of ethanol on the in vitro release of some opioid drugs, including 
tramadol hydrochloride, from a number of SR formulations employing diverse release 
technologies has been investigated following the withdrawn of a once-daily formulation of an 
opioid drug from the US market. Studies had shown that simultaneous ingestion of ethanol 
modified its release characteristics and induced dose-dumping, which urged the FDA to 
consider the issue of potential and harmful changes of the release characteristics of new and 
marked extended-release formulations caused by ethanol ingestion [26]. 
The dissolution studies showed that SD HASCA tablets formed a hard gel, which 
maintained SR properties and was resistant to exposure to a simulation of the pH variations 
through the gastrointestinal tract as well as to ethanolic conditions. Both SD HASCA and 
commercial formulations formed a denser gel in ethanolic medium, although the diameter and 
appearance of the formulations after 7 hours release did not change much (Fig. 4.6). 
Moreover, the moderate cracks that appeared on the tablet surface during the dissolution tests 
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in a pH gradient did not affect drug-release, which suggests that the risk of undesired burst 
release in vivo might be low.  
 
 
 
Figure 4.6 700-mg tablets with 100 mg of tramadol hydrochloride in: (a) pH gradient and (b) 
40% ethanol hydro-alcoholic medium (b); Tridural® 100 mg in: (c) pH gradient and (d) 40% 
ethanol hydro-alcoholic medium. 
 
 
In fact, an in vivo study where SD HASCA tablets containing acetaminophen and 
sodium chloride were administered to fasted, healthy human volunteers suggested that the 
formed gel is strong enough to maintain its integrity while traversing the stomach, resisting the 
vigorous peristaltic contractions which, in the fasted state, clear the stomach of any residual 
material (commonly knows as housekeeper waves) [17]. However, this in vivo study was 
carried out on a very small number of volunteers, and thus its results have to be considered 
carefully. Moreover, the very high crushing strengths observed for these tablets are likely to 
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prevent possible accidental breaking and crushing. These findings support the value of SD 
HASCA as a robust excipient for oral sustained drug-release, which may reduce the likelihood 
of severe adverse affects that can occur in the case of an accidental dose-dumping due to 
misuse (breaking, crushing, bisection of the tablets or simultaneous alcohol ingestion) of the 
medication. 
 
 
4.6 Conclusions 
SD HASCA is an interesting excipient for sustained drug-release in solid oral dosage 
forms. It is biodegradable, inexpensive and allows facile manufacturing of tablets by direct 
compression. Tablets made from SD HASCA show independence of drug-release from CF, 
high crushing strengths, and are amenable to twice-daily and once-daily formulations. The 
mechanical strength of the SD HASCA gel formed when the tablets are exposed to either a pH 
gradient or to an ethanolic medium suggest that these tablets are likely to withstand the 
mechanical stresses that occur after oral administration as well as co-administration with 
alcohol, preventing undesired disintegration of the tablets in the gastrointestinal tract with 
consequent dose dumping. Moreover, the properties exhibited by SD HASCA tablets suggest 
this polymer is a promising and robust excipient for oral sustained drug-release, which may 
possibly minimize the likelihood of dose dumping and consequent adverse effects, if 
inadvertent or deliberate misuse of the medication such as simultaneous ingestion of alcohol, 
occurs. 
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5.1 Presentation of the article and contribution of the authors 
This article presents the results of the evaluation of influence of α-amylase on the in 
vitro drug-release profiles and mechanisms from a once-daily acetaminophen formulation 
(Acetaminophen SR) and a once-daily tramadol hydrochloride formulation (Tramadol SR), 
both containing SD HASCA as the only SR excipient. In addition, the results of the study 
regarding the influence of the residence time in simulated gastric fluid on the α-amylase-
catalyzed erosion of both SD HASCA formulations are also described. This article was 
submitted to ISRN Pharmaceutics on January 22, 2014. 
 
The contribution of each author to the publication was: 
Teresa Nabais – Execution of all dissolution testing; analysis of data resulting from dissolution 
testing; writing of the article. 
Grégoire Leclair – Project coordinator and director at the time of the publication; revision of 
the article. 
 
 
5.2 Abstract 
Spray-dried high-amylose sodium carboxymethyl starch (SD HASCA) is a promising 
pharmaceutical excipient for sustained-release (SR) matrix tablets produced by direct 
compression, allowing the development of twice-daily and once-daily formulations.  
The presence of α-amylase in the gastrointestinal tract and the variations of the gastric 
residence time of non-disintegrating dosage forms may affect the presystemic metabolism and 
the drug-release from SD HASCA tablets. In this study, the influence of α-amylase on the in 
vitro drug-release profiles and mechanisms from a once-daily acetaminophen formulation 
(Acetaminophen SR) and a once-daily tramadol hydrochloride formulation (Tramadol SR), 
both containing SD HASCA as the only SR excipient, was evaluated. The influence of the 
residence time in acidic medium on the α-amylase-catalyzed erosion of both SD HASCA 
formulations was also investigated. α-Amylase concentrations ranging from 0 IU/L to 20000 
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IU/L did not significantly affect the drug-release profiles of acetaminophen and tramadol 
hydrochloride from SD HASCA tablets. Moreover, the drug-release properties from both SD 
HASCA formulations were not significantly different when the residence time in acidic 
medium was 1 h or 3 h. An increase in α-amylase concentration led to an increase of polymer 
erosion over drug diffusion as the main mechanism controlling drug-release, for both 
formulations and both residence times in acidic medium. However, the increment in α-
amylase-catalyzed erosion was more relevant for Tramadol SR and for a residence time in 
acidic medium of 1 h. As such, α-amylase did not significantly affect the drug-release profiles 
from both SD HASCA SR formulations, regardless of the residence time in acidic medium 
even if the mechanism of release itself may be affected.  
 
 
5.3 Introduction 
Starch is a natural polymer that can be submitted to various types of modifications, 
such as chemical [1], physical (i.e. gelatinization) [2], or enzymatic [3] modifications. 
Substituted amylose (SA), a chemically modified starch produced through the reaction of 
high-amylose corn starch with a substituent, has been introduced as a hydrophilic excipient for 
orally administered sustained-release (SR) drug delivery systems. Modified starches present 
advantages as hydrophilic polymers for sustained drug-release, such as a relatively low cost, 
accessibility, biocompatibility, biodegradability and good in vivo performances [4,5].  
Spray-dried high-amylose sodium carboxymethyl starch (SD HASCA) has been 
proposed as a suitable and nontoxic excipient for oral SR matrix tablets prepared by direct 
compression [6,7]. SD HASCA, a chemically-modified starch has been produced by reacting 
sodium chloroacetate/chloroacetic acid with high-amylose corn starch. This polymer has 
shown excellent in vitro sustained drug-release properties with no increase in the burst-effect 
at the beginning of dissolution, when used as the only SR excipient in formulations containing 
a considerable quantity of soluble materials. This was previously demonstrated using 
acetaminophen and sodium chloride and a low quantity of polymer [4,5,8]. A first in vivo 
study where a formulation containing SD HASCA, acetaminophen and sodium chloride 
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(referred to herein as Acetaminophen SR) was administered orally to healthy human 
volunteers has also demonstrated extended drug absorption, showing that the tablets 
maintained their integrity while traversing the stomach and resisted α-amylase biodegradation 
in the small intestine [5]. The model drug chosen in this clinical study was acetaminophen, 
which has a plasma elimination half-life (t1/2) ranging from 1 to 4 h [9]. Following the positive 
results of the Acetaminophen SR study, further development was pursued using a clinically 
relevant drug. Tramadol hydrochloride, a centrally acting synthetic analgesic with a half-life 
between 5 and 7 h [10] was chosen as this second model drug. 
Oral formulations intended for twice-daily and once-daily administration and 
containing only SD HASCA and tramadol hydrochloride, a readily soluble drug, have been 
successfully developed. In vitro drug-release studies have shown that these SR tablets formed 
a gel with high mechanical strength when exposed to a series of buffers simulating the pH 
variations through the gastrointestinal tract or to an ethanolic medium, showing excellent SR 
properties regardless of the medium used [11].  
Further findings which have proven the potential of SD HASCA as an efficient SR 
excipient included a considerable increase in the total drug-release time when the tablet weight 
(TW) increased, tablets with high crushing strengths, facilitating their production at industrial 
level, and no significant influence of compression force (CF) on drug-release [4,8,11]. 
After oral administration, starch and its derivatives are digested by α-amylases present 
in certain regions of the gastrointestinal tract. In humans, the digestion of starch involves 
initially a partial digestion by salivary amylase resulting in the degradation of the polymeric 
substrate into shorter oligomers, followed by further hydrolysis by pancreatic α-amylase into 
maltose, maltotriose and small maltooligosaccharides in the gut. α-Amylase is an endo-
specific enzyme that catalyzes the hydrolysis of α(1→4) glycosidic bonds of starch and other 
polysaccharides in a random manner, reducing the molecular size of starch [12]. This enzyme 
is present in bacteria, fungi, plants, and in the salivary and pancreatic glands of many animals 
[13]. α-Amylase is also able to degrade chemically modified starches [14-16].  
A previous dissolution study on tablets produced from substituted amylose polymers 
(SA,G-2.7) revealed a slightly faster drug-release in the presence of α-amylase [14]. 
Moreover, glucose, maltose and maltotriose, all soluble oligosaccharides, have been identified 
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as products of the hydrolysis of cross-linked high-amylose starch by α-amylase the enzyme 
[15].  
SR dosage forms, especially those designed for once-daily administration, contain 
amounts of drug that can potentially cause serious adverse effects if released too quickly in the 
gastrointestinal tract. This potential risk added to the fact that α-amylase present in the 
gastrointestinal tract may potentially influence the hydrolysis of starch-based excipients for 
pharmaceutical tablets and, thereby, lead to drug-release rates different from the desired rates, 
makes the study of the influence of this enzyme on drug-release from SD HASCA 
formulations of essential importance.  
In this study we propose to evaluate the impact of α-amylase-catalyzed hydrolysis of 
tablets containing SD HASCA on the in vitro drug-release profiles of a once-daily 
acetaminophen formulation (Acetaminophen SR) and a once-daily tramadol hydrochloride 
formulation (Tramadol SR), as well as the influence of the residence time in acidic pH on the 
degree of hydrolysis by α-amylase. 
 
 
5.4 Materials and methods 
5.4.1 Materials 
Amorphous HASCA were provided in powder by Roquette Frères (Lestrem, France), 
and contained 65% ± 5% of amylose and 35% ± 5% of amylopectin. The degree of 
substitution (DS) of the polymers was equal to 0.045 (number of moles of substituent/number 
of moles of anhydroglucose) [4]. Acetaminophen was purchased from Laboratoires Denis 
Giroux inc. (St-Hyacinthe, Quebec, Canada), sodium chloride (crystals, lab grade) from 
Anachemia Ltd. (Montreal, Quebec, Canada) and tramadol hydrochloride from Jubilant 
Organosys Ltd. (Nanjangud, Mysore, India). All chemicals were of reagent grade and were 
used without further purification. α-Amylase (EC 3.2.1.1) from Bacillus species (1260 IU/mg) 
was supplied by Sigma (St. Louis, MO, USA). 
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5.4.2 Preparation of SD HASCA formulations 
SD HASCA was prepared from amorphous HASCA as previously described [8]. 
Tablets were prepared by direct compression, i.e., blending the ingredients in a mortar using a 
pestle and then compression. 
Acetaminophen SR tablets (240 mg) were prepared from a blend of acetaminophen 
(40%), sodium chloride (27.5%) and SD HASCA (32.5%). This blend was compressed to a 
target weight of 600 mg at 2.5 tons/cm2 for 20 seconds using a 30-ton manual hydraulic press 
(C-30 Research & Industrial Instruments Company, London, U.K.) equipped with round flat-
faced tooling (diameter 12.6 mm). Tramadol SR tablets (200 mg) were prepared from a blend 
of tramadol hydrochloride (25%) and SD HASCA (75%). This blend was compressed to a 
target weight of 800 mg and a target thickness of 7.4 mm using a single-stroke press machine 
(Manesty F3 Machine, Manesty Machines Ltd., Liverpool, UK) equipped with round flat-
faced tooling (diameter 11.1 mm).  
 
 
5.4.3 Drug-release evaluation 
5.4.3.1 Dissolution studies 
The dissolution profiles of SD HASCA SR matrix tablets in simulated gastric fluid 
(stage I) and simulated intestinal fluids (stage II and stage III) were evaluated using a USP 
apparatus 2 (900 mL, 37°C, 50 rpm) [17]. During stage I, the tablets were exposed to 
simulated gastric fluid conditions without enzymes (SGF, pH 1.2), for periods of 1 or 3 h. 
During stage II the tablets were exposed to phosphate buffer (pH 6.8) simulating the pH in the 
jejunum (SIF I) and containing α-amylase (0, 5,000 or 20,000 IU/L), for an additional 3 h. 
Levels of α-amylase were based on a previous biodegradation study [15]. Finally, the tablets 
were exposed to a second phosphate buffer (pH 7.4) with no enzymes, simulating the pH in 
the ileum (SIF II), until the end of the assay (total time of 24 h). All standard buffer solutions 
were prepared according to the USP. 
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Acetaminophen SR tablets were placed on stainless steel meshes positioned at the 
bottom of the dissolution vessels to avoid adhesion of the tablets to the vessel [5]. Similarly, 
Tramadol SR tablets were placed inside perforated cylindrical plastic cages to avoid eventual 
floating to the surface of the medium or adhesion to the vessel [11]. 
Each experiment was performed in triplicate. After each sampling, an equivalent 
volume of fresh medium was added. Samples were filtered through syringe filters (0.45 mm, 
nylon). Release was followed by UV spectrometry. The drug-release results are expressed as 
cumulative percentage (%) in function of time (h).  
 
 
5.4.3.2 Statistical analysis and release profiles comparison 
The arithmetic mean and the standard deviation of the cumulative % of drug released 
at predetermined time intervals were calculated. 
The dissolution profiles were compared using a similarity factor f2 as proposed by 
Moore and Flanner [18]: 
 
€ 
f2 = 50 × log 1+ 1 n( ) Rt −Tt( )
t=1
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    (1) 
 
where Rt and Tt are the percent dissolved of the reference and test products at each time point t 
and n is the number of pool points. Two dissolution profiles are similar if f2 is between 50 and 
100 (according to the Food and Drug Administration and the European Agency for the 
Evaluation of Medical Products). However, the closer to 100, the more similar the dissolution 
profiles are. The dissolution profiles were also compared using the values of the time to 
release 25% (T25%), 50% (T50%) and 90% of drug (T90%). 
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5.4.3.3 Drug-release mechanism characterization 
Drug-release from SD HASCA tablets is controlled by a combination of Fickian 
diffusional release and relaxation/erosion of the polymer chains (case-II relaxational release), 
even in the absence of α-amylase [4]. Moreover, in mediums containing α-amylase, enzyme-
catalyzed polymer erosion might play a major role in the mechanism of drug-release. Peppas 
at al. [19] proposed a two-component model for this problem as detailed in Eq. (2), where the 
first term models the Fickian diffusion contribution (F) and the second term models the 
relaxation/erosion (R) contribution. 
 
€ 
Mt M∞ = k1tm + k2t 2m          (2) 
 
where Mt is the cumulative amount of drug released at time t, M∞ is the total cumulative 
amount of drug released, Mt/M∞ is the fraction of drug released, k1 is the Fickian kinetic 
constant and k2 is the relaxational/erosion kinetic constant, and m represents the purely Fickian 
diffusional exponent. 
 
The exponent m was determined from the aspect ratio, 2a/l (where 2a is the diameter 
and l is the thickness ), of the tablets as described previously [19]. 
Eq. (2) can be used to analyze the first 60% of a release profile, regardless of 
geometric shape. Therefore, this equation was fitted to the experimental dissolution data, 
consisting of the fraction of drug released up to Mt/M∞ = 0.6. This fitting was calculated by 
nonlinear regression using the Wolfram Mathematica® 8 software (Wolfram Research, Inc., 
Champaign, IL), in order to determine the values of the kinetic constants k1 and k2, and of the 
correlation coefficient, R2, for each dissolution profile. 
According to Peppas at al. [19] Eq. (3) leads to the ratio of erosion over Fickian 
contribution, as follows: 
 
€ 
R F = k2 k1( ) tm          (3) 
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where R and F are the percentage of drug released due to the relaxational/erosion and Fickian 
mechanism, respectively. 
The ratio k2/k1 was, thereby, used to analyze the mechanism of drug-release and the 
quality of the fitting was given by R2.  
 
 
5.5 Results and discussion 
5.5.1 Influence of α-amylase and of the residence time in SGF on the drug-
release profiles from SD HASCA tablets 
5.5.1.1 α-Amylase does not significantly affect the drug-release profiles 
In view of the high doses of drug that SR dosage forms may contain and the possible 
increase in drug-release rate from SD HASCA tablets caused by α-amylase present in the 
gastrointestinal tract, dissolution tests using SIF fluids with enzymes were essential to further 
address the potential of this new excipient. Indeed, dissolution tests with α-amylase are 
regularly performed in the pharmaceutical industry. 
Figures 5.1 (A) to 5.2 (B) show the effect of α-amylase concentration on the in vitro 
drug-release from Acetaminophen SR and from Tramadol SR [5,11].  
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Figure 5.1 (A) Effect of α-amylase concentration on the release of acetaminophen from 
Acetaminophen SR in a simulated gastrointestinal pH, where the residence time in simulated 
gastric fluid (pH 1.2) was 1 h, and the concentrations of α-amylase in simulated intestinal 
fluid (pH 6.8) were: 0 IU/L (dashed line), 5000 IU/L (dotted line) and 20000 IU/L (continuous 
line).  
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Figure 5.1 (B) Effect of α-amylase concentration on the in vitro release of acetaminophen 
from Acetaminophen SR in a simulated gastrointestinal pH, where the residence time in 
simulated gastric fluid (pH 1.2) was 3 h, and the concentrations of α-amylase in simulated 
intestinal fluid (pH 6.8) were: 0 IU/L (dashed line), 5000 IU/L (dotted line) and 20000 IU/L 
(continuous line). 
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Figure 5.2 (A) Effect of α-amylase concentration on the in vitro release of tramadol 
hydrochloride from Tramadol SR in a simulated gastrointestinal pH, where the residence time 
in simulated gastric fluid (pH 1.2) was 1 h, and the concentrations of α-amylase in simulated 
intestinal fluid (pH 6.8) were:  0 IU/L (dashed line), 5000 IU/L (dotted line) and 20000 IU/L 
(continuous line).  
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Figure 5.2 (B) Effect of α-amylase concentration on the in vitro release of tramadol 
hydrochloride from Tramadol SR in a simulated gastrointestinal pH, where the residence time 
in simulated gastric fluid (pH 1.2) was 3 h, and the concentrations of α-amylase in simulated 
intestinal fluid (pH 6.8) were: 0 IU/L (dashed line), 5000 IU/L (dotted line) and 20000 IU/L 
(continuous line). 
 
 
The tablets were exposed for 3h to SIF I (pH 6.8) with 0 IU/L, 5000 IU/L and 20000 
IU/L of α-amylase, before being transferred to SIF II (pH 7.4) without α-amylase. When 
immersed in SGF, a solid gel layer started forming quickly at the surface of both SD HASCA 
formulations. This layer developed towards the core as the series of media diffused into the 
tablet. Although the presence of α-amylase in the SIF I led to a slight increase in the drug-
release rates from both SD HASCA formulations, the results, as indicated by f2 values higher 
than 50 (Table 5.1), revealed that the differences between the drug-release profiles were not 
significant. As shown in Table 5.1, only the f2 value between the release profiles from 
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Tramadol SR at 0 IU/L and 20000 IU/L of α-amylase, when the tablets were exposed to SGF 
for 1 h, decrease to a value of 46.86. On the other hand, the highest f2 values were observed 
between the release profiles from Acetaminophen SR, when the enzyme concentration rose 
from 5000 IU/L to 20000 IU/L. A possible reason for this occurrence is the higher quantity of 
hydrophilic SD HASCA present in Tramadol SR (600 mg) compared to Acetaminophen SR 
(195 mg), which make the first formulation more susceptible to the effect of α-amylase. 
 
 
Table 5.1 Similarity factors (f2) between the release profiles from Acetaminophen SR and 
Tramadol SR at different α-amylase concentrations. 
Formulation Time (h) in SGF  
(pH 1.2)  
f2 between release profiles at different α-amylase concentrations 
  0 vs. 5000  
IU/L 
0 vs. 20000  
IU/L 
5000 vs. 20000 
IU/L 
Acetaminophen SR 1  61.34 55.84 84.06 
 3  68.85 66.04 92.72 
Tramadol SR 1  59.77 46.86 61.62 
 3  64.72 58.63 78.21 
 
 
The high calculated f2 values show that SD HASCA formulations performs well in the 
presence of α-amylase, at least for the range of α-amylase concentrations tested. It has been 
reported that the access to the α-amylase active site involved in the amylolytic process is 
limited by the presence of the carboxymethyl groups, probably via a steric and/or an ionic 
interaction of carboxymethyl groups with the active site [20]. Consequently, the presence of 
the carboxymethyl groups of SD HASCA may have enhanced the resistance of the polymer to 
α-amylase-catalyzed hydrolysis. Another explanations for the similarity between the release 
profiles may be given by the transformation of starch into a more crystalline form during 
hydrolysis [21], which is less easily degraded by the enzyme [22-24], and/or the inhibition of 
the enzymatic degradation by reaction by-products, such as maltose and maltotriose, which 
can reduce the rate of starch hydrolysis as the reaction progresses [22-25]. In addition, some 
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studies have described a facilitated enzyme access to the site of amylolysis for high-amylose 
carboxymethyl starches produced with a higher DS due to their high hydrophilicity. The 
substitution of the starch hydroxyl groups with the highly hydrophilic carboxymethyl sodium 
groups induces an increase of the hydrophilicity and relative solubility of this modified starch, 
even in cold water, and leads to a higher drug-release rate [20,26]. A higher affinity of α-
amylase (Bacillus species) for a soluble substrate than for a solid one has also been reported 
[25]. Since SD HASCA was produced with low DS, it possesses sufficient carboxymethyl 
groups to convey adequate resistance to α-amylase but not enough groups to promote intense 
α-amylase-catalyzed-hydrolysis caused by very high hydrophilicity. In addition, the higher the 
enzyme concentration was, the more significant the contribution of enzyme-catalyzed erosion 
was.  
Although acetaminophen is less soluble than tramadol hydrochloride, Acetaminophen 
SR contained a high quantity of soluble materials (240 mg of acetaminophen and 165 mg of 
sodium chloride) and a lower quantity of SD HASCA polymer than Tramadol SR. 
Nevertheless, the release profiles from Acetaminophen SR and Tramadol SR were similar, 
especially for the first half of the release, as indicated by the close values of T25% and T50% 
for all enzyme concentrations and both residence times in SGF, shown in Figures 5.1 (A) – 5.2 
(B)), and by f2 values between 66.48 and 78.96. The similarity between the release profiles 
from the two tested SD HASCA formulations showed that the model drug used and the other 
excipient present in the formulation did not significantly affect α-amylase-catalyzed-erosion 
and, consequently, drug-release. 
 
These results showed that the model drug used, the quantity of polymer and the type of 
excipients in the formulation did not significantly affect α-amylase-catalyzed-erosion and, 
thus, drug-release. 
 
 
5.5.1.2 Residence time in SGF does not significantly affect the drug-release profiles 
As a result of the effect of food on gastric emptying, the gastric residence time of any 
non-disintegrating oral dosage form varies depending on whether it was administrated in the 
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fasted or fed state. The unpredictable gastric residence time can influence drug-release from 
SR dosage forms and lead to variable drug bioavailability. Therefore, it was important to study 
the effect of varying the exposure time to SGF on drug-release from SD HASCA tablets in the 
presence of α-amylase.  
Table 5.1 shows that the f2 values between the release profiles at different α-amylase 
concentrations were slightly lower when the tablets were exposed to SGF for 1 h compared to 
3 h, for both formulations. Moreover, Table 5.2 shows that the f2 values between the release 
profiles when the residence time in SGF was 1 h versus 3 h decreased as the concentration of 
enzyme increased, also for both formulations. An interpretation of these results can be given 
by the fact that when the tablets were exposed to SGF for 1 h, the acidic buffer penetrated less 
deeply into their core, creating a narrower gel layer with an acidic environment. Thus, the SIF 
I with α-amylase had to traverse a shorter acidic pathway when diffusing through the gel 
layer. Besides, α-amylase is inactive in low pH, and thus a narrower acidic gel layer possibly 
resulted in inferior enzyme inactivation. These phenomena resulted in a little more important 
contribution of α-amylase-catalyzed erosion to the overall drug-release rate when the 
formulations were immersed in SGF for 1 h, which led to a slightly higher release rate. The 
values of T25%, T50% and T90% for Acetaminophen SR and Tramadol SR, seen in the 
Figures 5.1 (A) – 5.2 (B), also suggest a very slightly increase in the release rate when the 
residence time in SGF was 1 h and α-amylase was present in SIF I, especially noticeable for 
the values of T50%. However, as described above, these differences in drug-release rates were 
not significant. 
A previous publication demonstrated that the in vitro release of acetaminophen from 
Acetaminophen SR was not influenced by variations of both the acidic pH value and residence 
time in the acidic medium, which simulated various possibilities of gastric pHs and residence 
times in the fasted and fed states [5]. The f2 value of 91.02 (Table 5.2) found in the present 
study between the release profiles from Acetaminophen SR exposed to SGF for 1 h and 3 h at 
0 IU/l of enzyme, and the relative proximity of the values of the T25%, T50% and T90% for 
the same release profiles (Figs. 5.1 (A) and 5.1 (B)) were in agreement with the results of that 
study. These findings are important because formulations that possess pH-independent release 
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properties are preferable for oral SR delivery, given that they are less likely to be affected by 
intra- and inter-subject variations of both gastric pH and gastric emptying time. 
 
 
Table 5.2 Similarity factors (f2) between the release profiles from Acetaminophen SR and 
Tramadol SR at different residence times in simulated gastric fluid (pH 1.2). 
Formulation α-amylase  
concentration  
(IU/L) 
f2 between release profiles at different residence times in SGF 
(pH 1.2) 
  1 vs. 3 h 
Acetaminophen SR 0  91.02 
 5000 75.75 
 20000 65.14 
Tramadol SR 0  81.61 
 5000  84.32 
 20000  60.45 
 
 
5.5.2 Contribution of α-amylase-catalyzed erosion to the overall drug-
release mechanism 
The determined k2/k1 ratios (Table 5.3) show that diffusion was the predominant drug-
release mechanism in most cases. The only exception was when Tramadol SR tablets were 
exposed to SGF for 1 h and to SIF I with 20000 IU/L of α-amylase, since k2/k1 ratio was 
superior to 1, and thus erosion was the predominant mechanism. In the case of Acetaminophen 
SR in the same conditions the contribution of diffusion and erosion were equivalent, i.e., k2/k1 
was equal to 1. The contribution of the erosion mechanism to the overall drug-release rate 
increased as the concentration of enzyme increased for both formulations and both residence 
times in SGF, except for Acetaminophen SR tablets exposed to SGF for 3 h and to SIF I with 
20000 IU/L of α-amylase. Contrary to what was expected, in this case the k2/k1 ratio at 20000 
IU/L was equal to the ratio at 5000 IU/L, which is in agreement with the small difference 
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observed between the release profiles. The k2/k1 ratios also demonstrate that the contribution 
of the erosion mechanism was indeed more significant when the tablets were immersed in 
SGF for 1 h, especially in the presence of enzyme and in the case of Tramadol SR.  
 
Table 5.3 Values of 2a/l, Aspect Ratio (where 2a is the diameter and l is the thickness of the 
tablet); m, the estimated Fickian diffusion exponent; k2/k1, the erosion and diffusion kinetic 
constants ratio; and R2, the correlation coefficient, for Acetaminophen SR and Tramadol SR, 
the two residence times in the acidic medium and the three α-amylase concentrations tested. 
 
 
 
These results support the assumptions described above that a narrower acidic gel layer 
formed during 1 h of exposure to the acidic buffer and that a higher quantity of polymer 
favored α-amylase action. For the same reason, the lower quantity of SD HASCA present in 
Acetaminophen SR and the larger acidic gel layer formed during 3 h of exposure to SGF 
explain why increasing α-amylase concentration from 5000 IU/L to 20000 IU/L did not result 
Formulation 
Residence time 
in SGF (pH 1.2) 
α-amylase 
concentration 
(IU/L) 
2a/l m k2/k1 R2 
Acetaminophen 
SR 
1 
0 
5000 
20000 
4.040 0.45 
0.45 
0.45 
0.47 
0.71 
1.01 
0.9993 
0.9995 
0.9996 
 
3 
0 
5000 
20000 
4.040 0.45 
0.45 
0.45 
0.32 
0.45 
0.45 
0.9995 
0.9997 
0.9999 
Tramadol SR 1 
0 
5000 
20000 
1.499 0.43 
0.43 
0.43 
0.15 
0.65 
1.79 
0.9995 
0.9994 
0.9994 
 
3 
0 
5000 
20000 
1.499 0.43 
0.43 
0.43 
0.22 
0.56 
0.89 
0.9995 
0.9988 
0.9975 
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in superior erosion in this case. The lowest value of R2 was 0.9975 and, therefore, the quality 
of the least squares fitting of the Eq. 3 to the set of data points was excellent. 
At 0 IU/L of α-amylase in the SIF I, drug-release from SD HASCA tablets is 
controlled by a combination of drug diffusion through the gel layer and erosion at the surface 
of the matrix caused by the predominance of interactions water-polymer over interactions 
polymer-polymer [4]. The extent of the contribution of erosion to the overall drug-release rate 
can be negligible or become more important as the concentration of polymer in the tablet, and 
thus the gel-strength, decreases, as demonstrated in this study by a superior k2/k1 ratio for 
Acetaminophen SR at 0 IU/L of enzyme, as well as in a previous study [4]. On the other hand, 
in the presence of α-amylase, erosion of the matrix due to the hydrolysis of α(1→4) 
glycosidic bonds in the gel layer by α-amylase plays a crucial role in the control of drug-
release, being that role more significant as the enzyme concentration increases. 
Figure 5.3 illustrates the influence of α-amylase concentration on the drug-release rate 
in function of release-time from Acetaminophen SR tablets immersed in SGF for 1 h. When 
there was no α-amylase in the medium, the drug-release profile can be divided into two stages. 
First, a burst effect occurred, which corresponded to the fast drug dissolution and release from 
the tablet surface before the gel layer was fully formed. Second, the drug-release rate 
decreased continuously until the end of the dissolution process. This decrease was due to the 
growth of the diffusion pathway that drug molecules have to traverse, as a result of the gel 
barrier that progressively forms as the medium penetrates into the core of the tablet. This 
release behavior is characteristic of a mainly diffusion-controlled mechanism [27]. When α-
amylase was added to the SIF I, a minor increase in the drug-release rate was observed for the 
3 h period during which the tablets were under the influence of α-amylase. As expected, that 
rise was more important for a higher enzyme concentration. Figure 5.3 also suggests that the 
enzymes that penetrated deep into the matrices while the tablets were exposed to SIF I with α-
amylase kept their activity for about one to two hours after they were transferred to the SIF II 
with no enzymes, which happened 4 h after the beginning of drug-release.  
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Figure 5.3 Acetaminophen-release rate from Acetaminophen SR tablets exposed 1 h to 
simulated gastric fluid (pH 1.2), and 3 h to simulated intestinal fluid (pH 6.8) with 0 IU/L 
(dashed line), 5000 IU/L (dotted line) and 20000 IU/L (continuous line) of α-amylase. The 
arrows represent the time at which the tablets were placed (1 h) and were withdrawn (4 h) 
from the medium with α-amylase. 
 
 
Table 5.4 shows that drug-release from Tramadol SR was predominantly controlled by 
diffusion when there was no α-amylase in the medium, since R/F remained below 1 for all 
time points. In the case of drug-release from Acetaminophen SR, the contribution of erosion 
became significant 5.5 h or 12.5 h after the beginning of the release process, when the tablets 
were immersed 1 h or 3 h in SGF, respectively. However, the presence of α-amylase in the 
medium seemed to have a greater impact on Tramadol SR, since the contribution of erosion 
for drug-release became significant quicker, especially for the higher enzyme concentration.  
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Table 5.4 Time at which R/F became equal or superior to 1, for the residence times in the 
simulated gastric fluid (pH 1.2) and the α-amylase concentrations tested. 
Formulation Time in pH 1.2 (h) α-amylase 
concentration (IU/L) 
Time when R/F ≥ 1 (h) 
Acetaminophen SR 1 0 5.5 
  5000 2 
  20000 1 
 3  0 12.5 
  5000 6 
  20000 6 
Tramadol SR 1 0 - 
  5000 3 
  20000 0.25 
 3  0 - 
  5000 3.8 
  20000 1.3 
 
 
As explained before, at 0 IU/L of α-amylase, the much larger quantity of SD HASCA 
present in Tramadol SR compared to Acetaminophen SR enhanced the resistance of the first 
formulation to erosion because of the strength of the hydrophilic gel formed, resulting in 
diffusion of drug molecules through the gel layer being the predominant drug-transport 
mechanism during the entire drug-release process. In contrast, the lower quantity of polymer 
and the high quantity of soluble materials present in Acetaminophen SR may have led to the 
creation of a more open porous network during the dissolution process, increasing the 
importance of the erosion mechanism in the absence of enzyme at a certain point, which 
happened earlier when the residence time in SGF was 1 h for the causes already described. On 
the other hand, when α-amylase was present in SIF I, the higher content in wettable SD 
HASCA and the high solubility of tramadol hydrochloride of Tramadol SR, promoted α-
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amylase penetration and the susceptibility of this formulation to enzyme-catalyzed erosion. 
The higher the enzyme concentration was, the more significant the R/F ratio was.  
It could be expected that the addition of an electrolyte to Acetaminophen SR would 
also propel the fast penetration of SIF I with enzymes inside the tablet. However, a previous 
study has shown that this is not the case [5]. This phenomenon can be explained by the 
Donnan equilibrium [28]. According to this theory, in a gel network with immobile negative 
charge, in this case from the ionized carboxymethyl groups, the presence of solubilized 
sodium mobile counterions inside the gel network, resulting from the dissociation in alkaline 
medium, may reduce the osmotic pressure and, as a consequence, the penetration of medium 
into the tablets. 
 
 
5.6 Conclusions 
The present study shows that α-amylase does not significantly affect the drug-release 
profiles from two different SD HASCA formulations, regardless of the residence time in 
acidic medium. These findings support the results of a clinical study, where Acetaminophen 
SR was administered to healthy human subjects, which showed that the tablets released the 
drug over an extended period of time and resisted α-amylase biodegradation while transiting 
the gastrointestinal tract. The application of a two-component model that allows the 
investigation of the contribution of the diffusion and the erosion mechanisms to the overall 
drug-release rate shows that depending on the tablet composition and α-amylase 
concentration, the mechanism controlling drug-release from SD HASCA tablets can switch 
from drug diffusion to polymer erosion. These results support the potential of SD HASCA as a 
promising excipient for oral SR matrix tablets, since they show that the presence of α-amylase 
in the gastrointestinal tract and variations of the gastric emptying of SD HASCA tablets do not 
have a significant impact on their drug-release properties, at least for the residence times in 
acidic medium and the α-amylase concentrations tested.  
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Chapter 6. General discussion, conclusions and 
perspectives 
6.1 General discussion 
The main objective of this research was to further demonstrate the qualities of SD 
HASCA for future use as a safe and efficient excipient in the production of oral SR dosage 
forms, and thus provide additional arguments for the industrial development of this excipient. 
For this purpose, dissolution tests that simulated physiological conditions that may influence 
the performance of SD HASCA dosage forms in the gastrointestinal tract and an exploratory 
clinical study were carried out. In addition, two twice-daily and two once-daily SD HASCA 
formulations containing doses of tramadol hydrochloride commonly administered in SR 
dosage forms were developed. Further clinical studies, pharmacokinetic evaluations and the 
development of IVIVC involving these four formulations and a greater number of volunteers 
were part of the initial plan of this research. However, it was not possible to perform these 
studies.  
 
 
6.1.1 Advantages of SD HASCA 
Glycidol, the substituent used to produce the first generation of SA polymers with 
high-amylose starch (SA,G-n), has shown potential toxicity, including evidence of 
carcinogenic activity (US Department of Health and Human Services (2007)). Therefore, 
further in vitro dissolution experiments (Cartilier, Ungur et al. 2005; Ungur, Yonis et al. 2005) 
were carried out to validate a substitution of the substituent in order to produce a safer SA 
polymer, and thus facilitate the acceptance of the excipient by the regulatory agencies. The 
new substituent was sodium chloroacetate, which has already been applied in the production 
of a well-know disintegrant agent, i.e., sodium starch glycolate, a sodium carboxymethyl 
starch containing low amylose content (e.g., Explotab® or Glycolys®) (Edge and Miller 2005). 
The improved safety and consequent easier approval of HASCA represent an important 
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advantage of this new excipient. Subsequently, a process to produce the new excipient using 
spray drying was designed in order to prepare the scale-up and promote easier and economical 
industrial production of SD HASCA (Brouillet, Baylac et al. 2010). 
 
SD HASCA matrix tablets are produced by direct compression, which is the easiest 
way to manufacture an oral dosage form. Besides, due to the excellent binding properties of 
SD HASCA there is no need to add a binder to the formulation. All formulations developed in 
this study presented high crushing strength values, independently of the model drug chosen, 
the presence of sodium chloride in the formulation, the concentrations of each of the 
ingredients in the tablet and the TW. This feature may potentially provide the means for 
simplifying formulation development and improving overall operational costs and time while 
preserving the quality of the product, since a single excipient is the solution for more than one 
feature. Moreover, these high crushing strengths reduce the likelihood of accidental misuse by 
the patients, such as breaking or crushing of tablets. 
Two hypotheses were put forward to explain these good binding properties of SD 
HASCA. First, as the HASCA particles did not possess any binding properties before spray 
drying and this procedure resulted in a reduction of the particle size of the polymer, the 
particle size reduction and the consequent increase of the surface area of the particulate 
product may provide higher number of binding points. Secondly, it was suggested that the 
combination of water and ethanol in the spray-drying procedure has a plasticizer effect, 
leading to melting of the polymer under compression, which intensified the densification of 
the matrices (Brouillet, Baylac et al. 2010). 
 
The lack of influence of the CF applied (within a range normally employed at the 
industrial level) to produce the tablets on the release profiles of tramadol hydrochloride from 
SD HASCA matrices (containing 14.3% of drug and 85.7% of polymer) indicated that the 
matrix porosity, if any, was very low and had no significant effect on drug-release. The same 
independence between CF and drug-release was also observed in a previous study (Brouillet, 
Bataille et al. 2008) for tablets containing SD HASCA with 70% of amylose instead of 60% 
and spray-dried with a slightly different final ethanol/HASCA ratio, acetaminophen as the 
model drug (40%), and sodium chloride (27.5%). These results show that the independence 
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between drug-release and the applied CF was not affected by the different composition of the 
polymer, the final ethanol/HASCA ratio, the substitution of sodium chloride for tramadol 
hydrochloride as the electrolyte in the formulation and the model drug used, which emphasizes 
the versatility of this new polymer as an excipient for the production of SR dosage forms. 
 
The network formed by the SD HASCA chains when in contact with an aqueous 
medium was strong enough to permit the matrices to keep their SR properties, even in the 
presence of high loadings of soluble drugs such as tramadol hydrochloride. This strong gel is 
also important because the mechanical strength of a SR dosage form and its capacity to resist 
the powerful peristaltic contractions occurring in the gastrointestinal tract in the fasted state is 
an essential requisite in the development of this type of dosage forms. A weak mechanical 
strength may lead to premature drug-release and, therefore, to the failure of the formulation 
with respect to its ability to extend drug-release.  
 
Dissolution tests comparing the release profiles of a SD HASCA formulation and a 
HPMC formulation containing the same percentages of acetaminophen, sodium chloride and 
polymer showed that the drug-release from the HPMC formulation was slightly slower (Figure 
6.1). However, the visual observation of the matrices during the dissolution test revealed that 
the degree of swelling of the gel formed by SD HASCA was moderate when compared to 
HPMC, a hydrophilic polymer commonly used in SR. In addition, the mechanical resistance of 
the gel formed by SD HASCA seemed to be superior compared the to gel formed by HPMC 
because HPMC showed more gradual polymer erosion during the dissolution tests. However, 
studies on the degree of erosion were not performed. This mechanical strength may represent 
an advantage of the SD HASCA polymer for SR applications for the reasons already 
described.  
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Figure 6.1 Cumulative percent of acetaminophen released in vitro from : SD HASCA 
matrices containing 40% of acetaminophen, 27.5% of NaCl and 32.5% of polymer; : HPMC 
matrices containing 40% of acetaminophen, 27.5% of NaCl and 32.5% of polymer; and from 
: HPMC matrices containing 40% of acetaminophen, 0% of NaCl and 60% of polymer. The 
number of replicates was three. 
 
 
6.1.2 Influence of pH, gastric residence time, α-amylase and an alcoholic 
medium on the drug-release from SD HASCA matrices 
Because of the prolonged residence time of SD HASCA tablets in the gastrointestinal 
tract, their in vivo performance is more susceptible to the environmental factors these 
formulations will encounter when transiting along the digestive system. As described in the 
section 1.7 of this thesis, these variables are very complex and difficult to simulate, and no 
dissolution test can reproduce precisely the in vivo release environment. However, the 
development of dissolution test methods for new SR dosage forms should involve an 
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assessment of at least some of the physiological conditions the dosage form will come across 
in the lumen of the gastrointestinal tract. Thereby, some of these gastrointestinal physiological 
conditions were simulated in vitro in this research. 
 
First, the in vitro performance of SD HASCA formulations was investigated using a 
series of dissolution media simulating the pH range along the gastrointestinal tract (SGF, SIF I 
and SIF II), the residence time in each pH and possible variations in the gastric pH and 
residence time caused by the ingestion of food. A SGF and residence time values in SGF 
simulating fasting conditions (10 min and 1 h in pH 1.2) as well as the effect of food on gastric 
pH and residence time (3 h in pH 3.5 and 6 h in pH 4.5) were employed in the case of the 
formulation containing acetaminophen in order to better foresee the effect of these 
physiological variants on the drug-release from SD HASCA matrices. These values were in 
accordance with values reported in the literature, although these physiological factors vary 
greatly. In addition, the drug-release profiles after 1 or 3 h in SGF, followed by SIF I without 
enzymes, were also compared for Acetaminophen SR and Tramadol SR. The drug-release 
profiles from SD HASCA tablets showed to be independent of both the SGF value and the 
residence time in SGF, regardless of the formulation and the model drug used. A possible 
explanation for this occurrence was given by the simultaneous presence of an electrolyte and 
the carboxylic groups of the polymer, creating a possible buffer environment in the matrix, 
which may have rendered the formulation insensitive to pH changes of the surrounding 
medium. The pH-independence of the release kinetics of SD HASCA matrices represents an 
advantage of these formulations given that it greatly limits the influence of intra- and inter-
subject variability of these physiologic parameters on the release kinetics from SD HASCA 
matrices. 
 
SD HASCA is a chemically modified starch product, and thus it is digested by salivary 
and pancreatic α-amylases. The production of pancreatic α-amylase is induced by food intake. 
Since SD HASCA tablets may contain amounts of drug that may lead to adverse effects if 
released too fast, it was important to investigate the influence of the hydrolysis of this starch-
based excipient by α-amylase on the rate and mechanisms of drug-release from SD HASCA 
  
249 
formulations. This investigation involved both Acetaminophen SR and Tramadol SR. The 
effect of varying the exposure time to SGF on the α-amylase-catalyzed erosion of these 
formulations was also evaluated because gastric residence time can be rather unpredictable as 
a result of the effect of food on gastric emptying.  
The results of this part of the investigation showed that α-amylase-catalyzed erosion of 
both formulations did not result in a significant increase in the drug-release rates, at least for 
the range of α-amylase concentrations tested. Explanations found for this minor influence 
were given in part by the limited access to the α-amylase active site caused by the presence of 
the carboxymethyl groups of SD HASCA (Calinescu, Mulhbacher et al. 2005). The 
transformation of starch into a less digestible form and/or inhibition of the enzymatic 
degradation by reaction by-products may also reduce the rate of starch hydrolysis as the 
reaction progresses (Leloup, Colonna et al. 1991; Gallant, Bouchet et al. 1992; Leloup, 
Colonna et al. 1992; Planchot, Colonna et al. 1995). In addition, high-amylose carboxymethyl 
starches produced with a higher DS have been associated with a more facilitated enzyme 
access to the site of amylolysis because of their higher hydrophilicity (Lemieux, Gosselin et al. 
2009). SD HASCA has a low DS, and thus it may possess enough carboxymethyl groups to 
help hinder the access of the enzyme to the active site implied in the amylolytic process but 
not enough groups to promote intense α-amylase-catalyzed-hydrolysis caused by very high 
hydrophilicity. 
The drug-release profiles from Acetaminophen SR and Tramadol SR were similar for 
all enzyme concentrations and both residence times in SGF (except for a slight difference in 
one case) regardless of the different composition and polymer content of each formulation. 
These results showed that the model drug used, the quantity of polymer and the type of 
excipients in the formulation did not significantly affect α-amylase-catalyzed-erosion and, 
thus, drug-release. 
The results regarding the influence of the residence time in SGF on the α-amylase-
catalyzed erosion of SD HASCA tablets showed that the residence time did not significantly 
affect the enzyme activity and, consequently, the drug-release profiles from these 
formulations. There was, though, a slightly more important contribution of α-amylase-
catalyzed-erosion to the overall drug-release rate when the formulations were immersed in 
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SGF for 1 h when compared to 3 h. This effect increased as the enzyme concentration 
increased and led to a moderately higher drug-release rate. An explanation for this occurrence 
was given by the fact that after 1 h of exposure to SGF a narrower acidic gel layer was created. 
α-Amylase becomes inactive in low pH and, therefore, a shorter acidic diffusion pathway may 
have resulted in inferior enzyme inactivation and in an earlier access of the SIF I with 
enzymes to the core of the tablet. However, the differences in the drug-release rates were not 
significant.  
 
The resistance of the gel formed by SD HASCA to an alcoholic medium was assessed 
in order to assure the development of formulations that will withstand eventual co-
administration with high doses of ethanol after oral administration and, thus, prevent the 
occurrence of undesirable outcomes. In 2005, the FDA warned of the possibility that the 
presence of alcohol in the gastrointestinal tract interacts with modified-release dosage forms, 
increasing the risk of alcohol-induced dose dumping, due to tablet rupture and erosion, and 
consequent accumulation in the body. A general regulatory approach to promote the design of 
modified-release dosage forms that are not sensitive to alcohol was outlined (Meyer and 
Hussain 2005). To achieve this goal, it is essential to evaluate the dose dumping potential in 
the early stages of product development so that only robust product designs are developed. 
Therefore, the importance of dissolution studies using a hydro-alcoholic medium.  
The results of these studies showed that both SD HASCA and Contramid® (a cross-
linked starch), the excipient of the commercial formulation used for comparison, formed a 
very viscous and strong gel in the hydro-alcoholic medium. The release rate from both 
formulations was significantly slower in the alcoholic environment than in a pH gradient, 
which suggests that it was more difficult for the drug to diffuse through the gel layer when the 
formulations were immersed in the hydro-alcoholic dissolution medium because of the higher 
strength of the gel. It was hypothesised that this decline in the drug-release rate was due to the 
eventual precipitation of amylose chains as Vh-amylose crystals. Further studies on the 
influence of ethanol on the solubility of SD HASCA are necessary to understand the decrease 
in release rate. Another explanation is a different solubility of tramadol hydrochloride in the 
pH gradient and in the ethanolic medium. 
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6.1.3 Factors influencing the gel layer formation and drug-release 
As described before, the formation of a gel layer around the dry core of the matrix in 
response to water penetration (Figure 6.2 a)) is the most important aspect of the release 
mechanism and kinetics from SR systems using hydrophilic polymers as the retarding 
excipient. This gel layer acts like a barrier against fast inward medium penetration and fast 
drug diffusion through and out of the matrix. 
 
The dissolution profiles of a number of formulations with different total TW and 
different drug contents and containing only tramadol hydrochloride and SD HASCA were 
evaluated in a series of buffers simulating the pH throughout the gastrointestinal tract. As it is 
usually observed for hydrophilic matrices, the total release time from SD HASCA tablets 
increased significantly in function of the TW, and can thus be used to modulate the total 
release time from these formulations. A study suggested that the surface, thickness and 
structure of the gel layer may be nearly the same for each TW since the medium penetrates at 
the same rate to a certain depth of the tablet, regardless of its size (Varma, Kaushal et al. 
2004). Therefore, if one considers the dry and/or partially hydrated core of the SD HASCA 
matrix as a drug reservoir (Figure 6.2 a)), the increase in the total release time as a function of 
TW and size, may be, in part, explained by the larger size of this drug reservoir as the 
weight/size increases. However, studies using techniques such as image analysis should be 
performed to confirm this hypothesis. 
In addition, as the TW decreases the formation of an external tight gel network capable 
of controlling water and drug diffusion becomes more difficult. Therefore, when tablets are 
very thin the matrix may become totally hydrated and gelled rapidly, likely resulting in a faster 
erosion of the matrix. Contrarily, increasing TW and TT heightens the contribution of the 
diffusion mechanism. This may explain why the tablets produced with a SSP machine led to 
slower drug-release rates, since they were thicker and slightly narrower. 
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Figure 6.2 600-mg SD HASCA tablet matrices (40% acetaminophen, 27.5% NaCl, 32.5% SD 
HASCA) after immersion in a pH gradient simulation the pH evolution of the gastrointestinal 
tract (pH 1.2 for 1 h, pH 6.8 for 3 h, and pH 7.4 until the end of the dissolution test): a) 16 h of 
immersion (gel layer formation), and b) 22 h of immersion (total hydration of the matrix). 
Figure reproduced from (Brouillet, Bataille et al. 2008) with permission of Elsevier Ltd. 
 
 
 
This research also showed that another factor affecting the gel layer formation is the 
drug content and solubility. A more hydrophilic and, consequently, water soluble drug, like 
tramadol hydrochloride, together with a high drug content will increase the drug concentration 
in the gel and will promote the diffusion of the dissolution medium into the tablet. Above a 
certain threshold, the quantity of water may be such that the interactions between water and 
the polymer chains become superior to the interactions between polymer chains, resulting in 
progressive erosion of the gel layer. When polymer disentanglement is more rapid than water 
penetration the polymer gel layer will not grow and the drug-release rate will increase. 
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In addition, the presence of α-amylase in the medium seemed to hinder the continuous 
growth of the polymer gel layer due to erosion of the polymeric chains, and thus accelerates 
drug-release, being this effect higher as the concentration of enzyme rises.  
 
An optimized amount of sodium chloride was added to the formulation containing 
acetaminophen to help maintain the integrity of the structure of the gel layer when the tablets 
were immersed in a pH gradient, as an increase in the drug-release rate was observed at the 
time of the appearance of cracks on the tablet surface. As tramadol hydrochloride is also an 
electrolyte, no extra electrolyte was added to the second type of formulations of this research. 
The small fissures that appear on the tablet surface of the formulations containing tramadol 
hydrochloride did not significantly affect the drug-release profiles. A possible explanation 
found for this occurrence was that the addition of an optimal amount of electrolyte may 
maintain an equilibrium between a) hydrogen bounds formed, among others, through the 
association of –COOH groups, which increase gel strength and help maintain matrix structure, 
and b) swelling of the polymer chains due to the repulsion between them caused by –COO¯ 
groups, which provides the matrix with its necessary elasticity.  
 
 
6.1.4 In vivo studies and establishment of a Level A IVIVC 
An exploratory clinical study was performed in the early stages of development to 
assess the SR properties of a selected SD HASCA formulation containing acetaminophen in 
vivo. For this purpose, the pharmacokinetic parameters of the SD HASCA formulation were 
compared to those of a commercial IR formulation, after oral administration of these two 
formulations to healthy volunteers under fasting conditions. Furthermore, taking into account 
the importance of establishing a relevant correlation between in vitro drug-release and in vivo 
absorption in the early stages of the development of new dosage forms, a Level A IVIVC was 
attempted for the SD HASCA formulation. 
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The comparison of the pharmacokinetic parameters estimated from the plasma 
concentration versus time curves resulting from the SD HASCA formulation and the 
commercial IR formulation demonstrated a prolonged absorption of acetaminophen after oral 
administration of SD HASCA matrix tablets. Also, it suggested that the total amounts of drug 
absorbed by the body (calculated after dose adjustment) were similar for the SR formulation 
and the IR formulation, irrespective of the absorption rate.  
Furthermore, this study showed that there was no burst-effect while the tablets passed 
through the stomach and through the intestine. Therefore, the gel formed by SD HASCA was 
strong enough to resist the strong peristaltic contractions occurring in the fasted state as well 
as hydrolysis by α-amylase in the intestine. These observations confirmed the hypothesis 
established while testing the formulations in vitro that it is possible to produce robust dosage 
forms using SD HASCA which do not show significant disintegration and/or hydrolysis 
throughout the gastrointestinal tract and which show pH-independent release. However, the 
results of the in vivo study have to be interpreted cautiously because they were carried out 
using a limited number of volunteers.  
 
The methodology used for the evaluation of IVIVC involved the in vitro drug-release 
characterization of a selected formulation, assessment of the hypothetical drug absorption 
profile using the Wagner-Nelson method and, finally, plotting of the percent of drug absorbed 
in vivo at specific time points against the percent dissolved in vitro at the same time points.  
The relationship between the in vitro drug-release time course and the amount of drug 
absorbed from SD HASCA matrix tablets presented certain deviations from the ideal linear 
relationship and suggested a faster release rate in vivo. Some of the explanations for these 
results could be indeed a faster release in vivo or a possible high elimination rate of 
acetaminophen. It was, therefore, concluded that acetaminophen was not the most appropriate 
drug for this type of dosage form because of its high elimination rate, and that a new model 
drug with longer elimination t1/2 compared to acetaminophen was needed to continue the 
development of SD HASCA as an excipient for SR. Since it is known that drugs with 
intermediate to short, but not very short t1/2 values, provide the best candidates for SR 
products, the new drug chosen was tramadol hydrochloride, which has a t1/2 between 5 and 7 
hours. In addition, this clinical study also suggested that the Wagner-Nelson method was 
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possibly not the most appropriate deconvolution method. A slightly deviation of the intercept 
value from zero was also observed, and was explained by a probable longer time for hydration 
of the tablets in vivo, leading to a delay in the begging of drug-release.  
 
In conclusion, the first clinical study showed that new SD HASCA formulations with a 
new model drug, further dissolution studies evaluating these formulations and a new clinical 
study are required to continue the development of SD HASCA. An improved Level A IVIVC 
is necessary so that the set of dissolution conditions used to establish the correlation is able to 
provide a prediction of the in vivo behaviour of these formulations. A description of some of 
the dissolution experiments that can be performed to have a more accurate simulation of the 
conditions in the gastrointestinal tract, and thus an improved Level A IVIVC, are given in a 
following section. 
 
 
6.1.5 Mechanism controlling drug-release from SD HASCA matrices: 
Fickian diffusion versus relaxation/erosion 
It was hypothesized that Fickian diffusion of drug molecules through the gel layer is 
not the only transport mechanism controlling drug-release from SD HASCA matrices. Indeed, 
the results of this research showed that the polymer disentanglement and erosion while the 
matrix hydrates are also involved in the control of the kinetics of drug-release, even when 
there is no α-amylase in the medium.  
 
The determination of k2/k1 ratios (where k1 is the Fickian kinetic constant and k2 is the 
relaxational/erosion kinetic constant) permitted a better understanding and characterization of 
the mechanisms governing the release of drugs from matrix tablets produced with SD 
HASCA, either when these tablets were exposed to α-amylase or when there was no enzyme 
in the medium. This ratio represents the contribution of the relaxation/erosion of chains 
compared to the contribution of Fickian diffusion. 
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When α-amylase was added to the SIF I, the determination of the k2/k1 ratios 
demonstrated that the contribution of erosion to the overall drug-release rate increased with 
the concentration of enzyme for both Acetaminophen SR and Tramadol SR and both residence 
times in SGF. The values of k2/k1 also confirmed a slightly more significant effect of erosion 
when the tablets were exposed 1 h to SGF and, therefore, sustained the hypothesis that a 
narrower acidic gel layer favoured α-amylase action. In this case, erosion of the matrix caused 
by hydrolysis of α-(1→4) glycosidic bonds in the gel layer by α-amylase plays a role in the 
control of drug-release, increasing that role as the enzyme concentration increases. The higher 
content in hydrophilic polymer and the higher solubility of tramadol hydrochloride of 
Tramadol SR may have promoted the penetration of medium with enzyme and, therefore, the 
susceptibility of this formulation to enzyme-catalyzed-erosion relatively to Acetaminophen 
SR, especially for superior enzyme concentrations. 
As described before, it was hypothesized that when there is no α-amylase in the SIF I, 
drug-release from SD HASCA formulations is controlled mainly by diffusion but also by 
erosion on the surface of the matrices, which happens when the interactions water-polymer 
exceed the interactions polymer-polymer. Therefore, in this case, the contribution of erosion to 
the overall drug-release rate is related to the relative concentration of polymer in the 
formulation. When the polymer concentration is higher, diffusion is the major transport 
mechanism and the total release time is longer. This hypothesis was confirmed by a very low 
k2/k1 ratio and a R/F below 1 for all time points in the case of for Tramadol SR, the 
formulation that contained a higher polymer concentration. In contrast, the lower quantity of 
polymer and the high quantity of soluble materials of Acetaminophen SR may have led to the 
formation of a more porous network during the dissolution process, resulting in a more 
important contribution of erosion. This was demonstrated by a superior k2/k1 ratio for 
Acetaminophen SR when compared to Tramadol SR. 
 
 
 
 
 
  
257 
6.2 Conclusions and perspectives 
This research demonstrated the potential of SD HASCA as a promising new polymer 
for the production of SR solid oral dosage forms. Besides safe for future use in patients, SD 
HASCA tablets presented excellent binding properties with no addition of a binder and drug-
release independence from the CF applied to produce them. The results of the clinical study 
confirmed the hypothesis formulated during the evaluation of SD HASCA formulations by 
dissolution testing, i.e., the gel formed by this polymer is able to extend the absorption of the 
drug after oral administration and is strong enough to resist both the peristaltic contractions 
and the biodegradation by α-amylase occurring in the gastrointestinal tract. The gel formed by 
SD HASCA in a hydro-alcoholic medium allowed sustained drug-release and was also strong, 
which adds to the safety potential of SD HASCA. Dissolution testing experiments also showed 
that the drug-release from SD HASCA tablets was independent of both the pH of the SGF and 
the residence time in the SGF. However, variations in the residence time in the SGF slightly 
affected the α-amylase-catalyzed erosion of SD HASCA formulations. The application of a 
two-component model that allows the investigation of the contribution of the diffusion and the 
erosion mechanisms to the overall drug-release rate confirmed the hypothesis that the kinetics 
of drug-release from SD HASCA tablets are the result of a mix of Fickian diffusion of drug 
molecules through the matrix and erosion of polymer chains, and that the contribution of one 
mechanism versus the other depends primarily on the composition of the formulation and the 
concentration of α-amylase in the SIF.  
However, future studies should be carried out to further characterize the polymer, 
evaluate its behaviour in vivo and support scale-up. Some possible prospective studies are 
described hereafter.  
 
 
6.2.1 Characterization of the gel layer formed by SD HASCA 
Prospective studies regarding the characterization of the gel layer formed by SD 
HASCA should be carried out. Examples of these studies are the evaluation of water uptake, 
the characterization of the moving fronts during the hydration of the matrices, the rate at 
  
258 
which the gel formed by SD HASCA swells, the growth of the gel thickness in function of 
time and the characterization of solvent concentration gradients, i.e., solvent penetration, in 
SD HASCA matrices. These studies are important because the process of solvent transport 
into swellable polymer matrices and the corresponding dimensional changes that occur have a 
major influence on the profile of drug-release from these matrices. Therefore, the 
characterization and correlation of these phenomena is likely to allow a better predictability 
and an enhanced control over the process of drug-release from these matrices.  
The characterization of the gel layer in a pH gradient as well as in a hydro-alcoholic 
medium should be considered. 
 
Many approaches have been undertaken to quantify the swelling process and 
characterize moving fronts during the hydration of various pharmaceutical formulations. One 
of the methods that could be employed to characterize the gel layer is image analysis. This 
technique is simple and precise and permits the characterization of the changes occurring at 
the surface as well as inside the tablets during solvent absorption. This method has been used 
before to characterize swelling and solvent concentration gradients in large matrices (Moussa 
and Cartilier 1996; Moussa, Lenaerts et al. 1998). This technique allows the identification of 
several regions in the tablet, each color corresponding to the degree of hydration of a specific 
region. Image analysis also allows the recording of three-dimensional swelling and, therefore, 
the simultaneous evaluation of percentage of axial and radial swelling of the matrices 
(relatively to the original diameter or thickness of the tablet) in function of time, the 
calculation of bulk swelling using the formula of a cylinder, as well as the evolution of the gel 
layer thickness during hydration in function of time (Moussa and Cartilier 1996). 
Nuclear magnetic resonance (NMR) imaging has also been used to investigate 
hydrophilic swellable polymers. For instance, the concentration changes due to solvent uptake 
and the evolution of the shape of the tablet at different time intervals were followed in cross-
linked high-amylose starch tablets (Baille, Malveau et al. 2002). In the same way as image 
analysis, it allows the study of dimensional changes in both the gel layer and the core of 
swellable matrices (Rajabi-Siahboomi, Bowtell et al. 1994). In comparison with other 
techniques NMR has the advantage of being a noninvasive and nondestructive technique, as 
opposed to image analysis. It allows the observation of the interior of an object under 
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investigation without experimental interruption, physical slicing, or other manipulations 
(Malveau, Baille et al. 2002). The technique can be easily used to monitor simultaneously 
different areas of interest in the tablet and qualitative/quantitative results can be obtained 
(Malveau, Baille et al. 2002). The effect of factors such as pH and ionic strength (Wang, 
Assaad et al. 2011), tablet size (Malveau, Baille et al. 2002), temperature (Therien-Aubin, 
Baille et al. 2005) and drug-loading on solvent uptake and tablet swelling, as well as on gel 
layer formation at the water/tablet interface (Therien-Aubin, Zhu et al. 2008) in the case of 
cross-linked high-amylose starch tablets has been evaluated using this technique. 
The behaviour of the gel layer thickness in swellable matrices such as HPMC has also 
been evaluated using colorimetric techniques. For instance, a study used a calorimetric 
technique to investigate the swelling, diffusion and erosion front positions at different 
releasing times and the effect of drug loading on the front position and movement within the 
gel layer (Colombo, Bettini et al. 1999). 
 
Assessment of water uptake by SD HASCA matrices could be carried out using 
gravimetric measurements. This method consists basically of weighting the tablets before 
incubation in a dissolution buffer, removing each tablet from the buffer at appropriate time 
intervals, carefully removing the excess of liquid from the surface of the tablets with filter 
papers, and immediate weighting. Water uptake is determined by comparison with the dry 
weight. New samples are weighed for every time interval. 
Gravimetric measurements could be also performed for estimation of the percentage of 
enzymatic erosion after determined degradation periods. A method previous described for this 
purpose (Azevedo, Gama et al. 2003) involved the same steps described for the assessment of 
water uptake, except that in this case the buffer contained α-amylase, followed by washing of 
the tablets with distilled water and drying in an oven, cooling until a constant weight was 
achieved and weighting for determination of weight loss. A control consisting of incubating 
the tablets in buffer alone was also used. The effect of factors such as varying the enzyme 
concentration, TW and the model drug on the percentage of enzyme degradation could be 
studied using this method. 
In addition, SEM could be useful to analyze the surface morphology of SD HASCA 
tablets before and after enzymatic degradation. 
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6.2.2 In vivo studies and the establishment of a Level A IVIVC  
As mentioned above, further bioavailability studies in a larger number of volunteers 
and the establishment of a Level A IVIVC using the developed once-daily and twice-daily SD 
HASCA formulations as well as bioequivalence studies between these formulations and 
commercially available SR tramadol formulations were part of the planned experiments for 
this research. These clinical studies had as a goal to further substantiate the potential of SD 
HASCA as a new excipient for oral SR and support its industrial process scale-up.  
Therefore, clinical studies using the developed SD HASCA formulations or new SD 
HASCA formulations with different drug candidates should be performed. These studies 
should involve a larger number of volunteers for a better statistical analysis of inter- and intra-
individual variability. A different deconvolution approach, such as the Loo-Riegelman 
method (2-compartment model) or a model-independent method, could be applied to calculate 
the percentages of drug absorbed in function of time for each volunteer. Besides the evaluation 
of the bioavailability and pharmacokinetics of the formulations, the establishment of a Level A 
IVIVC, if possible, should be attempted. Bioequivalence studies comparing SD HASCA 
formulations with commercially available tramadol SR formulations could also be performed. 
Other possible investigation is the influence of food, and the associated delayed gastric 
emptying, on the drug-release characteristics of SD HASCA formulations using volunteers in 
the fed state, so as to ensure that the prolonged delivery of the drug is maintained, regardless 
of dietary status. 
 
In the case of difficulty in achieving a point-to-point relationship between the in vitro 
release time course and the in vivo response time course, the subsequent development of new 
dissolution methods could be undertaken to help attain a Level A IVIVC. To develop an in 
vitro method that is directly correlated with in vivo absorption, statistically designed studies 
should be carried out to investigate the effects of various in vitro testing conditions on drug-
release using USP dissolution apparatuses (Qiu, Garren et al. 2003). In this research it was 
demonstrated that pH and α-amylase (in the range of enzyme concentrations tested) do not 
significantly influence drug-release from SD HASCA matrices in vitro. These findings 
represent an advantage since it is generally easier to obtain a good IVIVC with SR dosage 
  
261 
forms that are essentially unaffected by such factors. However, it is important to evaluate other 
variables, including agitation intensity, choice of apparatus, surfactant and ionic strength of 
the dissolution medium. These dissolution variables can be modified and adjusted in order to 
alter the dissolution profile and facilitate the establishment of a Level A IVIVC using the 
shape of the in vivo profile as a target for the in vitro data to match. 
When dissolution rate depends on those variables, the dissolution profiles from 
formulations with varying in vitro release rates should be determined using a discriminatory in 
vitro test methodology. This dissolution methodology will better reflect the in vivo behaviour 
of the formulations and should be used to establish the IVIVC. In this case, a Level A IVIVC 
is based on the hypothesis that the same linear regression equation holds for all formulations 
(frequently three) with different release rates. 
A validated Level A IVIVC can be used in the scale-up process of SD HASCA, for 
example, when changing equipment such as the spray drier used in the production of the 
polymer, in the optimization of SD HASCA formulations, or as a surrogate for human 
bioequivalence studies, which may reduce the number of bioequivalence studies performed 
during the initial approval process. 
 
 
6.2.3 Industrial feasibility of spray drying and the compressing methods 
used in this study  
6.2.3.1 Spray drying 
In pharmaceutical technology, spray drying is a very important process used for 
obtaining dried substances with distinct properties. A typical application of spray drying in the 
production of excipients is spray-dried lactose, used to improve the compression properties of 
other powders (Sollohub and Cal 2010). Spray drying results in a product with better 
properties compared to other drying methods, since it produces homogenous powders 
(Sollohub and Cal 2010). 
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The spray drier used in this research to produce SD HASCA (Büchi B-290 Mini Spray-
Dryer, Flawill, Switzerland) is a mini device used at laboratory scale, which dries small 
quantities of aqueous solutions and suspensions. In order to scale-up production of SD 
HASCA, tests using an industrial spray drier have to be carried out. The resultant product 
should be analysed in order to investigate the eventual effect of changing scales on its 
characteristics and consequent modifications in the performance of SD HASCA as a SR 
excipient. For example, X-ray diffraction (XRD) can be used to characterize the crystalline or 
amorphous state of SD HASCA powder samples. This is important since the scale-up may 
alter some of the parameters employed in spray drying, such as inlet temperature and the 
internal moisture content of the chamber, which can affect the crystalline structure of the 
powder (Sollohub and Cal 2010). Scanning electron microscopy (SEM) can be used to study 
the morphology of the samples prepared with an industrial spray drier as well as generate 
information regarding the apparent particle density and porosity.  
When carrying out the spray drying scale-up it should be kept in mind that the final 
ethanol/HASCA ration should limit the quantity of ethanol used in the process to produce the 
polymer as mush as possible for economical, environmental and safety reasons, while still 
allowing easy spray drying. 
 
 
6.2.3.2 Tablet compressing machines 
The 30-ton manual hydraulic press (C-30 Research & Industrial Instruments Company, 
London, U.K.) used in this study is a manual press that only allows the compression of a tablet 
at a time, and thus it is only adequate for the production of small batches at laboratory scale 
for research purposes. The exact value of CF applied to compress the tablets using this 
machine is adjustable. 
The single-stroke press machine (Manesty F3 Machine, Manesty Machines Ltd., 
Liverpool, UK) used to change the shape of the tablets is an automatic press with variable 
speed, which can produce 42 to 85 tablets/minute. However, as it was used in this work to 
produce very small batches it was hand-operated. Only one pair of punching die can be erected 
on this press. This machine is capable of exerting a maximum CF of 4 tons/cm2. It has a scale 
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to adjust the pressure applied to produce the tablets. The crushing strengths of the tablets must 
be measured and then readjusted if necessary. This press has industrial applications. However, 
modern rotary tablet presses holding a high number of punches can produce much larger 
quantities of tablets/minute and, thus, are a more adequate type of tablet presses to be used in 
large manufacturing of pharmaceutical products. A major study should be performed 
regarding the flow and compaction properties of the SD HASCA powder in order to allow the 
production of SD HASCA matrix tablets using industrial presses. 
 
 
6.2.4 Other possible studies 
SEM and porosimetry studies should be employed to examine the melting process 
observed for SA,G-2.7 in the case of SD HASCA tablets. These further studies are important 
since, as mention before, it was hypothesised that the increased crushing forces of the SD 
HASCA tablets were obtained, partly, by an intense densification of the matrices and melting 
under compression.  
 
Moreover, although the results of this research showed that the influence of α-amylase 
on the drug-release profiles from SD HASCA formulations was not significant, further studies 
using formulations with materials that can help hinder the action of the enzyme, such as 
maltose, a degradation product of the α-amylase-catalyzed hydrolysis of SD HASCA, could 
be performed. 
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